https://biospectrumindia.com/rssfeed/states/karnataka karnataka https://biospectrumindia.com/news/104/28644/takeda-joins-hands-with-karnataka-leaders-to-call-for-year-round-dengue-preparedness.html https://biospectrumindia.com/news/104/28644/takeda-joins-hands-with-karnataka-leaders-to-call-for-year-round-dengue-preparedness.html Tue, 13 Oct 2026 16:45:45 +0530 As climate change, rapid urbanisation and shifting rainfall patterns continue to reshape dengue transmission across India, public health leaders, policymakers, scientists and civil society convened for "From Awareness to Action: Advancing Dengue Prevention in Karnataka." The multi-stakeholder dialogue culminated in the endorsement of a 4-Point Call-to-Action aimed at transitioning the state from seasonal outbreak response to continuous, year-round dengue preparedness. The high-level forum was organised with participation from Takeda Biopharmaceuticals India; U.T. Khader Fareed, Minister for Health and Family Welfare, Government of Karnataka and Madhu Bangarappa, Minister for School Education and Literacy, Government of Karnataka, alongside more than 20 state government representatives, leading public health institutions, researchers, innovators, academia and civil society organisations. U.T. Khader Fareed, Minister for Health and Family Welfare, Government of Karnataka said, "Karnataka's recent decline in dengue cases is encouraging, but it is not a signal to become complacent. The environmental conditions that drive dengue transmission continue to evolve, and future outbreaks remain a real possibility. Our next step is to strengthen how we predict, prevent and manage dengue by exploring new innovations in surveillance, diagnostics, vector monitoring, vaccination and community-based prevention. As scientific understanding advances, Karnataka will continue to evaluate emerging innovations and adopt approaches that are proven to be safe, effective and beneficial for our communities." Public health experts from ARTPARK, Institute of Health Management & Research, Tata Institute for Genetics and Society, and leading epidemiologists highlighted that dengue remains a complex and evolving public health challenge. While vector control remains essential, experts noted that sustainable control requires a broader and more integrated strategy. Building on the discussions, participants identified 4-Point Call to Action, that could help strengthen Karnataka’s dengue preparedness: Making dengue prevention year-round: Transitioning from monsoon-focused crisis response to continuous, 365-day engagement by integrating behaviour change communication (BCC) across schools, workplaces, and communities; prioritising positive incentives ahead of penalties. Closing the loop of care: Linking community-level screening directly to rapid diagnosis, timely primary healthcare referral, and structured follow-up. Making data work: Harmonising state and municipal surveillance data, strengthening ward-level analytics, enabling citizen reporting, and ensuring transparent treatment costs. Backing innovation: Funding locally adaptable, youth-driven solutions and tech-enabled vector monitoring through pilot initiatives across Bengaluru and Karnataka.   ]]> https://biospectrumindia.com/news/104/28645/nusynth-technologies-raises-rs-36-5-cr-to-strengthen-indias-chemical-innovation-capabilities-for-pharma-sector.html https://biospectrumindia.com/news/104/28645/nusynth-technologies-raises-rs-36-5-cr-to-strengthen-indias-chemical-innovation-capabilities-for-pharma-sector.html Tue, 13 Oct 2026 16:50:57 +0530 Mysuru-based startup NuSynth Technologies, an R&D-led process innovation collaborative platform for complex chemistry, has raised RS 36.5 crore in Seed funding. The round was co-led by Avaana Capital and Shastra VC. Over the last two decades, India has built significant capacity in chemical manufacturing. However, many critical molecules continue to rely on complex, multi-step synthesis routes that carry higher material and energy cost, use import-dependent intermediates and hazardous reagents, and pose challenges during commercial scale-up.  This creates a compelling opportunity to deepen domestic R&D and build native chemical process innovation capabilities that yield higher efficiency, sustainability, and commercial scalability. NuSynth addresses this challenge by redesigning chemical processes from first principles, not through incremental tweaks. By re-evaluating starting materials, reaction pathways, and process economics, their platform develops synthetic routes engineered for superior cost efficiency, yield, cycle time, safety, sustainability, and scalability. Beginning with high-value sectors like pharmaceuticals and electronics chemicals, the company building process innovation capability that extends across multiple chemistry-led sectors,  over time. “Over the last two decades, India has built significant strength at manufacturing established chemistry. We believe the next chapter will be defined by our ability to innovate on the underlying chemistry itself,” said Poorvank Purohit, Co-Founder & CEO, NuSynth Technologies. The new capital will support the development of NuSynth’s R&D and technology capabilities, initial portfolio of proprietary processes, scale-up capabilities and team. Shruti Srivastava, Partner, Avaana Capital, said: “The next phase of India’s growth in high-performance industrial chemistry will increasingly be shaped by the ability to originate proprietary synthesis pathways that are fundamentally more efficient and commercially scalable over time." ]]> https://biospectrumindia.com/news/104/28633/dst-signs-agreement-with-peptris-towards-rs-86-cr-rdi-collaboration-to-accelerate-ai-based-drug-discovery-and-development.html https://biospectrumindia.com/news/104/28633/dst-signs-agreement-with-peptris-towards-rs-86-cr-rdi-collaboration-to-accelerate-ai-based-drug-discovery-and-development.html Mon, 12 Oct 2026 12:46:35 +0530 In a significant move towards accelerating the development of next-generation therapies through Artificial Intelligence (AI), the Technology Development Board (TDB) of the Department of Science and Technology (DST), Government of India has signed an agreement with Peptris Technologies, Bengaluru, for financial support of Rs 86 crore under the Research Development and Innovation (RDI) Fund. The project, called VIGOR: Moving AI-Discovered Molecules from the Lab to the Clinic, has a total project cost of Rs 172 crore (approximately $1.72 billion). The aim is to advance four experimental drugs to technology readiness levels (TRLs) 4 to 6, requiring preclinical development, validation, and preparation for clinical trials. Financial support will be provided through optionally convertible debt (OCD). The VIGOR programme includes four experimental drugs: PEPR111, which targets neuromuscular disorders and cancer; PEPRX101, which targets hair loss (alopecia); PEPR202, which targets neuropathy; and PEPR112, which targets diabetes mellitus (DMD). Each experimental drug is currently at the TRL-4 stage, and the project aims to advance it to TRL-6. The development programme envisages a structured progression over three years, including advanced preclinical and investigational new drug (IND)-enabling studies, formulation development, clinical trial preparation, and initiation activities, subject to relevant scientific and regulatory requirements. By supporting the progress of multiple candidates under a coordinated program, the project seeks to strengthen the process of translating AI-based research into potential therapeutic products. Its focus on select disease areas also represents an opportunity to direct innovation toward conditions where effective treatment options are limited. ]]> https://biospectrumindia.com/news/104/28621/karnataka-biosciences-companies-explore-partnerships-with-montana.html https://biospectrumindia.com/news/104/28621/karnataka-biosciences-companies-explore-partnerships-with-montana.html Thu, 08 Oct 2026 19:23:15 +0530 The Bengaluru leg of the visit of Montana Governor Greg Gianforte brought together a diverse group of Indian biotechnology, biopharmaceutical, medtech, genomics, bio-manufacturing, precision medicine and digital health companies, with several expressing interest in exploring research, technology, clinical development, manufacturing and market-access opportunities with Montana, USA. The CXO-level roundtable, facilitated by the Association of Biotechnology Led Enterprises (ABLE), was held as part of Governor Gianforte’s India visit on October 7–8. The Montana delegation includes senior state officials, economic development representatives, private-sector companies and representatives from Montana State University. The interaction provided Indian companies an opportunity to understand Montana’s capabilities in bioscience research, biopharmaceutical manufacturing, academia and technology development, and identify areas for potential collaboration. The Indian participation reflected the breadth of Karnataka’s biosciences ecosystem. Immuneel Therapeutics, represented by its corporate development and scientific leadership, highlighted its work in CAR-T therapies and its interest in exploring opportunities with the Montana ecosystem. Iom Bioworks presented its work on engineered gut microbes and their potential application in cancer recovery. The company’s research could open avenues for collaboration in microbiome research, translational science and clinical development. Virion Therapeutics, a clinical-stage biotechnology company, is developing novel T-cell-based immunotherapies that use proprietary checkpoint modifiers to restore, enhance, broaden and sustain immune responses, with the objective of developing treatments for cancer and chronic infectious diseases. The company is looking at opportunities to advance its translational and clinical research through international collaborations. In the medical technology space, Cardiotrack highlighted its AI-powered portable electrocardiogram devices and telemedicine platform aimed at making early heart-disease detection more affordable and accessible across India. Its combination of medical devices, digital health and artificial intelligence presents potential opportunities for technology and healthcare collaborations in the US. BrainSight AI presented its functional brain-mapping technology designed to provide clinicians with additional information during neurological procedures and treatments. The company is preparing for entry into the US market and is exploring clinical research collaborations, making academic and healthcare institutions in the US a potential avenue for expansion. The genomics and life-sciences manufacturing segment was represented by Azooka Labs, a Bengaluru-based biotechnology startup incubated at the Indian Institute of Science. The company develops genomic workflow solutions, sustainable DNA/RNA sample-collection kits and non-toxic bio-reagents. Its interest in international partnerships aligns with the growing need for sustainable and accessible genomic technologies. Laurus Bio brought expertise in microbial precision fermentation and integrated bio-manufacturing. As a contract development and manufacturing organisation, the company works across sectors including biopharma, alternative proteins, personal care and food nutrition, creating potential opportunities for collaboration with Montana companies and research institutions in advanced biomanufacturing. In cell therapy and regenerative medicine, Eyestem is developing therapies for retinal diseases and is conducting Phase II clinical trials in India. The company’s interest in international clinical and research partnerships could create opportunities to connect with Montana’s academic and healthcare ecosystem. Prana Xenotransplants (Prana XT) presented its work on addressing the critical shortage of human organs through gene-edited porcine organ transplantation. Its programme integrates gene editing, cloning and surgical technologies and spans research, regulatory development and clinical readiness. Collaboration with US academic and research institutions could support the company’s efforts to advance this emerging field. The roundtable also highlighted opportunities beyond conventional healthcare. Devigere Biosolutions is developing clean-label, sustainable and functional protein concentrates from Indian pulses such as mung bean and cowpea for applications in functional foods, nutraceuticals, sports nutrition and skincare. The company's work could complement Montana’s interests in agriculture, food innovation and value-added bioproducts. String Bio showcased its bio-manufacturing capabilities, including products for agriculture and bio-stimulants, highlighting the potential intersection between biotechnology, agriculture and sustainable production. The academic and incubation ecosystem was represented by the dhaRti BioNEST Incubation Centre at IIT Dharwad, a research and technology incubator focused on translating academic R&D into commercial life-science solutions. The centre provides another potential bridge between Indian research institutions and Montana’s universities and innovation ecosystem. Akshaisarathi Health Care Solutions presented its multidisciplinary approach to healthcare innovation, bringing together medical consultants, IT professionals, data analysts, pharmaceutical chemists and biotechnologists to develop solutions for personalised and precision medicine. Environmental biotechnology and climate-related applications were also part of the discussion. Aspalli Green Sustainable Ecosystem, based in Raichur, Karnataka, showcased its patented Seed Womb technology for land restoration and reforestation. The technology is designed to improve survival rates and accelerate tree growth while reducing water requirements, creating potential areas of collaboration around sustainable land restoration, afforestation and environmental innovation. The range of companies participating in the roundtable demonstrated that the potential India–Montana relationship extends well beyond conventional biotechnology. From CAR-T and cancer immunotherapy to microbiome science, precision medicine, brain mapping, genomics, cell therapy, xenotransplantation, precision fermentation, functional proteins, agricultural biotechnology and reforestation, Indian companies identified multiple areas where Montana’s academic, research and business ecosystem could support their international growth. For the participating Indian companies, Montana offers potential access to research institutions, universities, clinical networks, technology partners and the wider US innovation ecosystem. In turn, the engagement provides Montana with an opportunity to connect with one of India’s most dynamic life-sciences clusters and companies developing technologies for global markets. The Bengaluru interaction therefore marked a first step towards converting the Governor’s trade mission into specific business, research and technology partnerships. The companies expressed interest in taking discussions forward with Montana-based organisations, particularly around joint research, clinical studies, technology development, biomanufacturing, academic partnerships and entry into the US market.   Narayan Kulkarni narayan.kulkarni@mmactiv.com ]]> https://biospectrumindia.com/news/104/28625/montana-governor-invites-indian-bioscience-industry-academia-to-collaborate-on-rd-and-market-access.html https://biospectrumindia.com/news/104/28625/montana-governor-invites-indian-bioscience-industry-academia-to-collaborate-on-rd-and-market-access.html Thu, 08 Oct 2026 21:22:58 +0530 Montana Governor Greg Gianforte has invited Indian bioscience companies, research institutions and academia to explore partnerships with the US state in research and development, manufacturing, clinical translation and market access, positioning Montana as a potential gateway for Indian life-sciences companies seeking entry into North America. Speaking at a Bengaluru roundtable with Indian biotechnology and life-sciences companies during his India visit on October 7, Gianforte highlighted the rapid transformation of Montana from an agriculture-led economy into an emerging hub for bioscience, advanced manufacturing, photonics and quantum technologies. “Montana is a gateway to North America for Indian companies,” Gianforte said, stressing the state's emphasis on building long-term relationships rather than transactions. He invited Indian companies to work directly with Montana's companies, universities and research institutions to develop mutually beneficial collaborations. According to Gianforte, bioscience is currently Montana's fastest-growing industry sector, with the state ranking sixth in the US for bioscience growth over the past five years. He pointed to the presence of major research and manufacturing capabilities, including GSK vaccine manufacturing operations, a National Institutes of Health infectious disease research laboratory and Rocky Mountain Labs, one of only 11 bioscience Level 4 laboratories in the US. He also highlighted Montana State University, which he described as a major research partner, with more than $300 million in annual research and development spending. Gianforte said Montana's research institutions and the state Department of Commerce were ready to facilitate introductions and partnerships for Indian companies. The Governor particularly highlighted opportunities in medical treatments and medical devices, saying Montana could help companies accelerate their path towards the North American market. He also drew attention to Montana's regulatory environment, including its “right to try” framework, which he said was designed to accelerate access to certain investigational treatments once safety requirements are met. Gianforte's invitation comes as Indian biotechnology companies increasingly look towards the US for clinical development, regulatory approvals, manufacturing and commercial expansion. Several Bengaluru companies at the roundtable are already pursuing US market opportunities across cell and gene therapy, precision fermentation, genomics, medical devices, oncology, drug development and digital health. The Governor also emphasised the importance of university-industry collaboration. Indian companies at the meeting expressed interest in working with Montana's academic and research ecosystem on areas including translational research, clinical trials, infectious diseases, cancer biology and medical technologies. Gianforte said Montana was open to hosting Indian companies and connecting them with relevant businesses, universities and institutions. “We'd love to host you and introduce you to people in several places so that you can form your own relationship directly with Montana as a gateway into the North American marketplace,” he said. The discussions also reflected opportunities beyond healthcare, including agriculture, bio-based manufacturing and value-added products. Gianforte noted the strong historical connection between Montana's agriculture economy and its emerging technology sectors, while participants from India highlighted potential collaboration in bio-ingredients, precision fermentation, plant proteins and agricultural biotechnology. The Governor endorsed the action-oriented approach proposed by the Association of Biotechnology Led Enterprises (ABLE) to convert the dialogue into concrete commercial and research partnerships. ABLE proposed developing a “bio-bridge” between Montana and India, with an initial objective of bringing together companies from both sides and creating opportunities for business collaboration within 90 days. Gianforte said he hoped the Bengaluru meeting would mark the beginning of a long-term relationship between Montana and India's bioscience ecosystem, rather than remain a one-off engagement.   Narayan Kulkarni narayan.kulkarni@mmactiv.com ]]> https://biospectrumindia.com/news/104/28605/bts-2026-to-offer-global-platform-for-technology-innovation-and-international-collaboration-dr-manjula.html https://biospectrumindia.com/news/104/28605/bts-2026-to-offer-global-platform-for-technology-innovation-and-international-collaboration-dr-manjula.html Tue, 06 Oct 2026 21:09:28 +0530 The Bengaluru Tech Summit (BTS) 2026 is set to expand its international footprint, offering participating countries a platform to showcase cutting-edge technologies, government initiatives, industry capabilities and academic strengths to a global audience, said Dr Manjula N, Secretary to Government, Department of Electronics, IT, Biotechnology and S&T, Government of Karnataka, at the Global Innovation Alliance (GIA) Meet held in Bengaluru on October 6. Dr Manjula provided an overview of BTS 2026 and highlighted the opportunities available to international partners through the Summit’s international exhibition, conference and country delegations. She also outlined the various outreach activities being undertaken to strengthen international participation at the Summit. Scheduled from November 17 to 19, 2026, at the Bangalore International Exhibition Centre (BIEC), BTS 2026 will be held under the theme ‘AI & Beyond’ and is expected to bring together more than 90,000 attendees, including over 1,000 technology startups, 1,000 investors, 25,000 delegates, 700 speakers and 1,800 exhibitors, with participation from more than 75 countries. The Summit is positioned as a platform for international technology ecosystems to engage with India’s rapidly expanding innovation landscape, while enabling companies, startups, investors, researchers and policymakers to explore partnerships and market opportunities. The BTS 2026 conference will feature 16 tracks covering key technology and innovation domains, including IT & DeepTech, Electro-Semicon, Digital Health & Biotech, Startup Ecosystem, Data & Cybersecurity and Global Collaboration. The Summit will also introduce new tracks such as AI Universe, Finverse, Frontier Tech and Orange Economy, reflecting the expanding application of technology across financial services, frontier technologies and creative and cultural industries. The Global Stage will feature country sessions involving more than 16 nations, providing international delegations with an opportunity to present their technology capabilities and discuss areas of collaboration. A key highlight of BTS 2026 will be the co-location of embedded world India, the maiden India edition of the global event organised by NuernbergMesse India. The event will focus on electronics, semiconductors and embedded systems, adding another major technology dimension to the Summit. The Robotics & Autonomous Systems Arena, led by Bharat 1.AI, will bring robotics companies and researchers together for live demonstrations spanning industrial automation, logistics and medical robotics. The multi-pavilion exhibition will showcase innovations across sectors, with increased international participation and industry representation. BTS 2026 will also place significant emphasis on startups and their access to capital, mentorship and international markets. The programme will include Investor Pitching, one-to-one Mentoring sessions, a dedicated Startup Pavilion and Investor Connect, along with thematic sessions addressing scaling, fundraising and international market access. The Future Makers Conclave, expected to attract more than 10,000 startup founders, will bring together entrepreneurs and changemakers from diverse fields. The Summit will also feature the Rural IT Quiz, Bio Quiz, Bio Posters, IT, Bio and Exhibitor Awards and Global Leaders Reception. With its expanded exhibition, international participation and technology-focused conference programme, BTS 2026 is expected to provide a broad platform for global technology ecosystems to connect with Karnataka and India’s startup, research, investment and industry communities. ]]> https://biospectrumindia.com/news/104/28606/karnataka-hosts-global-innovation-alliance-meet-ahead-of-bengaluru-tech-summit-2026.html https://biospectrumindia.com/news/104/28606/karnataka-hosts-global-innovation-alliance-meet-ahead-of-bengaluru-tech-summit-2026.html Tue, 06 Oct 2026 21:12:45 +0530 The Government of Karnataka hosted the Global Innovation Alliance (GIA) Meet in Bengaluru on October 6, to strengthen international participation and collaboration ahead of the Bengaluru Tech Summit (BTS) 2026, scheduled for November 17–19 at BIEC. Dr Manjula N, Secretary to Government, Department of Electronics, IT, Biotechnology and S&T, provided an overview of BTS 2026 and highlighted opportunities for international partners to showcase their technologies, government initiatives, industry capabilities and academic strengths through the Summit’s exhibition, conference and country delegations. The meet was attended by Priyank Kharge, Minister for Home, IT & Bt and e-Governance, Government of Karnataka; Dr Avinash Menon Rajendran, Managing Director, KITS & KEONICS and Director, Department of E, IT, Bt and S&T, Government of Karnataka; Dr E V Ramana Reddy, (Retd.), Chairman, Karnataka Skill Development Authority; and Jagdish Patankar, Event Curator, BTS 2026 and Executive Chairman, MM Activ Sci-Tech Communications. Representatives from GIA partner countries and international agencies, including Japan, the US, Germany, France, South Korea, Australia, Sweden, Italy, Switzerland, Canada and the Netherlands, among others, also participated in the meet. BTS 2026, themed ‘AI & Beyond’, is expected to bring together more than 90,000 attendees, 1,000 startups, 1,000 investors, 700 speakers and 1,800 exhibitors from over 75 countries. ]]> https://biospectrumindia.com/news/104/28607/karnataka-unveils-new-global-innovation-framework-ahead-of-bengaluru-tech-summit-2026.html https://biospectrumindia.com/news/104/28607/karnataka-unveils-new-global-innovation-framework-ahead-of-bengaluru-tech-summit-2026.html Tue, 06 Oct 2026 21:17:09 +0530 Karnataka is repositioning its global innovation engagement from event-led interactions to sustained partnerships, with the State preparing to roll out a new engagement framework and a dedicated physical platform for international innovation collaborations, Priyank Kharge, Minister for Home, IT & Bt and e-Governance, Government of Karnataka, said on October 6, 2026 in Bengaluru. Speaking at the Global Innovation Alliance (GIA) Meet, organised by the Department of Electronics, IT, Biotechnology and S&T ahead of the Bengaluru Tech Summit (BTS) 2026, Kharge highlighted the need to convert Karnataka’s international partnerships into tangible opportunities for startups, companies, institutions and investors. The GIA Meet brought together representatives from partner countries and international trade missions, including Sweden, Italy, Australia, Poland, Switzerland, Austria, the Netherlands, the US, Vietnam, Denmark, Belgium, Luxembourg, Israel, France, South Korea, Spain, Japan, Canada, Germany, Tunisia, Czech Republic and New Zealand. The Government of Karnataka is now strengthening the GIA framework to make international engagement more structured, reciprocal and outcome-oriented. The proposed framework will focus on four areas: global startup mobility and market access; international institutional partnerships; global visibility and strategic engagement; and governance through a dedicated International Desk. A key component of the next phase is GIGA – Global Innovation and Growth Alliance, a proposed permanent physical infrastructure in Bengaluru that will provide international startups, innovation agencies, delegations and institutions with workspace, meeting and programme facilities. It is intended to connect international partners with Karnataka’s Centres of Excellence, incubators, universities, industry and investors. The initiative signals a shift towards creating a more permanent landing platform for international companies and innovation organisations seeking to establish partnerships and explore opportunities in Karnataka. The GIA network, launched in 2017 under the Karnataka Unit for International Co-operation, has grown from 10 partner countries in 2018 to more than 40 countries in 2026. ]]> https://biospectrumindia.com/news/104/28587/c-camp-in-collaboration-with-ashraya-hastha-trust-selects-11-biology-driven-startups-to-accelerate-climate-action.html https://biospectrumindia.com/news/104/28587/c-camp-in-collaboration-with-ashraya-hastha-trust-selects-11-biology-driven-startups-to-accelerate-climate-action.html Thu, 01 Oct 2026 21:32:29 +0530 Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP), in collaboration with Ashraya Hastha Trust, has selected the first cohort of 11 startups from its India-wide “Call for Climate Solutions 2026,” that was launched earlier this year. This announcement took place on 29th September, 2026 during a half-day convening at C-CAMP on Advancing Sustainability and Climate Action. The “Call for Climate Solutions 2026,” was launched by the Centre of Excellence (CoE) for Sustainability and Climate Action at C-CAMP in early 2026 with a mission to identify and nurture impactful deep-tech innovations at the interface of biology and climate science, that drive climate action and sustainability in India and the world. The CoE will offer these 11 selected startups a funding support of up to Rs 50 lakh, access to high-end incubation labs, scientific and business mentorship, assistance on scale-up for market deployment and networking opportunities with key stakeholders from the industry. These selected startups include Genepath Diagnostics India, Prodancy, AeroDel Technology Innovations, Intello Labs, String Bio, Tealaa Innovations, Ossus Biorenewables, BPC Bio Bioproducts (Amylo), Earthkind Foods Biotech, Intrinsic Foundries (IIOT Innovation), and Bisket Labs. These startups have developed solutions that are focused on reducing greenhouse gas emissions and carbon footprints, enabling climate-resilient healthcare, and advancing climate-resilient and sustainable agriculture. During the event, C-CAMP in partnership with Ashraya Hastha also announced the next round of call for application for 2026 from climate innovators for on-field validation of climate solutions. This call seeks breakthrough field-ready solutions working at the intersection of climate change with environment, health, agriculture, & sustainability. On offer will be support for joint projects for on-field tech validation of up to Rs 50 lakh, curated government and industry connects for future scale up and partnerships and strong ecosystem access including pilot facilitations. ]]> https://biospectrumindia.com/news/104/28575/prodoc-ai-secures-seed-funding-to-develop-intelligence-layer-for-indian-hospitals.html https://biospectrumindia.com/news/104/28575/prodoc-ai-secures-seed-funding-to-develop-intelligence-layer-for-indian-hospitals.html Wed, 30 Sep 2026 15:27:52 +0530 Prodoc AI, a Bengaluru-based healthcare AI startup, has raised an undisclosed amount in a seed funding round led by Dr A. Velumani Family Office. The round also saw participation from Dr. Kunal Shet, and Parth D. Bhasin. Both Dr Shet and Bhasin participated in the investment round as existing users of the platform. Hospitals currently utilise multiple independent systems across departments, including HIS, EMR, CRM, billing, telephony, and diagnostics. Prodoc AI addresses this fragmentation by building a Patient Journey OS that connects these isolated communication channels. The software creates an intelligence layer across existing technology to manage patient context and coordinate actions without requiring hospitals to replace their current infrastructure. The platform handles workflows related to patient acquisition, appointment conversion, OPD intelligence, care coordination, follow-ups, partner and referral management, Voice AI, and general hospital operations. Prodoc AI currently operates in over 100 hospitals, processes more than one million patient engagements monthly, and supports over 50 software integrations.   The company plans to use the newly raised capital to advance its Agentic AI capabilities, increase the number of available system integrations, and build AI agents designed to support complex hospital workflows across care coordination, patient engagement, operations, and revenue processes. Looking ahead, the long-term objective of the company is to function as the definitive intelligence layer across the entire patient journey. By expanding its technological footprint, Prodoc AI aims to help hospitals move toward a more connected, responsive, and highly patient-centric healthcare delivery model. ]]> https://biospectrumindia.com/news/104/28535/5c-network-launches-ai-integrated-centre-of-excellence-for-nuclear-medicine-in-bengaluru.html https://biospectrumindia.com/news/104/28535/5c-network-launches-ai-integrated-centre-of-excellence-for-nuclear-medicine-in-bengaluru.html Wed, 23 Sep 2026 21:43:02 +0530 5C Network, one of India’s largest AI-native radiology platforms, has announced the launch of its remote Centre of Excellence (CoE) for Nuclear Medicine. Headquartered in Bengaluru, the distributed, remote-delivery network is engineered to solve India’s acute shortage of nuclear medicine physicians by providing high-precision, sub-specialty remote reading capabilities directly to hospital scanners across the country. This launch directly addresses a critical bottleneck in Indian healthcare. Over 500 PET-CT installations and 350 SPECT/gamma cameras rely on just ~800 nuclear medicine physicians nationwide. With PET-CT reporting restricted strictly to licensed specialists, a pool growing by only ~40 physicians annually while scan volumes surge 13% scanners outside major metros operate far below capacity. 5C’s Centre of Excellence bridges this gap, unlocking an estimated national market potential of nearly 7,500 daily PET-CT studies.  By utilising a distributed remote-reading framework, the CoE connects local scanners to a national panel of credentialed specialists, embedding standardised reporting criteria - such as PERCIST, Lugano, PSMA-RADS, and SSTR-RADS and integrating AI decision-support tools for lesion tracking, SUV quantification, and response assessment to assist physicians with speed and precision. To lead the CoE, 5C Network has appointed Dr Ajit Shinto, a veteran with 20+ years of expertise who commissioned India's first digital PET-CT scanner and has reported over 30,000 studies. Having established nuclear medicine departments across Kovai Medical Center, Amala Institute, Apollo Proton Cancer Centre, and Bharath Hospital, Dr Shinto chairs WARMTH’s Rhenium Task Force, serves as Co-Editor-in-Chief of the International Journal of Nuclear Medicine and Research, and is Principal Investigator on the NOBLE and 68Ga Basket trials.  ]]> https://biospectrumindia.com/news/104/28510/karnataka-approves-marine-biotechnology-policy-2026-2031-to-build-high-value-blue-bioeconomy-.html https://biospectrumindia.com/news/104/28510/karnataka-approves-marine-biotechnology-policy-2026-2031-to-build-high-value-blue-bioeconomy-.html Sun, 20 Sep 2026 16:09:56 +0530 The Government of Karnataka has approved the Karnataka Marine Biotechnology Policy 2026-2031, a five-year framework aimed at unlocking the economic potential of the State’s marine and coastal resources and positioning Karnataka as a leading hub for Marine Biotechnology and the Blue Bioeconomy. With a 343.3-km coastline, established marine science and fisheries institutions, a growing biotechnology ecosystem and a strong base of scientific talent, Karnataka seeks to move beyond traditional coastal activities towards high-value applications in marine biotechnology, biomanufacturing, seaweed-based products, marine biomaterials and sustainable marine enterprises. The policy aims to grow Karnataka’s Blue Bioeconomy from approximately $2 billion to $6–8 billion by 2031, while helping the State secure a larger share of India’s emerging Blue Bioeconomy opportunity. It will focus on translating marine science and research into commercial applications, strengthening coastal innovation infrastructure, creating new enterprise and employment opportunities, and promoting sustainable utilisation of marine resources. The policy has a proposed five-year budget of Rs 120 crore, including investments in KIMBE, Marine Biotechnology Zones, the Seaweed Value Addition PLI, the Karnataka Pilot Blue Carbon Certification Programme. The policy seeks to strengthen the entire value chain from research and bioprospecting to product development, prototyping, commercialisation and investment, enabling greater participation from startups, industry and research institutions. ]]> https://biospectrumindia.com/news/104/28511/karnataka-approves-sustainable-data-centre-policy-2026-2031.html https://biospectrumindia.com/news/104/28511/karnataka-approves-sustainable-data-centre-policy-2026-2031.html Sun, 20 Sep 2026 16:16:26 +0530 The Government of Karnataka has approved the Karnataka Sustainable Data Centre Policy 2026 2031, a five-year policy framework designed to establish the State as a globally competitive, sustainable and well-connected destination for Data Centre investments. The policy seeks to strengthen Karnataka’s digital infrastructure backbone at a time when the rapid growth of Artificial Intelligence, cloud computing, IoT, 5G, Global Capability Centres (GCCs), FinTech and other emerging technologies is driving unprecedented demand for computing capacity. The policy brings together investment facilitation, digital infrastructure, sustainability and ecosystem development, with a focus on attracting domestic and international investments across the Data Centre value chain. It also seeks to expand Data Centre infrastructure beyond Bengaluru, strengthening emerging regional digital corridors and supporting Karnataka’s broader Beyond Bengaluru vision. Rs 1,300.45 crore revised budget framework has been cleared for the implementation of the five-year policy. The policy will be implemented through a phased five-year roadmap, beginning with policy operationalisation, investor facilitation and identification of Data Centre Zones and Parks, followed by ecosystem expansion, R&D, skilling, sustainability-linked incentives and consolidation of Karnataka’s position as a sustainable Data Centre hub. ]]> https://biospectrumindia.com/news/104/28506/biomoneta-research-launches-indoor-air-purification-and-microbial-decontamination-device-avata-air.html https://biospectrumindia.com/news/104/28506/biomoneta-research-launches-indoor-air-purification-and-microbial-decontamination-device-avata-air.html Fri, 18 Sep 2026 16:51:25 +0530 Bengaluru-based Biomoneta Research has announced the launch of Avata Air, an indoor air-purification and microbial decontamination device, in collaboration with Panasonic. The product is now available through Panasonic’s MirAIe Lifestyle platform, marking Biomoneta’s entry into the Indian consumer air-care market. Unlike conventional air purifiers that primarily focus on dust, smoke and particulate matter, Avata Air has been designed to address both common airborne pollutants and invisible biological contaminants present in indoor environments. The company’s medical-grade product, Avata Rx, received clearance from the United States Food and Drug Administration as a Class II medical device. Avata Air is a separate consumer product, but incorporates the same underlying ZeBox technology used in the US FDA-cleared Avata Rx platform. “Avata Air represents an important milestone in Biomoneta’s journey,” said Arindam Ghatak, Co-founder and Chief Executive Officer of Biomoneta Research. “For more than a decade, we have worked to understand how airborne microorganisms can be captured and eliminated safely in occupied spaces. Through this collaboration with Panasonic, we can now bring the same core technology developed for demanding healthcare environments into Indian homes.” ]]> https://biospectrumindia.com/news/104/28481/karnataka-government-builds-news-partnerships-to-strengthen-digital-healthcare.html https://biospectrumindia.com/news/104/28481/karnataka-government-builds-news-partnerships-to-strengthen-digital-healthcare.html Mon, 14 Sep 2026 21:54:26 +0530 Bharat1.ai has formally entered into a Memorandum of Understanding (MoU) with the Centre of Excellence for HealthTech, MedTech, and Assistive Technologies (CHARAKA CoE), an initiative by the IT BT Department, Government of Karnataka, to establish the Swasthya AI Lab. This state-of-the-art facility is dedicated to accelerating holistic health outcomes through secure, high-integrity data infrastructure for innovative discoveries in the age of AI and Beyond. A Memorandum of Understanding (MoU) has also been announced between the Jalappa Foundation for Innovation and Incubation (JFII), Sri Devaraj Urs Academy of Higher Education and Research, Karnataka (SDUAHER) and CHARAKA CoE.This collaboration marks an important step towards creating a stronger ecosystem for HealthTech, MedTech and AssistiveTech innovation, bringing together academia, healthcare, technology, entrepreneurship and incubation. CHARAKA CoE has also signed an MoU with the Telemedicine Society of India, reflecting another step towards building a stronger health innovation ecosystem, bringing innovation closer to the medical community and creating more opportunities for people to learn, experiment and build. ]]> https://biospectrumindia.com/news/104/28472/danaher-expands-global-capability-and-rd-presence-in-bengaluru.html https://biospectrumindia.com/news/104/28472/danaher-expands-global-capability-and-rd-presence-in-bengaluru.html Sat, 12 Sep 2026 13:40:55 +0530 Danaher Corporation, a US-headquartered global science and technology company, is expanding its Global Capability Centre (GCC) and R&D presence in Bengaluru, with its Indian subsidiary DHR Holding India leasing 1,80,121 sq. ft. of office space in Whitefield, at Rs 88 crore for the next 5 years.The new space will add to Danaher’s growing GCC footprint in India, supporting its global technology, engineering and R&D capabilities. This new development directly augments Danaher’s existing India Development Center (IDC), which currently serves as a central operational node for the global conglomerate. The IDC represents 14 Danaher operating companies and has about 800 professionals, with capabilities spanning software engineering, product and hardware development, AI, machine learning, and data science. Danaher's portfolio includes Beckman Coulter, Cytiva, Cepheid, and Leica Biosystems. United by the proprietary Danaher Business System (DBS), the corporation empowers researchers and healthcare professionals globally to solve the most critical challenges in disease detection and biotechnology.   ]]> https://biospectrumindia.com/news/104/28475/15-startups-4-student-teams-win-prizes-worth-rs-35-cr-at-c-camp-national-bio-entrepreneurship-competition-2026.html https://biospectrumindia.com/news/104/28475/15-startups-4-student-teams-win-prizes-worth-rs-35-cr-at-c-camp-national-bio-entrepreneurship-competition-2026.html Sat, 12 Sep 2026 17:40:56 +0530 Fifteen startups and four student teams were announced as the winners of the 9th edition of C-CAMP’s National Bio Entrepreneurship Competition (NBEC) 2026, held on 12 September, in the presence of Dr Kiran Mazumdar Shaw, Executive Chairperson, Biocon Limited. The competition has been conducted with the support of the Department of IT, BT, S&T, Government of Karnataka as Home State Ecosystem Partner. The winning startups received a total of Rs 35+ crore in cash prizes and investment opportunities, while student-led teams secured Rs 4 Lakh in cash prizes across various awards presented at the Finale held at The Lalit Ashok, Bengaluru. All winners will also receive mentorship and handholding support through partnerships with key industry leaders. Social Alpha is investing Rs 10 crore for Credawn (Marrow Ease: An intelligent, powered bone marrow sampling system guided by real time marrow localisation & feedback); Rural Surgery; Lightprobe; 1000 Farms (For Nitrogenie - a rhizosphere-targeted microbial delivery bioformulation using biological “hooks” to enhance nitrogen fixation, microbial soil persistence, crop yield, soil health & chemical fertiliser reduction); Openwater (For OYSTER - a compact, proprietary electrochemical greywater treatment), and Renu Medtech (InsuPatch: A made-in-India affordable insulin patch pump with novel delivery technology). IIMA Ventures will invest Rs 2.5- 3 crore in Lightprobe (For a microscope for next-generation digital pathology for cancer) and Medrinz Bio (Transforming orthopedics with antimicrobial implants and 3D printed bone regenerator). Ideaspring Capital is investing Rs 15 crore in Lightprobe, Renu Medtech and Premas Lifesciences (For Development and Multicentric Validation of an India-Focused NGS-Based Glaucoma Panel for Early Risk Assessment and Precision Ophthalmology). Enzia Ventures is investing Rs 1-2 crore in Renu Medtech and Lightprobe. Indian Healthcare Angels in investing Rs 2 crore in Renu Medtech, Cellarim (For Cell-Free BioForge: A Scalable, Modular Platform for Rapid, On-Demand Biomanufacturing), Skiom (For Improvement of skin barrier function for Atopic dermatitis management containing fermentation based ingredients though skin microbiome modulation) and BioMarkIQ (VarSee™ Lung: An AI-read blood test for early-stage lung cancer detection in India’s existing diagnostic infrastructure). Java Capital is investing Rs 2 crore in Quantum Biosciences (Quantum Sentinel: An NV-center quantum sensing platform for early prediction of post-surgical acute kidney injury via real-time reactive oxygen species detection); Lightprobe, Cellarim and Premas Lifesciences. C-CAMP is investing an undisclosed amount in Medrinz Bio, Modern Village (Agri Rover Vyom -a digital platform which helps farmers for all their requirements) and Earthkind (For Bio-Fermented Speciality Oil using engineered oleaginous microorganisms) TiE Global is investing an undisclosed amount into Renu Medtech, Rural Surgeries, Lightprobes, Premas Lifesciences and Cellarim. Anicut Capital is investing an undisclosed amount into Lightprobe, Callarim, Earthkind and Openwater. The student winners included Bushra Naaz from SKUAST Kashmir, Jammu & Kashmir, is working on Sustainable Plant-Based Meat Analogues; Pankaj & Mehak from Dr. B.R. Ambedkar NIT Jalandhar are working on Sustainable Khimp Fibre Extraction and Bio-Fabric Development for Rural Livelihood Generation and Eco-Friendly Textile Innovation; Aayush Chandra Jha & Yawar Habib at IIT Delhi are developing India's First Dual-Biomarker Rapid Cardiac Diagnostic Assay; while Adarsh Saju & Aswin Tony at College of Engineering & Medical College, Trivandrum are working on AI-Powered Early Cerebral Palsy Screening for Infants. This year’s competition, attracted 3200+ registrations from across 34 States and UTs, including a significant number from Tier 2 and Tier 3 cities. Moreover, 40% of the applicants were female innovators. ]]> https://biospectrumindia.com/news/104/28436/karnataka-aims-to-build-technology-innovation-bridge-with-australia.html https://biospectrumindia.com/news/104/28436/karnataka-aims-to-build-technology-innovation-bridge-with-australia.html Sat, 05 Sep 2026 13:48:09 +0530 The Government of Karnataka has signed a Memorandum of Understanding (MoU with inQ Innovation Global, Australia, to build a Technology & Innovation Bridge between Karnataka and New South Wales. Minister for Electronics, IT & Biotechnology, Government of Karnataka, Priyank Kharge, was present at the MoU signing. The partnership aims to create structured pathways for Karnataka startups and technology companies to access global markets, investors, industry networks and innovation ecosystems. With a focus on DeepTech and emerging technologies, the collaboration will drive engagement across AI, HealthTech, Biotechnology, CleanTech, Defence & Aerospace, Quantum Computing, Digital Infrastructure, AVGC-XR and Gaming. The MoU will also strengthen connections between startups, investors, research institutions, universities and industry, creating opportunities for market access, startup mobility, research collaboration and global scale-up. This indicates a step towards connecting Karnataka's innovation ecosystem with global opportunities and enabling startups to scale beyond borders. ]]> https://biospectrumindia.com/news/104/28432/dr-moopen-family-picks-up-additional-stake-in-aster-dm-quality-care-worth-rs-350-cr.html https://biospectrumindia.com/news/104/28432/dr-moopen-family-picks-up-additional-stake-in-aster-dm-quality-care-worth-rs-350-cr.html Fri, 04 Sep 2026 20:48:28 +0530 Union (Mauritius) Holdings, owned and promoted by Dr Azad Moopen and family, has acquired 46.09 lakh equity shares of Bengaluru-based Aster DM Quality Care, representing approximately ~0.57% of the company’s paid-up equity share capital, from TPG-backed Centella Mauritius Holdings.   With the recent purchase of additional stake, the Moopen family now has increased shareholding in Aster DM Quality Care to ~24.58%. The shares were acquired on September 2, 2026, at a price of Rs 760 per share, for an aggregate consideration of approximately Rs 350.34 crore.   The acquisition further strengthens the promoter family’s ownership interest in Dr Moopen-led Aster DM Quality Care and underscores the Moopen family’s commitment to the company’s long-term growth. It also reflects the family’s confidence in the potential of the larger, integrated healthcare platform, Aster DM Quality Care, and its ability to deliver sustainable long-term value for shareholders.   Aster DM Quality Care Limited is one of India’s leading integrated healthcare providers, formed through the merger of Aster DM Healthcare Limited and Quality Care India Limited. The merged entity will bring together four leading healthcare brands - Aster DM, CARE Hospitals, Evercare and KIMSHEALTH, creating a scaled and diversified healthcare platform with a network of 39 hospitals across 28 cities and over 10,890 beds.     ]]> https://biospectrumindia.com/news/104/28426/medgenome-launches-oncotrack-mrd-to-transform-personalised-cancer-care-in-india.html https://biospectrumindia.com/news/104/28426/medgenome-launches-oncotrack-mrd-to-transform-personalised-cancer-care-in-india.html Thu, 03 Sep 2026 22:18:31 +0530 Advancing a new frontier in precision cancer care, MedGenome, India’s leading genomics‑driven diagnostics and research services company, has announced the launch of OncoTrack MRD, a personalised and Ultrasensitive NGS-based tumour‑informed Molecular Residual Disease (MRD) test. The test was unveiled at an event in Bengaluru, by leading oncologists Dr Niti Raizada, Dr Vinayak Maka, and Dr Rajeev Vijayakumar, along with Ramprasad Vedam, PhD, CEO, MedGenome Labs. The experts came together to discuss advancements in personalised cancer care in India, the importance of earlier detection of cancer relapse and the role of molecular monitoring in cancer care. MedGenome’s OncoTrackMRD is a comprehensive, personalised, tumour-informed, molecular residual disease test for patients previously diagnosed with cancer. Tailored to each patient using their own tumour tissue, the test analyses circulating tumour DNA to detect and measure residual cancer, identify potential recurrence earlier than conventional methods, and support treatment decisions. Developed in-house, its ultra-sensitive approach is designed to track tumour-specific signals, instead of relying on a generic set of mutations. OncoTrack MRD enables clinicians to monitor relapse throughout the course of cancer care through a simple, repeatable blood test that can be performed multiple times a year, as clinically appropriate. By tracking changes in tumour DNA over time, it provides insights into residual disease and treatment response and can help identify the risk of recurrence earlier. With convenient home sample collection and nationwide availability, OncoTrack MRD enables accessible, longitudinal monitoring for patients across India.    ]]> https://biospectrumindia.com/news/104/28414/medibuddy-appoints-industry-veteran-shalabh-shrivastava-as-head-of-operations.html https://biospectrumindia.com/news/104/28414/medibuddy-appoints-industry-veteran-shalabh-shrivastava-as-head-of-operations.html Wed, 02 Sep 2026 18:08:16 +0530 Bengaluru-based digital healthcare platform MediBuddy has announced the appointment of Shalabh Shrivastava as Head of Operations. The appointment strengthens the company’s leadership as it scales its healthcare offerings across enterprises, insurers and consumers. Shrivastava brings more than two decades of experience building and scaling high-volume operations across consumer technology, e-commerce, retail and consulting. Most recently, he led product, design and operations for Swiggy’s driver organisation, supporting one of India’s largest hyperlocal delivery networks.  At MediBuddy, he will focus on strengthening the systems and processes that support the company’s growing healthcare network, with an emphasis on building more effective operations, technology-led automation and the execution capabilities needed to scale. His appointment comes as MediBuddy enters a new phase of growth. The company reported its first EBITDA-positive quarter in Q4 FY26, with an annual revenue run rate exceeding Rs 1,500 crore. Online consultations also grew by more than 90% year-on-year during the quarter. Before Swiggy, he spent more than a decade at Flipkart, holding leadership roles across first-mile, last-mile and third-party logistics before becoming VP & National Head of Large & Furniture Supply Chain. During his tenure at Flipkart, he led 10X-scale transformation initiatives across the company’s small-parcel last-mile network and end-to-end volumetric supply chain. Earlier in his career, Shrivastava held roles at Reliance Retail, Cognizant and Ernst & Young, building experience across retail, consulting and investment banking. At Reliance Retail, he worked across loyalty, analytics and CRM, adding a customer and data-led dimension to his operational experience. Across these roles, Shrivastava has focused on a common challenge: building operating systems that can keep pace as businesses move from early scale to high-volume execution, while balancing efficiency, reliability and customer experience.   ]]> https://biospectrumindia.com/news/104/28405/xstep-raises-funding-from-titan-capital-to-scale-non-invasive-neurorehabilitation-platform.html https://biospectrumindia.com/news/104/28405/xstep-raises-funding-from-titan-capital-to-scale-non-invasive-neurorehabilitation-platform.html Tue, 01 Sep 2026 22:29:51 +0530 xStep, a Bengaluru-based neurotechnology startup that featured on Shark Tank India, has raised funding from Titan Capital to expand its non-invasive neurorehabilitation platform for people living with neurological disorders such as cerebral palsy, stroke, spinal cord injury and multiple sclerosis. The investment marks xStep's entry into the Titan Capital portfolio. The investment amount remains undisclosed. With the expansion of xStep, its non-invasive spinal neuromodulation platform, the company is helping India take an important step toward becoming a global hub for advanced neurorehabilitation. Neurological disorders are among the leading causes of long-term disability worldwide, yet access to advanced rehabilitation remains limited, especially in emerging markets. xStep is set on changing that by making its technology more affordable and easier to reach for patients and healthcare providers. Developed by SpineX Inc. (US) and manufactured by VIVATRONIX Tech (India), xStep combines non-invasive spinal neuromodulation with structured rehabilitation.  The funding will support commercial expansion across India, manufacturing scale-up, clinical evidence generation and regulatory work in both domestic and international markets. As part of its next phase, xStep has launched xStep One, an integrated neurorehabilitation experience centre in Bengaluru. Through a collaboration with Trexo Robotics, it has also brought the company's wearable robotic gait trainer for children to India, making xStep One one of the first centres in the country to offer both xStep spinal neuromodulation and Trexo robotic gait training within a single integrated rehabilitation programme. Over the next 12-24 months, xStep plans to build up its manufacturing, expand clinical collaborations in India and abroad, add to the evidence across neurological disorders, and keep developing technologies that connect neuroscience research with day-to-day patient care. It also plans to work more closely with clinicians, hospitals and rehabilitation centres so that this kind of care reaches more patients. ]]> https://biospectrumindia.com/news/104/28369/bioforum-the-data-masters-expands-global-footprint-with-new-office-and-gcc-in-bengaluru.html https://biospectrumindia.com/news/104/28369/bioforum-the-data-masters-expands-global-footprint-with-new-office-and-gcc-in-bengaluru.html Tue, 25 Aug 2026 15:06:12 +0530 Bioforum The Data Masters, a global biometric CRO supporting clinical development through data management, biostatistics, statistical programming, medical writing, and project management for clinical trial sponsors worldwide, has announced its expansion into India with the establishment of a local company and the opening of its new office in Bengaluru. The site is home to Bioforum's India Global Capability Centre (GCC), a strategic hub that brings together experienced clinical data managers, statistical programmers, standards experts, and technology specialists as part of the company's global delivery organization. The India GCC joins Bioforum's global operations across the United States, Europe, Colombia, and South Africa, strengthening the company's follow-the-sun delivery model and its ability to deliver clean, compliant, submission-ready clinical data around the clock. The India GCC is led by Dr Santhosh Kumar, Senior Vice President, India and Global Capability Center, who brings over 24 years of experience in the CRO and healthcare industry building and leading large-scale clinical data and global delivery organisations. The centre is expected to grow significantly over the coming year across clinical data management, statistical programming, clinical coding, validation, and other core delivery capabilities. ]]> https://biospectrumindia.com/news/104/28375/remidio-receives-us-patent-for-wearable-eye-imaging-technology.html https://biospectrumindia.com/news/104/28375/remidio-receives-us-patent-for-wearable-eye-imaging-technology.html Tue, 25 Aug 2026 18:26:43 +0530 Bengaluru-based Remidio Innovative Solutions has been granted US Patent for a 3D eye imaging technology built around a wearable form factor, smart glasses or a VR-style headset in place of a bulky slit lamp or ophthalmoscope. The device folds more than five separate exams into one. Slit lamp imaging, fundus imaging, and diffused anterior segment imaging, among others, are normally done on separate instruments, this design does all of them, and it can capture images of the eye without pupil dilation, using infrared illumination in place of the bright visible light conventional instruments rely on for a clear view of the back of the eye. That combination - no dilation, wearable rather than desk-mounted, is what makes the patent relevant to Remidio's broader Oculomics push. The retina is one of the few places in the body where blood vessels can be seen directly, non-invasively, and without radiation. This is why retinal imaging is backed by growing research and clinical validation as the best way to screen for conditions well beyond the eye, cardiovascular disease, diabetes, kidney disease, and neurodegenerative conditions among them – in a fast evolving field of research called Oculomics. A lighter, dilation-free imaging device is a step toward taking that kind of screening out of the specialist's chair and closer to the patient, and eventually, the consumer. ]]> https://biospectrumindia.com/news/104/28315/stempeutics-receives-us-patent-for-treatment-of-osteoarthritis-using-stempeucel-oa.html https://biospectrumindia.com/news/104/28315/stempeutics-receives-us-patent-for-treatment-of-osteoarthritis-using-stempeucel-oa.html Fri, 14 Aug 2026 22:08:34 +0530 Bengaluru-based Stempeutics Research, a group company of Manipal Education and Medical Group, has announced that the United States (US) Patent and Trademark Office (USPTO) has granted US Patent No. 12,661,377 for a treatment approach using its stem cell-based drug Stempeucel®-OA for osteoarthritis. The patent covers an ultrasound-guided, intra-articular treatment involving a single dose of 25 million ex vivo expanded, pooled and cultured adult bone marrow-derived mesenchymal stromal cells (Stempeucel®-OA), administered before a single injection of mid-molecular-weight hyaluronic acid. The therapy is intended to act at the cellular level, helping reduce inflammation and pain, improve joint function and support the preservation of cartilage quality in patients with Grade II and III knee osteoarthritis. The patented invention also covers methods associated with increasing levels of anti-inflammatory markers and decreasing levels of disease-progression markers in individuals with osteoarthritis. The development addresses a significant and growing clinical need, with an estimated 48.4 million people in India living with knee osteoarthritis in 2021. As the condition can progressively affect mobility, physical function and quality of life, treatment approaches aimed at addressing the underlying disease process remain an important area of clinical research. The company has filed more than 100+ patents and received over 60+ granted patents globally including US, Japan and EU.  ]]> https://biospectrumindia.com/news/104/28293/c-camp-onboards-two-dutch-medtech-startups-focusing-on-neurological-disorders-and-cardiac-health.html https://biospectrumindia.com/news/104/28293/c-camp-onboards-two-dutch-medtech-startups-focusing-on-neurological-disorders-and-cardiac-health.html Wed, 12 Aug 2026 13:13:05 +0530 Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP) has onboarded two Medtech startups from the Netherlands, positioning itself as a globally reckoning bio innovation destination. The startups are in the domains of neurological disorders and cardiac health. The move is catalysed by the Embassy of the Netherlands as a part of its commitment towards bilateral innovation bridge between the Netherlands and India that aims to promote exchange of innovators from mutual ecosystems. The agreements with the two startups were announced at C-CAMP premises in the presence of Dr Taslimarif Saiyed, C-CAMP Director-CEO and Anne Cremers, Acting Consul General of the Kingdom of the Netherlands in South India. Aikon Health, represented by founder Thiru Kanagasabapathi, has developed a modular, skin‑patch wearable for heart failure and an accompanying digital platform to capture longitudinal vital-sign and hemodynamic data that is interoperable with hospital/RPM systems. The technology can monitor clinically validated digital biomarkers and send out predictive alerts to support medication titration and reduce hospital readmissions. On the other hand, Alpha Brain Technologies, represented by Co-CEO & Tech lead, Mehrdad Seirafi, has developed a non-invasive, easy-to-wear medical device that predicts seizures before they happen, alerting the patient and caregiver ahead of time. ]]> https://biospectrumindia.com/news/104/28290/ayati-devices-raises-rs-15-cr-to-scale-ai-driven-diabetic-foot-diagnostics-platform.html https://biospectrumindia.com/news/104/28290/ayati-devices-raises-rs-15-cr-to-scale-ai-driven-diabetic-foot-diagnostics-platform.html Tue, 11 Aug 2026 15:17:14 +0530 Ayati Devices, a Bengaluru-based medical technology and device manufacturing startup developing precision diagnostic solutions for diabetic foot complications and peripheral vascular disease, has raised Rs 15 Crore in a Pre-Series A funding round led by Inflexor Ventures.  This marks the company's first institutional investment and will accelerate the commercialisation of its next-generation diagnostic technologies, expand its domestic and international presence, strengthen manufacturing capabilities, and deepen investments in research, regulatory approvals, artificial intelligence, and global talent. Ayati Devices has been incubated at IITB-SINE as part of the institute’s translational research programme. Ayati's technologies already hold regulatory clearances across major global markets, including CDSCO (India), the US FDA, CE Mark (Europe), and approvals in Sri Lanka, Malaysia, and the UAE.  The company has deployed over 10,000 devices across 30+ countries, backed by a growing international distributor network and clinical deployments at leading institutions such as Medicover Hospital and Aster Hospital.  The capital will fund Angiocam's commercialisation, expand go-to-market operations at home and abroad, strengthen manufacturing and supply chain capacity, accelerate R&D in AI-enabled diagnostics, secure further regulatory approvals, grow the IP portfolio, and build out engineering, clinical, regulatory, and global business development teams.  Looking ahead, Ayati will deepen its presence across Europe, the US, the Middle East, Southeast Asia, Australia, and Latin America through its distribution network, while evaluating direct commercial operations in key markets as demand scales. It will also expand its pay-per-test screening model across hospitals, primary care clinics, and community programmes, making preventive diagnostics far more accessible. ]]> https://biospectrumindia.com/news/104/28282/shankara-cancer-hospital-and-4basecare-partner-to-make-comprehensive-genomic-testing-more-affordable.html https://biospectrumindia.com/news/104/28282/shankara-cancer-hospital-and-4basecare-partner-to-make-comprehensive-genomic-testing-more-affordable.html Mon, 10 Aug 2026 16:37:25 +0530 4baseCare, a precision oncology company focused on making personalised cancer care accessible and affordable, has partnered with Shankara Cancer Hospital and Research Centre to strengthen its precision oncology capabilities by integrating advanced Next-Generation Sequencing (NGS)-based genomic testing into routine clinical practice. As part of the collaboration, Shankara Cancer Hospital has upgraded its molecular diagnostics laboratory with a high throughput and advanced Next Generation Sequencing platform and adopted TarGT™ Indiegene, 4baseCare's comprehensive genomic profiling assay. The test analyses over 1,200 cancer-associated genes using integrated DNA and RNA sequencing, enabling the detection of clinically actionable biomarkers that help oncologists make more informed, personalised treatment decisions. A key objective of the partnership is to make comprehensive genomic profiling more affordable and accessible. Through this initiative, TarGT™ Indiegene will be offered at a subsidised cost, allowing many more cancer patients to benefit from precision oncology who previously may not have had access due to the high cost of testing. ]]> https://biospectrumindia.com/news/104/28261/depuy-synthes-to-establish-global-capability-centre-in-bengaluru.html https://biospectrumindia.com/news/104/28261/depuy-synthes-to-establish-global-capability-centre-in-bengaluru.html Fri, 07 Aug 2026 21:19:09 +0530 Johnson & Johnson's DePuy Synthes, a global leader in orthopaedics, has announced plans to establish a new Global Capability Centre (GCC) in Bengaluru. The centre will serve as a global engine for innovation, engineering, and enterprise services. The GCC will bring together technology, data, and business capabilities to advance clinical innovation and operational excellence for patients, surgeons, and healthcare partners around the world. DePuy Synthes is working to establish the centre which will host disciplines including software development, data & AI, enterprise applications, technology services, cybersecurity and more upon launch. "India is one of the fastest-growing markets in the world for orthopaedic care, and this investment deepens our long-term commitment to patients, surgeons, and colleagues here, " said Namal Nawana, Worldwide President, DePuy Synthes. Over the next 18–24 months, DePuy Synthes expects to build a team of approximately 500 professionals in Bengaluru, with room to grow as the centre matures. The centre will be led by Nicholas Parrotta, Chief Information Officer, DePuy Synthes, with support from experienced technology leaders who will support the planning, establishment and future operations of the centre, including: Jai Ganesh, Chief Technology Officer, DePuy Synthes will provide leadership for technology engineering, architecture, infrastructure, cybersecurity engineering, and digital platforms for DePuy Synthes. Nagaraj Bhat, GCC Leader, DePuy Synthes, will assist in the establishment of local operations and its leadership team. The centre is expected to be established in phases, with initial operational activities, including recruitment beginning in August 2026. ]]> https://biospectrumindia.com/news/104/28267/karnataka-has-consistently-invested-in-creating-an-ecosystem-to-turn-innovation-into-economic-opportunity-dr-n-manjula.html https://biospectrumindia.com/news/104/28267/karnataka-has-consistently-invested-in-creating-an-ecosystem-to-turn-innovation-into-economic-opportunity-dr-n-manjula.html Fri, 07 Aug 2026 23:57:53 +0530 “Deep-tech leadership is not built by isolated breakthroughs; it is built by ecosystems that enable science to scale into solutions. Karnataka has consistently invested in creating that ecosystem—where researchers, startups, industry and government work in partnership to turn innovation into economic opportunity. Bengaluru INDIA NANO embodies that approach” said Dr N. Manjula, Secretary, Department of Electronics, IT, BT and Science & Technology, Government of Karnataka. Speaking at the concluding ceremony of Bengaluru INDIA NANO 2026, India's flagship international conference and exhibition on nanotechnology, she said “As nanotechnology converges with AI and other frontier technologies, we are committed to ensuring that Karnataka remains the place where the world’s next generation of deep-tech solutions is conceived, commercialised and scaled.” Organised by the Department of Science & Technology, Government of Karnataka, Karnataka Science & Technology Promotion Society (KSTePS) and Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), the 14th Edition of Bengaluru INDIA NANO concluded on August 5  after three days of scientific exchange, technology showcases and international collaboration. Centred around the theme "Nanotech's Next Frontier: AI & Beyond – Conceive, Converge, Commercialize," Bengaluru INDIA NANO 2026 explored the convergence of nanotechnology with artificial intelligence and other frontier technologies, while highlighting their transformative applications across semiconductors, healthcare, agriculture, energy and environmental sustainability.  The successful conclusion of the 14th edition reinforces Bengaluru INDIA NANO's role as India's premier platform for nanoscience and nanotechnology, fostering interdisciplinary research, promoting technology commercialisation, encouraging international collaboration and strengthening Karnataka's position as a global hub for advanced science, deep technology and innovation.   Narayan Kulkarni (narayan.kulkarni@mmactiv.com) ]]> https://biospectrumindia.com/news/104/28268/karnataka-to-chart-long-term-roadmap-for-nanotechnology-dr-navakanta-bhat.html https://biospectrumindia.com/news/104/28268/karnataka-to-chart-long-term-roadmap-for-nanotechnology-dr-navakanta-bhat.html Sat, 08 Aug 2026 00:01:50 +0530 Karnataka will prepare a comprehensive Vision Document to define the future of nanotechnology in the state over the next 10 to 20 years, bringing together academia, industry, startups and government to accelerate research, innovation and commercialisation. Announcing this during the valedictory session of 14th Bengaluru INDIA NANO, Dr Navakanta Bhat, Chairperson of the Vision Group on Nanotechnology, said the initiative has been undertaken at the direction of Minister for Home, Information Technology, Biotechnology and E-Governance, Priyank Kharge. “The Minister has tasked us with preparing a Vision Document that will serve as a blueprint for Karnataka’s nanotechnology ecosystem over the next decade or two. We will engage not only members of the Vision Group but also researchers, startups, industry leaders and other stakeholders to ensure the roadmap reflects collective aspirations and practical priorities,” Dr Bhat said. Inviting wider participation, he encouraged stakeholders across the ecosystem to submit ideas and recommendations that could be incorporated into the report. Highlighting Karnataka’s sustained commitment to research and innovation, Dr Bhat noted that the Department of Electronics, IT, Biotechnology and Science & Technology supports more than 100 research and development projects every year, making Karnataka one of the few states to invest consistently in cutting-edge scientific research. He also underscored the impact of the Government’s flagship ELEVATE programme, which provides non-dilutive grants to promising startups, enabling entrepreneurs to scale innovations without sacrificing equity. “The strength of Karnataka’s innovation ecosystem lies in supporting the entire journey—from research and ideas to innovation, products and commercialization. These interventions have helped position Karnataka as the country’s leading destination for advanced technologies, with nanotechnology emerging as one of the defining technologies of the future,” he said. Concluding the two-day conference, Dr Bhat thanked delegates from across India and overseas for their participation and announced that the 15th edition of Bengaluru INDIA NANO will be held from 1–3 August 2028. “We look forward to welcoming the global nanotechnology community back to Bengaluru for an even bigger and more impactful edition,” he said.   Narayan Kulkarni (narayan.kulkarni@mmactiv.com) ]]> https://biospectrumindia.com/news/104/28254/karnataka-to-lead-not-only-in-digital-technologies-but-also-in-nanotechnology.html https://biospectrumindia.com/news/104/28254/karnataka-to-lead-not-only-in-digital-technologies-but-also-in-nanotechnology.html Wed, 05 Aug 2026 12:53:53 +0530 “We want Karnataka to lead not only in digital technologies, but also in nanotechnology, advanced materials, semiconductors and deep-tech innovation,” said D K Shivakumar, Chief Minister of Karnataka. Speaking after the 14th edition of Bengaluru INDIA NANO, India's flagship international nanotechnology conference and exhibition, 3-day summit organised by the Department of Science & Technology, Government of Karnataka, Karnataka Science and Technology Promotion Society (KSTePS) and Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Shivakumar said “Karnataka has established itself as India’s technology capital, and today we are laying the foundation for the next era of scientific leadership. The future belongs to those who can translate research into real-world impact, and Bengaluru INDIA NANO demonstrates our commitment to building an ecosystem where science, industry and innovation come together to solve global challenges.” In his address Priyank Kharge, Minister for Home, IT, BT and e-Governance, government of Karnataka said “The next wave of innovation will be driven by the convergence of AI, nanotechnology, biotechnology and semiconductors. Karnataka is uniquely positioned to lead this transformation because of its strong research institutions, thriving startup ecosystem and progressive policy environment. Through platforms like Bengaluru INDIA NANO, we are accelerating the journey from scientific discovery to commercial innovation, creating technologies that are globally competitive while delivering meaningful impact for society.” Dr N. Manjula, Secretary, Department of Electronics, IT, BT and Science & Technology, government of Karnataka   said “Bengaluru INDIA NANO continues to strengthen its position as India’s premier nanotechnology platform by bringing together researchers, industry, startups and policymakers under one roof. This year’s theme, ‘Nanotech’s Next Frontier: AI & Beyond – Conceive, Converge, Commercialise,’ reflects our focus on fostering interdisciplinary collaboration and accelerating the commercialisation of breakthrough research. Our objective is to build partnerships that translate scientific excellence into scalable technologies and sustainable economic growth.” The event brings together leading scientists, researchers, industry leaders, startups, policymakers and students to accelerate research, innovation and commercialisation in nanotechnology.   Image caption- (From L-R) Priyank Kharge, Minister for Home, IT, BT and e-Governance, Government of Karnataka   and D K Shivakumar, Chief Minister of Karnataka releasing the Event Compendium of 14th edition of Bengaluru INDIA NANO on August 4, in Bengaluru ]]> https://biospectrumindia.com/news/104/28230/karnataka-strengthens-strategic-partnership-with-takeda-to-accelerate-life-sciences-innovation-and-global-capability-centre-growth.html https://biospectrumindia.com/news/104/28230/karnataka-strengthens-strategic-partnership-with-takeda-to-accelerate-life-sciences-innovation-and-global-capability-centre-growth.html Wed, 29 Jul 2026 00:00:00 +0530 The Department of Electronics, Information Technology, Biotechnology and Science & Technology (ITBT), Government of Karnataka, today hosted a senior leadership delegation from Takeda Pharmaceutical Company Limited to explore opportunities for expanding the company's Global Capability Centre (GCC) operations in Bengaluru and deepening collaboration with Karnataka's world-class life sciences and innovation ecosystem. The high-level meeting was chaired by Dr. Manjula N, IAS, Secretary, Department of ITBT & S&T, and attended by Dr. Avinash Menon Rajendran, IAS, Director, Department of ITBT, alongside senior officials from the Department, representatives from the Karnataka Digital Economy Mission (KDEM), the Centre for Cellular and Molecular Platforms (C-CAMP), and the Bangalore Bioinnovation Centre (BBC). The Takeda delegation was led by Lauren Duprey, Chief Transformation Officer, and included Malti George, Head of Global Capability Management; Tuba Erduran Ertek, Head of HR – Global Data, Digital & Technology and Finance; Tilak Banerjee, Site Lead – India Global Capability Center; Reshma Suresh, Talent Acquisition Partner; and Nara Jayaraman, India Site Coordinator – Data, Digital & Technology. The discussions focused on Karnataka's continued leadership as India's premier destination for Global Capability Centres and its growing role in enabling multinational organisations to transform GCCs into strategic centres for innovation, research and development, digital transformation, artificial intelligence, and product engineering. Speaking on the occasion, Dr. Manjula N, IAS, Secretary, Department of ITBT & S&T, Government of Karnataka, said: "Karnataka has built a globally competitive ecosystem where Global Capability Centres are increasingly driving innovation, research, and digital transformation for enterprises across sectors. Our collaborative ecosystem, supported by strong policy frameworks, world-class talent, and leading research institutions, enables global companies like Takeda to accelerate innovation and create high-value capabilities from Bengaluru." Takeda's Bengaluru Innovation Capability Center, the company's first innovation capability centre in Asia, plays a pivotal role in supporting its global operations through advanced capabilities in artificial intelligence-driven drug discovery, digital health technologies, data science, and research and development. The interaction also highlighted opportunities for closer engagement with Karnataka's thriving biotechnology ecosystem, including partnerships in talent development, translational research, innovation programmes, and digital health initiatives through organisations such as C-CAMP and the Bangalore Bioinnovation Centre. The meeting underscores Karnataka's commitment to strengthening long-term partnerships with global innovation-led enterprises and reinforcing Bengaluru's position as one of the world's leading destinations for life sciences, biotechnology, healthcare technology, and Global Capability Centres. As global pharmaceutical and healthcare companies continue to expand their innovation footprint, Karnataka remains focused on providing an enabling ecosystem that fosters research excellence, technological advancement, and sustainable economic growth through collaborative public-private partnerships. ]]> https://biospectrumindia.com/news/104/28219/karnataka-to-host-29th-edition-of-bengaluru-tech-summit-2026-on-nov-17-19-at-biec.html https://biospectrumindia.com/news/104/28219/karnataka-to-host-29th-edition-of-bengaluru-tech-summit-2026-on-nov-17-19-at-biec.html Mon, 27 Jul 2026 17:34:00 +0530 Karnataka Chief Minister DK Shivakumar has announced that the 29th edition of the Bengaluru Tech Summit (BTS 2026) will be held from 17–19 November 2026 at the Bangalore International Exhibition Centre (BIEC), with the theme "AI & Beyond." Positioned as Asia's largest technology event, BTS 2026 will build on nearly three decades of bringing together the global innovation ecosystem and is expected to attract technology leaders, entrepreneurs, investors, researchers and policymakers from across the world. Announcing the event, Shivakumar said the summit will reinforce Karnataka's leadership in technology and innovation while creating new opportunities for collaboration across emerging sectors including artificial intelligence, deeptech, electronics and semiconductors, biotechnology, startups, animation, visual effects, gaming and comics (AVGC), and other frontier technologies. One of the biggest additions to this year's summit is the co-location of the inaugural edition of embedded world India, organised in association with NuernbergMesse India. The event will feature a dedicated conference track and exhibition pavilion focused on electronics and semiconductors, reflecting India's growing ambition to become a global manufacturing and chip-design hub. The initiative is expected to strengthen collaboration between international technology companies and India's expanding semiconductor ecosystem while further enhancing Karnataka's position as a leading destination for advanced electronics manufacturing. Another new feature at BTS 2026 is the India edition of ChangeNOW, a globally recognised platform dedicated to environmental and social innovation. The co-located event will bring together innovators, startups, investors and policymakers working on sustainable technologies and climate solutions, expanding the summit's focus beyond digital transformation to include green innovation and impact-driven entrepreneurship. The summit is expected to host more than 1,800 exhibitors, 25,000 delegates, over 1,000 technology startups and more than 60,000 business visitors from 75-plus countries and 30-plus States and Union Territories, making it one of the world's largest platforms for technology, innovation and business collaboration. The three-day conference will feature multiple thematic tracks covering AI & DeepTech, FinTech, Health & Biotechnology, SpaceTech, the India–USA Tech Conclave and Global Collaboration, alongside emerging areas such as Digital Infrastructure & Data Centres, Circular Economy, Orange Economy and Electric Mobility. BTS 2026 will also showcase a large-scale multi-sector exhibition highlighting cutting-edge innovations, complemented by investor networking sessions, international business meetings and strategic partnership programmes. A major attraction for the startup ecosystem will be the Future Makers programme, designed to help high-potential startups connect with investors, mentors and global markets. The initiative will include investor pitching sessions, one-on-one mentoring clinics, startup showcases and the Future Makers Conclave, providing founders with opportunities to scale their businesses and access international networks. With artificial intelligence taking centre stage under the theme "AI & Beyond," the 2026 edition aims to strengthen Bengaluru's position as India's technology capital while showcasing Karnataka's expanding role in shaping the future of AI, semiconductors, biotechnology and sustainable innovation.   Photo caption - (L-R) Dr Kiran Mazumdar-Shaw, Chairperson, Vision Group on Biotech, Govt. of Karnataka; Priyank Kharge, Minister for Home, Electronics, Information Technology & Biotechnology and e-Governance, Government of Karnataka; D.K. Shivakumar, Chief Minister, Government of Karnataka; Sharath Kumar Bache Gowda, MLA, Hosakote Constituency and Chairman, KEONICS; and Kris Gopalakrishnan, Chairperson, Vision Group on IT, Govt. of Karnataka, during the CEO Breakfast Meet hosted by the Government of Karnataka ahead of Bengaluru Tech Summit 2026. ]]> https://biospectrumindia.com/news/104/28220/karnataka-hosts-ceo-breakfast-meet-industry-backs-stronger-collaboration-to-drive-states-next-tech-growth-phase.html https://biospectrumindia.com/news/104/28220/karnataka-hosts-ceo-breakfast-meet-industry-backs-stronger-collaboration-to-drive-states-next-tech-growth-phase.html Mon, 27 Jul 2026 17:51:07 +0530 The Karnataka Government recently brought together more than 200 technology industry leaders, entrepreneurs, investors and policymakers for its annual CEO Breakfast Meet, using the platform to engage directly with industry stakeholders on strengthening the State's innovation ecosystem and shaping the next phase of technology-led growth. The high-level interaction, was held in the presence of Chief Minister D.K. Shivakumar and Priyank Kharge, Minister for Home, Electronics, Information Technology, Biotechnology and e-Governance. The meeting reinforced the Government's collaborative approach to policymaking by seeking industry inputs on key priorities across emerging technology sectors. During the meeting, Dr Manjula N., Secretary, Department of Electronics, Information Technology, Biotechnology and Science & Technology, presented the Karnataka IT & DeepTech Landscape Progress Report 2025–26, highlighting the State's progress in technology, innovation and startup development. She outlined Karnataka's recent achievements, policy interventions and the roadmap for sustaining its leadership in the country's technology ecosystem. Industry leaders welcomed the Government's continued engagement with the private sector and acknowledged Karnataka's efforts to build a supportive innovation ecosystem. Discussions focused on maintaining the State's competitiveness in emerging sectors such as artificial intelligence, deeptech, biotechnology, electronics and semiconductors, defence and space technologies, fintech, and AVGC (Animation, Visual Effects, Gaming and Comics). The programme featured strategic perspectives from S. Gopalakrishnan (Kris), Chairperson of the Vision Group on IT, who shared his vision for strengthening Karnataka's leadership in IT and deep technologies. Dr Kiran Mazumdar-Shaw, Chairperson of the Vision Group on Biotechnology, highlighted the State's growing opportunities in biotechnology, life sciences and innovation-driven healthcare, emphasising the importance of research, entrepreneurship and industry-academia collaboration. Representatives from leading industry bodies including NASSCOM, IESA, TiE Bangalore, ABLE, IVCA and ABAI participated in an open-house discussion, bringing together CEOs, founders and innovators from IT & DeepTech, Biotech & HealthTech, Electronics & Semiconductors, Defence & Space Tech, FinTech and AVGC. Participants shared recommendations on policy reforms, talent development, infrastructure, research collaboration, startup funding and global market access to accelerate Karnataka's technology-led growth. A key outcome of the meeting was the industry's endorsement of the Government's consultative approach to policymaking. Business leaders appreciated the State's willingness to engage regularly with industry and offered recommendations to strengthen innovation, attract investments, support startups, expand research capabilities and enhance Karnataka's global competitiveness. The CEO Breakfast Meet reaffirmed Karnataka's commitment to maintaining close collaboration with industry, ensuring that future policies are aligned with evolving technology trends, business needs and the State's long-term ambition of remaining India's leading hub for innovation and advanced technologies. ]]> https://biospectrumindia.com/news/104/28221/priyank-kharge-unveils-innoverse-foundation-deeptech-programme-to-boost-karnatakas-innovation-ecosystem.html https://biospectrumindia.com/news/104/28221/priyank-kharge-unveils-innoverse-foundation-deeptech-programme-to-boost-karnatakas-innovation-ecosystem.html Mon, 27 Jul 2026 17:54:22 +0530 Karnataka Minister for Home, Electronics, Information Technology, Biotechnology and e-Governance Priyank Kharge has announced a series of new initiatives aimed at strengthening the State's deep technology ecosystem, including the launch of the Innoverse Foundation, the DeepTech Enabler Programme, and financial support for 33 promising startups under the Elevate NxT 2026 programme. The announcements underscore the State Government's continued focus on accelerating innovation, supporting DeepTech entrepreneurship and positioning Karnataka as India's leading technology and startup destination. Responding to suggestions from industry leaders, Kharge reaffirmed the Government's commitment to fostering an innovation-led economy and maintaining Karnataka's leadership as India's technology hub. "One of Karnataka's greatest strengths has been the trust and partnership we have built with industry. We believe that listening must lead to action, and every edition of this dialogue is followed by a structured roadmap with a strong focus on implementation. We remain committed to building a globally connected innovation ecosystem that drives technological leadership, entrepreneurship and inclusive growth," he said. The biggest announcement was the launch of the Innoverse Foundation, a Government of Karnataka initiative designed to position the State as a global DeepTech capital. The Foundation will mentor revenue-generating DeepTech startups, helping them move beyond product-market fit to become globally competitive companies. It will provide access to markets, capital and expert mentorship to accelerate commercialisation and business growth. The Government also announced the inaugural Open Call for the Innoverse Foundation's DeepTech Enabler Program, inviting startups to participate in the new initiative. The programme's campaign identity was unveiled alongside the launch. Another major announcement was the recognition of 33 winners of the Elevate NxT 2026 (DeepTech) programme, launched earlier this year as India's first dedicated DeepTech startup support initiative. The programme received 983 applications from startups across the country. Of the selected startups, 24 are from Bengaluru, while four are based in Hoskote, Udupi, Bidar and Hubballi. Five startups are from Delhi, Maharashtra and Telangana, and 12 of the 33 winners are women-led ventures, highlighting the increasing diversity of India's DeepTech ecosystem. Each winning startup will receive grant-in-aid ranging from Rs 85 lakh to Rs 1 crore to support research and development, product innovation and commercialisation. The programme also unveiled a preview of Bengaluru's upcoming Museum of Innovation, Startup & Technology, which will showcase Karnataka's innovation journey while promoting entrepreneurship and technological excellence. The new initiatives reflect Karnataka's strategy of complementing policy support with dedicated institutions, funding mechanisms and industry partnerships to strengthen its position as India's leading hub for DeepTech, biotechnology, advanced manufacturing and next-generation technologies. ]]> https://biospectrumindia.com/news/104/28174/medtech-firm-bioscan-research-raises-1-m-in-seed-round-for-market-expansion-.html https://biospectrumindia.com/news/104/28174/medtech-firm-bioscan-research-raises-1-m-in-seed-round-for-market-expansion-.html Wed, 22 Jul 2026 15:22:39 +0530 Bengaluru-based MedTech firm Bioscan Research, which is leveraging deeptech in optics, electronics, mechanics and software to develop, test, manufacture and commercialise affordable medical devices for early detection of brain injuries non-invasively, has raised $1 million in a seed round led by Unicorn India Ventures. The funds raised will be strategically deployed for market expansion, additional regulatory approvals, product upgradation and new IP creation. Incorporated in 2017, by Anupam Lavania and Shilpa Malik, Bioscan Research aims to improve traumatic brain injury patient outcomes via an objective assessment for early detection at a pre-symptomatic phase with the help of machine learning powered NIRS device - CEREBO. The flagship product CEREBO, is an advanced intra-cranial injury detector designed to assist in managing trauma patients, even in the absence of visible symptoms, ensuring timely intervention within the golden period. In the last 12 months the company has witnessed 5x growth and is redefining how critical conditions are identified—enabling faster clinical decisions, improved outcomes, and more accessible care worldwide. Over the next 12 months the company’s goal is to grow 3x and plans to expand in India and overseas markets. ]]> https://biospectrumindia.com/news/104/28159/bpl-medical-technologies-strengthens-respiratory-diagnostics-portfolio-with-jaeger-medical.html https://biospectrumindia.com/news/104/28159/bpl-medical-technologies-strengthens-respiratory-diagnostics-portfolio-with-jaeger-medical.html Mon, 20 Jul 2026 13:07:26 +0530 Bengaluru-based BPL Medical Technologies has announced its appointment as the authorised sales and service partner for Jaeger Medical's respiratory diagnostics portfolio in India. The appointment represents a strategic expansion of BPL MedTech's respiratory diagnostics portfolio, enabling hospitals and healthcare providers across the country to access globally trusted pulmonary diagnostics solutions supported by BPL's robust nationwide sales and service network. As respiratory diseases continue to place a growing burden on India's healthcare system, the need for accurate and timely diagnosis has become increasingly important. Through this collaboration, BPL Medical Technologies will offer Jaeger Medical's comprehensive portfolio of respiratory diagnostics solutions, including spirometry, pulmonary function testing (PFT) and cardiopulmonary exercise testing (CPET), supporting clinicians in the diagnosis, assessment and monitoring of a wide range of respiratory conditions. Germany-based Jaeger Medical's solutions are already used by leading healthcare institutions across India, including Apollo Hospitals, Manipal Hospitals, AIIMS and JIPMER. With BPL Medical Technologies now providing nationwide sales, installation, application support and after-sales service, hospitals can expect faster response times, dependable technical expertise and enhanced customer support throughout the product lifecycle. Together, Jaeger Medical's internationally trusted respiratory diagnostics portfolio and BPL Medical's pan-India reach will strengthen respiratory diagnostics capabilities across hospitals and diagnostic centres nationwide.   ]]> https://biospectrumindia.com/news/104/28119/cens-develops-advanced-ammonia-sensing-platform-to-prevent-serious-health-problems.html https://biospectrumindia.com/news/104/28119/cens-develops-advanced-ammonia-sensing-platform-to-prevent-serious-health-problems.html Tue, 14 Jul 2026 18:17:49 +0530 Researchers from the Bengaluru-based Centre for Nano and Soft Matter Sciences (CeNS), an autonomous institute of the Department of Science and Technology (DST), have developed an advanced ammonia sensing platform that is capable of detecting harmful ammonia gas even at extremely low concentrations while operating at room temperature. Ammonia is widely used in industries such as fertilizer production, refrigeration, chemical manufacturing, and agriculture. However, accidental exposure to ammonia can cause severe irritation to the eyes, skin, and respiratory system, while prolonged exposure can lead to serious health problems. Continuous and reliable monitoring of ammonia is therefore essential to ensure workplace safety, environmental protection, and public health. The sensor has been developed through a controlled surface conversion process, which creates abundant active sites for the adsorption of ammonia as well as enhances charge transport within the sensing layer.  The newly developed sensor performed exceptionally well and successfully detected extremely low ammonia concentrations such as 319 parts per billion (ppb), which is well below the recommended safety limits for commercial workplaces.  ]]> https://biospectrumindia.com/news/104/28112/forus-health-unveils-portable-digital-eye-clinic.html https://biospectrumindia.com/news/104/28112/forus-health-unveils-portable-digital-eye-clinic.html Mon, 13 Jul 2026 17:19:15 +0530 Forus Health, a Bengaluru-based health technology company focused on transforming eye care through innovation, has announced the launch of FH Eyepal, a portable Digital Eye Clinic that enables healthcare providers to deliver comprehensive eye examinations beyond conventional hospital settings. Developed to make quality eye care more accessible, FH eyepal transforms virtually any location into a fully equipped eye screening clinic within minutes. Designed as a compact, portable solution, it can be deployed across primary healthcare centres, community health programmes, corporate wellness initiatives, vision camps, and home based care, bringing quality eye care closer to the people who need it. Powered by FH POISE, Forus Health's proprietary artificial intelligence (AI) platform, retinal images are analysed instantly to identify potential abnormalities and support timely clinical decision making. By combining intelligent diagnostics with a connected digital workflow, FH eyepal helps improve screening efficiency, enables early detection of eye conditions and supports better continuity of care. Designed for flexible deployment across diverse healthcare settings, FH eyepal empowers healthcare providers to expand screening programmes, improve operational efficiency and deliver specialist-quality eye care to every community without the need for permanent clinical infrastructure. ]]> https://biospectrumindia.com/news/104/28114/hai-conclave-2026-calls-for-responsible-adoption-of-ai-across-indias-healthcare-ecosystem.html https://biospectrumindia.com/news/104/28114/hai-conclave-2026-calls-for-responsible-adoption-of-ai-across-indias-healthcare-ecosystem.html Mon, 13 Jul 2026 17:59:11 +0530 HAI Conclave 2026, held on 10 and 11 July 2026 in Bengaluru, concluded with more than 800 participants, new collaborations between healthcare providers, AI innovators and startups, and a shared call for responsible adoption of Artificial Intelligence across India's healthcare ecosystem. Hosted by Global Healthcare Academy (GHA), the two-day conclave brought together clinicians, researchers, healthcare leaders, policymakers, technology companies, startups and investors to explore how Artificial Intelligence is moving from innovation to real-world healthcare applications while keeping patient outcomes and clinical expertise at the centre. Held under the theme "Building Future-Ready Health Ecosystems," the conclave featured five scientific tracks covering AI in Drug Discovery, AI in Preventive Medicine, AI in Treatment, AI in Health Informatics and AI in Diagnostics. Across more than 40 keynote sessions, panel discussions and case-based presentations, experts showcased how AI is already transforming healthcare through faster drug discovery, earlier diagnosis, clinical decision support, precision medicine, improved workflows and expanded access to quality care. The conclave featured participation from 100+ speakers across healthcare, technology, academia and industry, highlighting practical applications of AI and reinforcing the importance of ethical implementation, clinical relevance and collaboration between healthcare professionals and technology innovators. A major highlight was The Pitch Dock, the dedicated Health AI startup pavilion that enabled startups to connect directly with hospital leaders, investors, technology partners and decision-makers. The platform accelerated conversations around adoption, partnerships and future investment while creating opportunities for real-world implementation of emerging healthcare solutions. Adding to the conclave's key milestones, the Global Surgical Institute (GSI), part of the Global Healthcare Academy ecosystem, unveiled ALEX, an AI-powered Patient Communication Simulator. Designed to strengthen clinical reasoning, communication and decision-making through immersive simulation, the launch reflects GHA's continued commitment to advancing AI-enabled healthcare education and preparing future-ready healthcare professionals. The conclave also featured a dedicated roundtable with Vice Chancellors from across different states, focusing on the role of Artificial Intelligence in strengthening India's education ecosystem. The discussion explored opportunities to integrate AI into healthcare education, build future-ready professionals and create responsible frameworks to prepare the next generation of healthcare leaders. Dr B. S. Ajaikumar, Executive Chairman, Global Healthcare Academy, said, "What we witnessed over the past two days was not simply interest in Artificial Intelligence, but genuine collaboration between healthcare and technology. The coming together of clinicians, researchers, innovators and policymakers reflects a shared commitment to ensuring that AI is developed and adopted responsibly to create meaningful impact for patients." Anitha Niranjan, Managing Director, Global Healthcare Academy, said, "HAI Conclave was envisioned as a platform where healthcare, technology and policy could come together to shape the future of health. The conversations started here should continue through partnerships, research, education and implementation, creating a connected Health AI ecosystem that drives meaningful change beyond the conclave." As conversations concluded, one message resonated across HAI Conclave 2026: The future of healthcare will not be shaped by technology alone, but by meaningful collaboration between clinicians, researchers, innovators, startups, investors and policymakers working together to improve patient care. By bringing together diverse stakeholders from across the healthcare and technology ecosystem, HAI Conclave 2026 has strengthened the foundation for a more connected, responsible and future-ready Health AI landscape. ]]> https://biospectrumindia.com/news/104/28098/enlife-research-secures-rs-6-cr-to-advance-ai-powered-blood-biomarker-platform-for-detecting-alzheimers-disease.html https://biospectrumindia.com/news/104/28098/enlife-research-secures-rs-6-cr-to-advance-ai-powered-blood-biomarker-platform-for-detecting-alzheimers-disease.html Thu, 09 Jul 2026 18:54:47 +0530 eNLife Research, a Bengaluru-based deep tech startup incubated at Foundation for Science Innovation and Development (FSID), Indian Institute of Science, is building an affordable, AI-driven diagnostic platform for Alzheimer's disease (AD) and other neurodegenerative diseases. The company has raised Rs 6 crore in a seed funding round led by Piper Serica VC Fund. The capital will be deployed to build and validate eNLife's blood-based biomarker platform, expand its Bengaluru-based R&D team, and take the company's first diagnostic assay from prototype to clinical-grade validation. eNLife is working towards making early Alzheimer's detection accessible to patients in India years before conventional diagnostics can identify the disease. The startup is developing a blood test that screens for a panel of 5 to 7 biomarkers linked to onset of AD like amyloid beta and detrimental forms of tau, the two hallmark proteins associated with Alzheimer's pathology. It is also designing next-generation assays capable of simultaneously tracking 25 to 100 biological markers to identify multiple forms of dementia and other neurodegenerative diseases years before the onset of clinical symptoms. The company is currently collaborating with researchers associated with leading institutions, including the Indian Institute of Science (IISc), the National Institute of Mental Health and Neurosciences (NIMHANS), the Tata Institute of Fundamental Research (TIFR), Hyderabad, and the Centre for Brain Research (CBR), Bengaluru, to develop India-specific biomarker datasets. ]]> https://biospectrumindia.com/news/104/28100/fibroheal-raises-rs-14-cr-to-expand-advanced-wound-care-technology.html https://biospectrumindia.com/news/104/28100/fibroheal-raises-rs-14-cr-to-expand-advanced-wound-care-technology.html Thu, 09 Jul 2026 22:19:05 +0530 Bengaluru-based Fibroheal Woundcare has successfully raised Rs 14 crore in fresh capital to accelerate its next phase of growth and expand into developed global markets. Founded with a vision to transform wound care through silk protein-based biomaterial innovations, Fibroheal has emerged as one of India's promising MedTech companies. The fresh investment will enable the company to strengthen its commercial capabilities, expand internationally, and accelerate the development of breakthrough biomaterial-based healthcare solutions. This milestone reflects not only the confidence of its investors but also the strength of India's innovation ecosystem in creating globally competitive healthcare technologies. With plans to enter developed markets and launch next-generation biomaterial products, Fibroheal is well positioned to make a significant global impact in the MedTech sector. The company is working towards bringing two game changing products – Fibroplug ORC – a bioresorbable material to arrest internal bleeding post surgeries; and a bone regenerative solution for infected bone injuries and other complex orthopaedic recoveries and is expected to launch in FY 2027. ]]> https://biospectrumindia.com/news/104/28082/novo-nordisk-gbs-and-mahe-to-advance-pharmacometrics-research-and-talent-development-in-india.html https://biospectrumindia.com/news/104/28082/novo-nordisk-gbs-and-mahe-to-advance-pharmacometrics-research-and-talent-development-in-india.html Wed, 08 Jul 2026 19:46:20 +0530 Bengaluru-based Novo Nordisk Global Business Services (GBS) and the Manipal Academy of Higher Education (MAHE) have expanded their long-standing collaboration to strengthen India's capabilities in pharmacometrics, a specialised scientific discipline that uses data, modelling and simulation to support drug development and clinical decision-making. As part of this collaboration, Novo Nordisk GBS is set to provide financial support of Rs 1.75 crore over five years to support the growing need for specialised talent, research capacity and advanced infrastructure in quantitative drug development. As medicines become increasingly complex and data-driven, pharmacometrics is playing a critical role in improving clinical trial design, understanding treatment responses across patient populations and supporting more informed drug development decisions. A key focus of the collaboration will be the establishment of an advanced pharmacometrics computing facility at MAHE, aimed at supporting research, training and scientific collaboration in the field. The initiative will also support one full-time PhD scholar and one post-doctoral fellow annually, helping create a specialised talent pipeline for quantitative drug development and clinical pharmacology. In addition, four to six specialised learning modules will be introduced under the theme Innovation for Quantitative Drug Development. These modules will cover areas such as Model-Informed Drug Development (MIDD), systems modelling approaches and translational frameworks for emerging therapeutic modalities, including cell and gene therapies and multi-specific therapies. The collaboration seeks to create greater opportunities for researchers and students to engage with real-world drug development challenges while strengthening India's participation in a field that is becoming increasingly important to global pharmaceutical innovation.   ]]> https://biospectrumindia.com/news/104/28085/strand-life-sciences-secures-indian-patent-for-blood-based-early-cancer-detection-technology.html https://biospectrumindia.com/news/104/28085/strand-life-sciences-secures-indian-patent-for-blood-based-early-cancer-detection-technology.html Wed, 08 Jul 2026 21:44:20 +0530 Bengaluru-based Strand Life Sciences has announced the grant of an Indian patent covering its integrated platform for early cancer detection using cell-free DNA (cfDNA) analysis. The patented platform brings together high-quality sequencing, rigorous quality control, biologically informed methylation and fragmentomic feature extraction, and machine learning to enable cancer detection and tissue-of-origin prediction from just a blood sample. Widespread methylation pattern changes across the genome are a hallmark of cancer. A key innovation in the patent, among others, is obtaining these methylation patterns using genome sequencing with minimal loss or failure, thus enabling sensitive early cancer detection.  "We believe this innovation represents an important step towards making precision cancer screening more accurate, scalable, and accessible," said Ramesh Hariharan, CEO, Strand Life Sciences.  The granted patent further strengthens the company's intellectual property portfolio in liquid biopsy and reinforces its strategy of developing integrated, AI-enabled molecular approaches for early cancer detection and precision oncology. ]]> https://biospectrumindia.com/news/104/28080/iisc-explores-use-of-ultrasound-to-attack-oral-cancer-cells.html https://biospectrumindia.com/news/104/28080/iisc-explores-use-of-ultrasound-to-attack-oral-cancer-cells.html Tue, 07 Jul 2026 20:56:58 +0530 Oral cancer is a major health challenge in India, where tobacco and areca nut use contribute substantially to the disease burden. Despite advances in surgery, chemotherapy, and radiotherapy, treatment remains difficult because current approaches can damage healthy tissues along with cancer cells, often affecting patients’ quality of life. In a new study, researchers at the Indian Institute of Science (IISc), in collaboration with clinicians at MS Ramaiah Medical College and Hospitals, Bengaluru, explored whether low-frequency ultrasound mechanical stimulation could selectively kill oral cancer cells. The team worked with patient-derived oral tumour samples that better reflect variations among Indian patients. The team found that oral cancer cells are surprisingly vulnerable to the moderate mechanical stimulations produced by ultrasound. This vulnerability appears to arise from reduced levels of Tropomyosin 2.1, a mechanosensory protein that helps body cells sense and withstand physiologically relevant mechanical stimulation. When exposed to ultrasound-driven mechanical stimulation, oral cancer cells underwent selective cell death, while healthy oral epithelial cells remained unharmed. The team also found that ultrasound drastically reduces the cancer cells’ ability to migrate and invade surrounding tissue. “The clinical collaboration was very important because it allowed us to work with patient-derived oral tumour samples rather than relying only on standard cell lines developed in Western countries,” said the researchers. “In the future, we want to test this approach in more physiologically relevant models and explore whether ultrasound can be combined with existing treatments to improve drug penetration and therapeutic outcomes.” ]]> https://biospectrumindia.com/news/104/28066/santaana-fertility-to-expand-network-across-bengaluru-with-investment-of-rs-50-cr.html https://biospectrumindia.com/news/104/28066/santaana-fertility-to-expand-network-across-bengaluru-with-investment-of-rs-50-cr.html Fri, 03 Jul 2026 03:12:04 +0530 Santaana Fertility is partnering with Magnet Hospitals, marking a new phase in the fertility chain’s journey. Under this partnership, an investment of Rs 50 crore will enable Santaana Fertility to scale into a network of 8 centres across Bengaluru. Founded on the clinical legacy of Dr Kamini Rao, Padmashri awardee, one of India’s pioneers in reproductive medicine, Santaana Fertility seeks to redefine fertility care by prioritising personalized & evidence-based treatment, and improved patient outcomes. This partnership allows Santaana Fertility to leverage Magnet Hospitals’ integrated, hospital-linked model to strengthen capabilities and expand patient access while building on its strong clinical foundation. The network will continue to follow a personalised and evidence based approach to IVF by identifying the root cause of infertility through comprehensive evaluations, including genetic testing, reproductive immunology, and male fertility diagnostics. This approach is designed to improve first cycle success rates while reducing unnecessary interventions, emotional burden, and long-term costs for patients. Santaana Fertility will retain complete clinical autonomy, with all medical decisions, ethical boundaries, and patient protocols driven exclusively by its clinical custodians. By institutionalising the multigenerational clinical competency of Dr Kamini Rao & Dr Vyshnavi Rao, the network aims to ensure consistent standards of care and outcomes across all centres. Recognising that fertility is both a medical and emotional journey, the network will continue to integrate counselling and financial guidance into its care model, helping patients navigate treatment with confidence and support. ]]> https://biospectrumindia.com/news/104/28051/mykare-ai-raises-3-2-m-to-address-healthcare-accessibility-and-gaps.html https://biospectrumindia.com/news/104/28051/mykare-ai-raises-3-2-m-to-address-healthcare-accessibility-and-gaps.html Tue, 30 Jun 2026 18:52:51 +0530 Bengaluru-based startup Mykare.ai has raised a total of $3.2 million, including an additional $1 million in its latest funding round. The round included participation from Andrew and Alfredo, founders of Papa.com, and a leading family office from the Middle East. At a time when investors are pouring billions into AI startups promising to revolutionise healthcare with futuristic technologies, Mykare.ai is focused on a far more fundamental problem: helping clinics and hospitals improve patient access, engagement and overall experience through better operational efficiency.     The startup is building an AI-native healthcare operating system that helps clinics and hospitals grow by automating the entire patient journey, from patient acquisition and appointment booking to follow-ups, feedback, and retention. Founded by Senu Sam, Mykare.ai aims to help healthcare providers scale with a single intelligent AI layer that works across fragmented systems. Its AI agents can acquire new patients, identify patient intent, answer calls through voice agents, book appointments, manage follow-ups, collect feedback, and automatically update CRM records, creating a unified patient journey. Mykare has expanded across the United States, United Kingdom, Middle East, and India, and currently has a waiting list of more than 20 hospitals and healthcare providers. The new funding will be used to enhance Mykare’s AI capabilities, accelerate product development, and support global expansion. ]]> https://biospectrumindia.com/news/104/28039/merck-inaugurates-global-capability-centre-in-bengaluru.html https://biospectrumindia.com/news/104/28039/merck-inaugurates-global-capability-centre-in-bengaluru.html Mon, 29 Jun 2026 15:41:02 +0530 Merck, a science and technology company, has opened Merck Global Capability Centre (MGCC) in Electronic City, Bengaluru, bringing together its existing India technology and services operations.   The integrated campus will house ~3300 professionals from across the company’s data, digital, process, and technology functions, further strengthening collaboration and innovation across businesses. Purpose-built across 17,000 sq.m. at the heart of Bengaluru's technology corridor, the campus features innovation labs, neurodiversity zones and collaborative workspaces designed to attract the best technical minds and enable them to do their finest work. The state-of-the-art campus marks a significant milestone in Merck India’s journey to foster greater integration, agility, and innovation through a more connected and future-ready workplace. At the heart of the new centre is Digital Enterprise Solutions (DES). As the organisation responsible for process optimization, enterprise platforms, data and AI, technology infrastructure, hyperautomation and process excellence, DES enables Merck to operate as one connected digital enterprise rather than a collection of siloed functions. The Bengaluru campus also houses business technologies, teams focused on digital innovation for Merck’s Life Science, Healthcare and Electronics businesses. Together, these capabilities create a cross-functional centre of excellence spanning AI, analytics, automation and enterprise technology to support innovation across healthcare, life science and electronics. The MGCC reinforces India’s growing role in Merck’s global innovation ecosystem, with the country now serving as the company’s fourth-largest workforce hub after Germany, the United States and China. ]]> https://biospectrumindia.com/news/104/28036/strides-pharma-sells-stake-in-subsidiary-pivot-path-to-ascent-capital-for-rs-100-cr.html https://biospectrumindia.com/news/104/28036/strides-pharma-sells-stake-in-subsidiary-pivot-path-to-ascent-capital-for-rs-100-cr.html Sun, 28 Jun 2026 18:16:07 +0530 Bengaluru-based Strides Pharma Science has announced a strategic investment by a consortium led by Ascent Capital, along with co-investor Vintage Classic, in its wholly owned subsidiary, Pivot Path. The transaction values Pivot Path at ~Rs 230 crore on a post-money basis, enables Strides to realise Rs 100 crore while retaining a ~20% stake, and includes a primary capital infusion of Rs 50 crore to accelerate Pivot Path's next phase of growth. The transaction reflects Strides' strategy of creating, scaling and unlocking value from high-potential businesses while retaining participation in their future growth. It also strengthens the company's balance sheet and provides growth capital for Pivot Path to pursue its expansion strategy. Pivot Path originated within Arco Lab, Strides' Global Capability Centre (GCC), where it developed capabilities across life sciences consulting, digital transformation, quality and compliance, and technology-enabled operational services. As demand from external pharmaceutical and life sciences companies grew, the business evolved into an independent platform serving industry-leading customers. To support its next phase of growth, serve global customers effectively, build agentic-AI platforms, and enable access to external capital, the business was carved out into Pivot Path pursuant to a Scheme of Arrangement approved by the National Company Law Tribunal (NCLT) in May 2026. Following completion of the transaction Pivot Path shall be reclassified as an Associate of the Company. Pivot Path has established a profitable operating platform serving specialised, high-value segments within the life sciences industry. For FY26, the carved-out business reported revenue of Rs 144.7 crore (including revenues for services rendered to Strides) and EBITDA of Rs 16.9 crore, demonstrating its operating scale and growth trajectory.   ]]> https://biospectrumindia.com/news/104/28028/shilpa-biologicals-announces-commission-of-adc-gmp-facility-in-dharwad.html https://biospectrumindia.com/news/104/28028/shilpa-biologicals-announces-commission-of-adc-gmp-facility-in-dharwad.html Thu, 25 Jun 2026 19:31:57 +0530 Shilpa Biologicals, a subsidiary of Shilpa Medicare, has announced the commissioning of a state-of-the-art Antibody–Drug Conjugate (ADC) GMP manufacturing facility in Dharwad, purpose-built and designed to meet global regulatory approval standards including US FDA, EMA, and other major health authority requirements. The facility is fully operational, with GMP qualification protocols now actively underway, placing Shilpa on a clear path to commercial readiness. This commissioning marks a natural and powerful evolution of Shilpa Medicare’s over 25 years of deep-rooted expertise in highly potent compound manufacturing. Since its early years, Shilpa has built one of India’s most robust high potency API platforms — a discipline demanding the most exacting standards of containment, safety engineering, process rigour, and regulatory compliance.  Sridevi Khambhampaty, CEO, Shilpa Biologicals commented, “The manufacturing of highly potent compounds has been a core pillar of Shilpa’s identity and this ADC drug substance facility adds a new sophisticated dimension to the capabilities of the Shilpa group, we now offer global biotech and pharma partners a uniquely integrated ADC facility built with the knowledge of our existing high potency manufacturing excellence.” With this commissioning, Shilpa Medicare becomes one of the very few companies in India to offer fully integrated, end-to-end ADC drug substance development and manufacturing — encompassing payload synthesis, linker development and manufacturing, monoclonal antibody production, ADC conjugation, and purification of GMP-scale drug substance. The manufacture of ADC drug substance demands specialised cytotoxic payload containment, precise conjugation chemistry, and rigorous biologic purification — all within a GMP-validated environment.  This positions Shilpa as a compelling, cost-competitive CDMO partner for global pharmaceutical and biotech companies seeking high-quality, integrated ADC drug substance solutions.   ]]> https://biospectrumindia.com/news/104/27998/karnataka-govt-strengthens-innovation-ecosystem-with-new-investments.html https://biospectrumindia.com/news/104/27998/karnataka-govt-strengthens-innovation-ecosystem-with-new-investments.html Sat, 20 Jun 2026 22:30:45 +0530 Karnataka is strengthening startup ecosystems beyond Bengaluru through strategic investments in regional innovation infrastructure and entrepreneurship support.With an investment of Rs 9.51 crore, the K-Combinator Accelerator in Mangaluru will provide early-stage startups with access to mentorship, industry networks, market opportunities, and growth support, further advancing innovation-led development across the State. According to the Global Startup Ecosystem Report (GSER) 2026, one of the world’s most authoritative benchmarks for startup ecosystems, based on data from 5.5 M+ companies across 350+ innovation ecosystems, Karnataka stands at no. 15 out of the top 40 global startup ecosystems. Karnataka continues to invest in the infrastructure that enables scientific discovery, innovation, and translational research.With an investment of Rs 6.8 crore at the Centre for Human Genetics, Bengaluru, the Government of Karnataka is strengthening capabilities in advanced biotechnology research, supporting emerging areas such as genomics, gene therapy, and life sciences innovation.These investments are critical to fostering world-class research ecosystems and reinforcing Karnataka’s position as India’s biotechnology capital. ]]> https://biospectrumindia.com/news/104/27963/autovrse-raises-2-4-m-to-transform-ai-powered-training-for-global-pharma-and-medtech-sectors.html https://biospectrumindia.com/news/104/27963/autovrse-raises-2-4-m-to-transform-ai-powered-training-for-global-pharma-and-medtech-sectors.html Mon, 15 Jun 2026 15:56:24 +0530 Bengaluru-based AutoVRse, India’s fastest-growing industrial AI transformation platform, has announced a $2.4 million funding round, co-led by Singularity AMC's Large Value Fund III and Early Opportunities Fund, and existing investor Lumikai, India's leading interactive media, digital platforms and games VC. AutoVRse deploys VR-based training and smart-glasses-enabled field guidance across pharmaceuticals, medical devices and healthcare. The company serves 500,000+ users at more than 50 enterprise customers across North America, Europe, the GCC and India, including five out of the Top-12 pharmaceutical companies globally (by market cap), one of the largest medical device manufacturers in the world, and several other major companies such as Intas, Abbott, Panasonic etc.  The company's platform, VRseBuilder, works directly with an enterprise's own domain experts — QA leads, cleanroom technicians, clinical applications specialists — to capture their procedural knowledge in a structured, machine-readable format. Every module is authored, reviewed and validated by these subject-matter experts (SME), ensuring that the AI layer is grounded in verified expert knowledge rather than generalised data. The result is an enterprise-grade "AI Brain": a continuously enriched knowledge layer that converts siloed expertise into structured operational intelligence accessible to every technician, field service engineer and researcher — exactly when they need it, in context, and on the device they are using. The new capital raised will be used to fund compliance certifications — critical in regulated healthcare environments operating under GMP, QSR and ISO frameworks — and deepen integrations with customer infrastructure including learning management (LMS) and quality management (QMS) systems. The company also intends to scale its go-to-market in North America, where it is already running deployments with several Fortune 500 companies, and further expand its presence in Europe, the GCC and India. ]]> https://biospectrumindia.com/news/104/27967/lumos-health-advisory-opens-applications-for-second-cohort-of-early-stage-startups.html https://biospectrumindia.com/news/104/27967/lumos-health-advisory-opens-applications-for-second-cohort-of-early-stage-startups.html Mon, 15 Jun 2026 16:20:50 +0530 Bengaluru-based Lumos Health Advisory has officially opened applications for its second cohort of early-stage healthcare startups. The startups working in high-impact healthtech and medtech domains are invited to apply before the application deadline of 25 June 2026. Lumos Health is powered by a strategic partnership between Anjali Ajaikumar, Director of HCG and Anthill Ventures, a global $100 million fund with strong investor and business networks spanning India, USA and Singapore. Together, they offer participating startups an unmatched combination of clinical infrastructure and commercial scale. This initiative is open to startups from across the globe. Through Lumos Health's partner hospital network and various partner, startups gain access to clinical trial support and real-world validation - enabling them to reach market significantly faster than through conventional routes. Accepted startups benefit from a comprehensive package of support including regulatory navigation, market access, clinical validation, capital and funding, expert mentorship, cohort sessions along with Infrastructure support. Solutions leveraging IoT-enabled remote monitoring, artificial intelligence and predictive analytics, self-testing, image-based pathology, blockchain, and medical big data are also strongly encouraged to apply. The first cohort of Lumos Health demonstrated the programme's potential to unlock synergies between innovative startups and the broader healthcare ecosystem. Alumni include companies such as ErlySign, RayIoT, KroniKare, AyuRhythm, Deep Holistics - all having benefited from Lumos Health’s clinical networks and Anthill's investor relationships. Lumos sits at a critical intersection - between seed stage and early expansion - where founders need the most hands-on support and the programme is designed precisely for that inflection point. In the past, Lumos has reviewed 500+ startups, had 350+ applications, and accepted 8 startups into its portfolio. ]]> https://biospectrumindia.com/news/104/27958/ian-angel-fund-leads-rs-8-cr-funding-round-in-bengaluru-based-startup-biodimension.html https://biospectrumindia.com/news/104/27958/ian-angel-fund-leads-rs-8-cr-funding-round-in-bengaluru-based-startup-biodimension.html Sun, 14 Jun 2026 13:05:57 +0530 IAN Angel Fund, the evergreen fund of IAN Group, has led a Rs 8 crore funding round in Biodimension, a Bengaluru-based life sciences startup specialising in New Approach Methodologies (NAMs) and tissue engineering. Existing investor Campus Angels Network, Dr Sampath Srisailam, also participated in the round along with other angel investors like Aaryan Baid. The fresh capital will be utilised to accelerate product development, expand laboratory infrastructure, strengthen scientific and commercial teams, and drive product commercialisation in India and international markets. Founded by Manojkumar S., Ranjith Kumar Velusamy, and Pradeep Arunachalam, Biodimension is building biofabricated human tissue and organoid models as ethical, human-relevant alternatives to animal testing. The company’s solutions help pharmaceutical, biotechnology, and cosmetic companies generate more predictive human data, enabling faster and more reliable decision-making across research, safety testing, and product development. Despite being one of the world’s largest pharmaceutical manufacturing hubs, India remains dependent on imported human tissue models and testing systems. Biodimension is addressing this gap through locally developed and manufactured alternatives that align with emerging global regulatory standards while offering significantly lower costs and faster access for researchers and industry. BioDimension’s portfolio includes BioDEpi, a reconstructed human epidermis model for safety and toxicity testing; BioDFT, a full-thickness human skin model that closely replicates real skin biology; BioDPigma, a pigmented skin model designed for advanced dermatological and cosmetic research; the Pan-Cancer Tumour Microenvironment (TME) Biobank, which supports cancer drug discovery and translational research; and BaaS (Bioassay as a Service), enabling pharmaceutical, biotechnology, and cosmetic companies to access validated human-relevant testing solutions on demand. Biodimension has already established collaborations with pharmaceutical companies, biotechnology firms, research institutions, and contract research organisations across India and Singapore. Looking ahead, Biodimension plans to expand its Pan-Cancer Tumour Microenvironment Biobank, introduce additional oncology and immunotherapy research models, and strengthen its Bioassay-as-a-Service platform. The company also aims to expand across Southeast Asia while building partnerships in Europe, the United States, and Japan. ]]> https://biospectrumindia.com/news/104/27941/4basecare-announces-close-of-series-b-round-at-rs-128-cr.html https://biospectrumindia.com/news/104/27941/4basecare-announces-close-of-series-b-round-at-rs-128-cr.html Thu, 11 Jun 2026 16:34:55 +0530 Bengaluru-based startup 4baseCare has raised a total of Rs 128 crore ($13.3 million) in funding, co-led by investors Ashish Kacholia and Lashit Sanghvi, with participation from existing backers Yali Capital, Infosys & growX ventures.This helps spearhead plans to expand the startup's hospital-linked genomics lab network across India, the Middle East, Southeast Asia, Latin America, and Central Asia. A significant portion of the capital will be utilised to scale its AI-driven precision oncology platform OncoTwin, to help oncologists derive treatment insights using clinico-genomic and real-world patient data.    ]]> https://biospectrumindia.com/news/104/27942/ihh-healthcare-collaborates-with-infosys-for-ai-powered-erp-transformation.html https://biospectrumindia.com/news/104/27942/ihh-healthcare-collaborates-with-infosys-for-ai-powered-erp-transformation.html Thu, 11 Jun 2026 16:39:39 +0530 Bengaluru-based tech giant Infosys, a global leader in AI first business consulting and technology services, has announced a strategic collaboration with IHH Healthcare, one of the world’s largest private healthcare providers, to drive a multi year, enterprise wide Enterprise Resource Planning (ERP) transformation programme. This collaboration will enable IHH to standardise and harmonise business processes across all its markets starting with Hong Kong, Malaysia, and Singapore. It will help streamline operations, enhance agility and scalability, optimise costs, and strengthen regulatory compliance. The collaboration brings together Infosys’ AI first capabilities through Infosys Topaz, an AI-first offering powered by generative and agentic AI technologies, to embed intelligence into IHH’s core business workflows. This approach will help IHH unlock AI-powered business value at scale. Infosys will help consolidate IHH’s legacy, siloed ERP landscape by integrating critical functions such as finance, procurement, supply chain, human capital management, and enterprise performance management. As part of this transformation, IHH will gain enhanced real-time data visibility and decision intelligence, strengthening its ability to drive faster, and insight-led decision-making. By establishing a centralised, digital enterprise foundation, Infosys will support IHH’s journey toward a more connected, data-driven, and future-ready healthcare ecosystem. ]]> https://biospectrumindia.com/news/104/27935/remidio-receives-grant-from-gates-foundation-to-advance-maternal-healthcare.html https://biospectrumindia.com/news/104/27935/remidio-receives-grant-from-gates-foundation-to-advance-maternal-healthcare.html Wed, 10 Jun 2026 11:58:05 +0530 Bengaluru-based Remidio Innovative Solutions has received a grant from the Gates Foundation to advance its Oculomics platform, which uses retinal imaging and AI to detect signs of systemic disease, for maternal health applications in low- and middle-income countries (LMICs). The initiative will focus on improving early risk assessment for major pregnancy complications, including pre-eclampsia (PE), anemia and gestational diabetes mellitus (GDM). The program will be carried out across countries in Africa and India, regions that together bear the overwhelming share of the global maternal and perinatal disease burden. "The women most at risk from pre-eclampsia and gestational diabetes are often the least likely to reach a laboratory or a specialist in time," said Dr Anand Sivaraman, Chief Executive Officer and Founding Director, Remidio. "A retinal image takes seconds and can be captured by a frontline worker with minimal training. This grant allows us to ask a clear question with real rigour: can the platform already deployed widely for diabetic retinopathy also help identify pregnancies at risk, in the places where that information is needed most." The biological link between retinal microvascular changes and systemic vascular and metabolic disease is now well established. Yet in the primary care and community settings where maternal mortality is concentrated, the diagnostic tools that currently support early risk stratification, namely complex laboratory assays, biochemical biomarkers and Doppler-based assessments, are largely unavailable at the point of care, requiring laboratory infrastructure, trained personnel and referral pathways that simply do not exist for most pregnant women in LMICs. Non-invasive retinal imaging, by contrast, is quick, easy to perform by frontline health workers with minimal training, and inherently scalable, making it uniquely suited to bringing advanced risk assessment to the front lines of antenatal care. Remidio's portable, smartphone-based retinal imaging platform is already widely deployed across primary care and community screening programmes for diabetic retinopathy, glaucoma and AMD. The grant will extend this platform into maternal health, with implementation across partner sites in Africa and India. ]]> https://biospectrumindia.com/news/104/27940/hoola-health-raises-5-m-to-expand-child-first-paediatric-healthcare-across-india.html https://biospectrumindia.com/news/104/27940/hoola-health-raises-5-m-to-expand-child-first-paediatric-healthcare-across-india.html Wed, 10 Jun 2026 22:00:52 +0530 Bengaluru-based startup Hoola Health, formerly known as BabyMD, India’s first holistic paediatric healthcare brand, has raised $5 million in funding, led by Peak XV’s Surge, with participation from existing investor W Health Ventures, doubling down on its commitment to the company, and angel investors including Ashish Gupta, Abhishek Goyal, Bijou Kurien, and other individual investors. The capital will be used to support expansion into new markets, strengthen technology capabilities and scale Hoola Health’s integrated care model.   Paediatric care in India has remained largely unchanged for decades, even as expectations around accessibility, infrastructure and holistic support have evolved. Young families are increasingly navigating parenthood without traditional support systems and with limited trusted options for ongoing paediatric and developmental care. Hoola Health aims to address these gaps through paediatric care designed around children, with a focus on convenience, trust and long-term support for the parent. The company currently provides primary and developmental paediatric care spanning consultations, vaccinations, diagnostics, therapies and specialist support, with plans to expand into additional areas including paediatric dental care.  The announcement also marks the company’s transition from BabyMD to Hoola Health, reflecting a broader ambition to serve children across multiple stages of growth. Since launching its first clinic in 2024, Hoola Health has expanded to five clinics in Bengaluru and served over 20,000 families in just 18 months.  Over the next two years, the company plans to open 30 additional clinics across Bengaluru, Hyderabad and Delhi NCR, while continuing to invest in specialist services, technology infrastructure and parent-focused support systems. In the near term, Hoola Health aims to deepen its presence across Bengaluru before expanding into new markets.                 ]]> https://biospectrumindia.com/news/104/27911/gvrp-stepsbio-unveil-new-formulations-rd-centre-in-bengaluru.html https://biospectrumindia.com/news/104/27911/gvrp-stepsbio-unveil-new-formulations-rd-centre-in-bengaluru.html Thu, 04 Jun 2026 19:28:42 +0530 GVRP (GV Research Platform), a Hyderabad-based research organisation, has announced the inauguration of the GVRP StepsBio Research Centre (GSRC), a strategic collaboration with Bengaluru-based startup Steps Biosciences that marks a significant milestone in India's pharmaceutical R&D landscape. Located within the 1BLR life sciences cluster Lifescapes in Bengaluru, the 15,000 sq. ft. facility is a dedicated Centre of Excellence for formulations research and development. GSRC represents GVRP's deliberate strategic expansion into high-complexity formulations, an area increasingly central to the global drug development pipeline and further cements Bengaluru's emergence as a premier destination for life sciences innovation. With sterile formulation laboratories engineered for complex dosage forms, including liquid and lyophilised injectables, ophthalmic solutions, and otic products, the facility supports controlled processing environments, aseptic operations, and rigorous material flow segregation to meet the highest quality standards. It also includes dedicated spaces for in-depth API characterisation, providing the scientific foundation for robust and predictable formulation development. StepsBio is actively building AI and machine learning capabilities within GSRC to support predictive formulation design, accelerate screening workflows, and enhance analytical interpretation positioning the centre at the intersection of computational and experimental science. ]]> https://biospectrumindia.com/news/104/27912/yellow-fertility-partners-with-fertilite-ivf-to-expand-presence-in-south-india.html https://biospectrumindia.com/news/104/27912/yellow-fertility-partners-with-fertilite-ivf-to-expand-presence-in-south-india.html Thu, 04 Jun 2026 22:21:05 +0530 Gurugram-based startup Yellow Fertility has partnered with Bengaluru-based Fertilite IVF to expand access to structured, evidence-based fertility treatment across South India. With this partnership, the Yellow Fertility network has grown to 20 centres, further strengthening its position as one of India’s fastest-growing fertility care networks and expanding access to advanced reproductive healthcare across the region. Fertilite IVF currently operates 2 centres in Bengaluru. The two organisations are expected to further expand across key cities in Karnataka and neighbouring Southern states in the next few years, with a focus on improving access to IVF and assisted reproductive technology (ART) services in both urban and emerging markets. The Bengaluru centres will provide a comprehensive range of fertility services, including IVF, IUI, fertility preservation, advanced ART procedures and personalised treatment pathways. Patients are expected to benefit from standardised clinical protocols, experienced medical teams and integrated care systems designed to improve treatment outcomes.  The collaboration is expected to strengthen the fertility care infrastructure in South India. It further aligns with Yellow Fertility’s broader growth strategy of establishing 100 IVF centres across India by 2030, aimed at expanding access to standardised, high-quality fertility care nationwide.   ]]> https://biospectrumindia.com/news/104/27898/aragen-to-manufacture-renaissance-pharmas-fda-fast-track-mab-in-bengaluru-facility.html https://biospectrumindia.com/news/104/27898/aragen-to-manufacture-renaissance-pharmas-fda-fast-track-mab-in-bengaluru-facility.html Tue, 02 Jun 2026 18:36:33 +0530 Aragen, a leading global Contract Research, Development, and Manufacturing Organisation (CRDMO), has successfully tech-transferred and manufactured the first commercial-scale GMP batches of Renaissance Pharma’s lead candidate, Daretabart – a humanised monoclonal antibody (mAb) targeting GD2 for high-risk neuroblastoma – in just 9 months. The anti-GD2 monoclonal antibody received Fast Track Designation from the FDA in April 2026 for the treatment of high-risk neuroblastoma (HRNB), a rare pediatric cancer. This milestone builds on a broader strategic partnership between the two companies, with Aragen having developed the cell line and initial process at its Morgan Hill site in California. GMP manufacturing for the programme has now transitioned to Aragen’s commercial biologics facility in Bengaluru, India at the commercial scale.  The Aragen Bengaluru site plans to have multiple 2KL bioreactors enabling both scale-up and scale-out. This manufacturing strategy will allow the same molecule to be run across bioreactors, supporting faster readiness towards clinical and commercial supplies. The manufacturing suite is capable of producing 60-70 batches annually at 2 KL scale with a turnaround of one batch every 4–5 days at full capacity. Additionally, the suite can be operated in a scale-out mode with two 2 KL bioreactors running in parallel to provide a batch size of 4KL. This facility supports both fed-batch and intensified fed-batch production. The successful transfer to Aragen’s newly built $40 million commercial facility in Bengaluru marks an acceleration in clinical production. During the technology transfer to the new site, which features up to 2KL single-use bioreactor, the titer was increased several folds, with right-first-time execution from bench to 2KL GMP scale.  This latest tech transfer marks the sixth programme to progress from early-phase development in Morgan Hill to clinical supply in Bengaluru, demonstrating a discovery-manufacturing model designed to accelerate biotech programmes toward BLA submission. ]]> https://biospectrumindia.com/news/104/27890/charaka-centre-of-excellence-inks-mou-with-bfi-to-strengthen-karnatakas-healthcare-innovation-ecosystem.html https://biospectrumindia.com/news/104/27890/charaka-centre-of-excellence-inks-mou-with-bfi-to-strengthen-karnatakas-healthcare-innovation-ecosystem.html Mon, 01 Jun 2026 19:51:53 +0530 CHARAKA – Centre of Excellence for HealthTech, MedTech & Assistive Technologies, Government of Karnataka, has signed a Memorandum of Understanding (MoU) with Blockchain For Impact (BFI) to strengthen Karnataka’s healthcare innovation ecosystem.The collaboration will focus on mentorship, policy and regulatory support, joint incubation initiatives, engagement with healthcare institutions, and district-level innovation sandboxes to enable real-world testing and validation of solutions.By creating structured pathways for innovators to develop, validate, and scale impactful healthcare technologies, this partnership reinforces Karnataka’s commitment to fostering innovation-driven healthcare and improving public health outcomes. The Centre of Excellence aims to position Karnataka,  already home to Bengaluru’s thriving startup ecosystem and major medtech players,  as a global hub for health technology and medical device innovation. ]]> https://biospectrumindia.com/news/104/27882/wadhwani-iisc-innovation-centre-to-strengthen-indias-quantum-and-deep-tech-innovation-ecosystem.html https://biospectrumindia.com/news/104/27882/wadhwani-iisc-innovation-centre-to-strengthen-indias-quantum-and-deep-tech-innovation-ecosystem.html Fri, 29 May 2026 22:26:43 +0530 Bengaluru-based Indian Institute of Science (IISc) has marked a significant milestone in India’s innovation journey with the recent  inauguration of the Wadhwani-IISc Innovation Centre and the successful hosting of Quantum Pitch Fest 2026, reinforcing the institute’s commitment to advancing deep-tech research, translational innovation, and entrepreneurship. The Centre has been established to catalyse deep-tech innovation, startup incubation, and industry collaboration, further strengthening IISc’s position as a leading hub for scientific research, translational innovation, and entrepreneurial excellence. The Wadhwani-IISc Innovation Centre is part of the Wadhwani Innovation Network (WIN) – a national initiative launched as part of the Rs 1,400+ crore collaborative investment announced last year by the Wadhwani Foundation in collaboration with ANRF, premier academic institutions, and government partners to strengthen India’s deep-tech innovation and research commercialisation ecosystem. The event also marked the launch of InQubate – a comprehensive quantum startup acceleration platform designed to nurture early-stage ideas and propel them into impactful enterprises. InQubate is powered by IISc’s quad ecosystem – the Quantum Research Park (QuRP), Wadhwani-IISc Innovation Centre, FQCI, and INUP – creating a seamless continuum from lab to market. With a mission to provide world-class mentorship, infrastructure, and collaborative opportunities, InQubate aims to empower innovators to transform quantum concepts into market-ready solutions while helping establish India as a globally competitive hub for deep-tech entrepreneurship. ]]> https://biospectrumindia.com/news/104/27859/neo-san-deploys-new-technology-for-sanitary-and-biomedical-waste-management-in-bengaluru-.html https://biospectrumindia.com/news/104/27859/neo-san-deploys-new-technology-for-sanitary-and-biomedical-waste-management-in-bengaluru-.html Wed, 27 May 2026 17:10:56 +0530 Neo San, a Bengaluru-based clean-technology startup that develops a range of highly efficient, on-site thermal waste-processors, has been awarded for their patented innovation by UpLink, the early-stage innovation engine of the World Economic Forum (WEF). In collaboration with the Government of Karnataka, the programme aims to address the various challenges in growing cities, and Neo San has been selected as a strategic partner to deploy its solutions across Bengaluru to manage reject-waste on-site, at various facilities. Launching soon under the name ‘SafeDispose Bengaluru', this solution will bring certified, on-site sanitary and biomedical waste-processing to government and private institutions across the city, taking away one of the most challenging aspects of waste management. A grant provided to Neo San will fund the deployment of Neo-X units that safely treat sanitary and biomedical waste at the point of waste generation. The units will be deployed phase-wise, at various institutions; colleges, schools, primary health centres, women’s hostels, government housing and other official buildings around Bengaluru, reaching over 5,000 women. This will also dignify waste collectors on-ground, who are often left sorting through such waste with their hands. Every Neo-X unit has real-time IoT monitoring of each cycle run and every kilo processed, thereby creating robust data for urban planning for the city. The SafeDispose Bengaluru initiative is aimed at eliminating open burning and manual waste handling at all these sites, conducting source segregation workshops, and generating India’s first field-verified compliance data under the Solid Waste Management Rules 2026 — creating a replicable template for institutional rollout across Karnataka and beyond. Karnataka State Pollution Control Board has reviewed and validated the technology for deployment across the city.  With more than 200+ machines deployed across India under managed service contracts — including at organisations such as SAP India, Taj Hotels, Airtel, Royal Enfield, RMZ, Embassy Group and others, Neo San is now expanding its presence across government and institutional infrastructures. ]]> https://biospectrumindia.com/news/104/27854/tata-elxsi-launches-material-intelligence-solution-vitel-for-medical-device-manufacturers.html https://biospectrumindia.com/news/104/27854/tata-elxsi-launches-material-intelligence-solution-vitel-for-medical-device-manufacturers.html Tue, 26 May 2026 16:45:39 +0530 Bengaluru-based Tata Elxsi, a global leader in design and technology services, has announced the launch of ViTel™, a Material Intelligence solution for Medical Device manufacturers, co-developed with Viridium AI, a material intelligence platform company. ViTel™ is being formally introduced at DeviceTalks Boston 2026 (on May 27 & 28), where Tata Elxsi is presenting its latest advances in AI-powered MedTech engineering and compliance. Medical device manufacturers are facing a new operating reality. Material decisions now affect margin, resilience, product velocity, and market access, yet critical product knowledge remains buried across BOMs, supplier documents, ERP and PLM systems, and expert teams. This makes every new regulation or customer requirement a costly manual exercise. ViTel™ addresses this by creating a reusable Material Intelligence layer across the enterprise, helping teams identify material and supplier dependencies, assess country-of-origin and sourcing exposure, evaluate alternatives, and understand where product or material risks affect cost, continuity, or market access. Powered by Viridium AI's Knowledge Cloud, Chemical Digital Twin, and science-constrained AI models, ViTel™ transforms scattered enterprise data into a living product-material knowledge graph connecting products, parts, materials, chemicals, suppliers, regulations, and evidence. ViTel™ draws on Tata Elxsi's three decades of Med-Tech engineering and regulatory expertise, knowledge that has been embedded into how the solution reasons about material risk, compliance, and sourcing decisions, not just how it is deployed. Tata Elxsi brings design-led and AI-first engineering, deep domain expertise, and access to global healthcare and medtech enterprises; Viridium AI brings platform and technology innovation. ViTel™ is co-developed through STEP UP, Tata Elxsi's co-innovation programme for high-potential deep-tech companies. ]]> https://biospectrumindia.com/news/104/27857/jncasr-designs-clear-technology-to-revolutionise-protein-imaging-for-cancer-detection.html https://biospectrumindia.com/news/104/27857/jncasr-designs-clear-technology-to-revolutionise-protein-imaging-for-cancer-detection.html Tue, 26 May 2026 19:44:07 +0530 A novel imaging platform called the Cleaveable Light-Erased Antibody Reporter (CLEAR), developed by researchers from Jawaharlal Nehru Centre for Advanced Scientific Research, Bengaluru (JNCASR), an autonomous institute of the Department of Science and Technology (DST), can help see an unprecedented number of proteins within a single biological sample using just one fluorescent marker. This could open new possibilities for high-resolution, multiplex imaging in cells and tissues, which could prove important for diagnostics and biological research. Proteins are the primary controllers of biological functions and are key targets of therapeutic activity as well as important indicators for the diagnosis of diseases. A comprehensive proteomic map of the tissue sample shows the identity of each protein and the exact spatial organisation in its original context. It can help pathologists understand cancer diagnoses or complex neurological disorders. However, measuring a large number of proteins in their original spatial context remains a major challenge. CLEAR has the potential to revolutionise biomedical research and clinical solutions by enabling detailed mapping of proteins in cells and tissues. This can help in early detection of cancers and neurological diseases, in particular, and aid in understanding the impact on immunity. ]]> https://biospectrumindia.com/news/104/27835/hcg-unveils-cancer-hospital-in-north-bengaluru-introducing-karnatakas-first-mr-linac.html https://biospectrumindia.com/news/104/27835/hcg-unveils-cancer-hospital-in-north-bengaluru-introducing-karnatakas-first-mr-linac.html Mon, 25 May 2026 18:54:10 +0530 HealthCare Global Enterprises Limited (HCG), India’s largest dedicated cancer hospital network, has announced the launch of its new comprehensive cancer hospital in Byatarayanapura (Hebbal), strengthening access to advanced oncology care in North Bengaluru. The new facility marks a major advancement in the region’s oncology landscape, bringing together clinical excellence, compassionate care and advanced technology to make world-class cancer treatment more accessible to people across Karnataka. Marking a significant milestone in precision oncology, the 110-bed facility introduces Karnataka’s first Elekta Unity MR-Linac, one of the world’s most advanced precision radiation therapy platforms. The technology combines high-quality MRI imaging with a linear accelerator to enable highly precise, adaptive cancer treatment. Designed as a full-spectrum oncology centre, the hospital brings together diagnosis, treatment, recovery support, and patient-centric care under one roof, making world-class cancer care more accessible to patients across North Bengaluru. Speaking on the launch, Dr B. S. Ajaikumar, Founder & Chairman of HealthCare Global Enterprises Limited (HCG), said: “Cancer care today has become increasingly data-driven, technology-oriented and focused on improving long-term outcomes. Our goal is not only to prevent recurrences, but also to make even advanced and metastatic cancers manageable through personalised, multidisciplinary care." The hospital is equipped with Accuray TomoTherapy with Radixact, further strengthening its radiation oncology capabilities, along with an 80-slice Digital PET-CT scanner for precise, high-resolution diagnostic imaging. In addition to advanced imaging and radiation therapy, HCG Hebbal features five robotic-assisted modular operation theatres, 19 chemotherapy daycare beds, 14 premium treatment bays, and a 15-bed ICU and HDU. The facility is also supported by a comprehensive range of diagnostic and clinical services, including endoscopy, bronchoscopy, ultrasound, X-ray, mammography, advanced laboratories, histopathology, frozen section services and blood storage. ]]> https://biospectrumindia.com/news/104/27814/agilent-and-veeda-lifesciences-open-joint-analytical-centre-of-excellence-in-bengaluru.html https://biospectrumindia.com/news/104/27814/agilent-and-veeda-lifesciences-open-joint-analytical-centre-of-excellence-in-bengaluru.html Wed, 13 May 2026 23:01:57 +0530 Agilent Technologies has announced a strategic collaboration with Veeda Lifesciences to strengthen regulatory‑aligned analytical and bioanalytical workflows supporting biopharma development, as GLP‑1 and other complex therapeutic modalities continue to advance rapidly through global pipelines. The collaboration brings together Agilent’s expertise in analytical workflow development with Veeda’s established bioanalytical, clinical research and regulatory capabilities, with the objective of enabling high‑quality, inspection‑ready analytical data across early development, clinical, and manufacturing stages. Together, the two organisations aim to support biopharma companies navigating increasingly complex regulatory and data expectations for next‑generation therapies. Central to the collaboration is the establishment of a joint Centre of Excellence (CoE) at Veeda’s biopharma facility in Bengaluru. Designed as a scalable analytics and regulatory‑readiness hub, the CoE will focus on the development and validation of end‑to‑end analytical workflows. The CoE will address the growing analytical demands associated with next‑generation therapies, including GLP‑1 based drugs - where sensitivity, throughput, and data integrity are critical to support regulatory confidence and program progression. By combining Agilent’s high-performance mass spectrometry with Veeda’s integrated bioanalytical and clinical research infrastructure, the partnership aims to extend services to sponsors across an expanding range of next-generation modalities with consistent, inspection-ready datasets. ]]> https://biospectrumindia.com/news/104/27799/bengaluru-based-startup-swishx-unveils-worlds-first-agentic-ai-platform-for-pharma-and-medtech.html https://biospectrumindia.com/news/104/27799/bengaluru-based-startup-swishx-unveils-worlds-first-agentic-ai-platform-for-pharma-and-medtech.html Tue, 12 May 2026 14:57:40 +0530 SwishX has announced its launch, introducing the world’s first Agentic AI platform built exclusively for pharmaceutical and medtech companies, aimed at transforming sales, marketing, distribution, and business growth through artificial intelligence. The Bengaluru-headquartered startup is targeting $5 million in contracted ARR and 100+ enterprise clients by end of current FY 2026-27, and plans expansion into Latin America, Southeast Asia, the Middle East, Africa, and Eastern Europe. SwishX has also raised $2.2 million in seed funding backed by Powerhouse Ventures, Blume Ventures, Sadev Ventures, Atrium Ventures, and other investors. These emerging markets, along with India, represent a $400 billion pharma and medtech opportunity, with commercial operations expected to grow to $770 billion by 2033 at a CAGR exceeding 12%. SwishX is organised around four hubs each having its own specialized AI Agents: Tender IQ (Tender & RFP Automation), Contract IQ (Hospital Rate Contract Automation), Marketing IQ ( HCP & Rep Engagement), Channel IQ (Channel Partner Engagement). The AI Agents capture siloed data, automate business workflows, learn nuances of every decision and build a functional memory to help business teams accelerate their commercial execution. While starting with India, SwishX is helping the pharma companies to further grow in other countries as well by combining AI with local market data of different countries. ]]> https://biospectrumindia.com/news/104/27751/mrmed-announces-significant-expansion-of-infrastructure-in-bengaluru.html https://biospectrumindia.com/news/104/27751/mrmed-announces-significant-expansion-of-infrastructure-in-bengaluru.html Mon, 04 May 2026 00:00:00 +0530 For patients managing cancer, autoimmune conditions, or complex metabolic disorders, reliable access to specialty medicines is not a convenience but a clinical necessity. Chennai-based startup MrMed, India's specialty and super-specialty medicine platform, is making a significant infrastructure bet on Bengaluru — among its top two revenue markets, as part of a broader strategy to deepen access to critical care medicines, expanding last-mile reach, improving delivery timelines, and strengthening supply reliability across one of its most active demand clusters. At the centre of this expansion is a new storage and distribution hub in Central Bengaluru, an 850 sq ft facility strategically located for rapid dispatch across the city, including areas that have historically seen limited access to specialty medicines. Complementing this is MrMed’s 2,000+ sq ft Bengaluru office, which functions as a central command centre overseeing operations not just for the city hub but coordinating fulfilment, supply, and service workflows across the country.  The development is complemented by deeper sourcing partnerships with local distributors and manufacturers, technology-driven improvements across order processing, billing, and dispatch, and last-mile delivery capabilities. Together, they have enabled MrMed to offer 24-hour delivery across approximately 110 pincodes (560001 to 562162), covering the majority of its catalogue — including oncology drugs, immunosuppressants, and GLP-1 therapies such as semaglutide and tirzepatide. "Bengaluru is one of our largest target markets which makes it the natural starting point for this level of investment," said Devashish Singh, Co-Founder & CEO, MrMed. "The operational challenge was never just speed — it was ensuring consistency across the entire order lifecycle, from real-time availability to last-mile delivery, at scale. What we've built here is a model we intend to replicate city by city." The company is now working to roll out this model in Delhi and Chennai, followed by Guwahati, Mumbai and Hyderabad. MrMed expects to achieve complete geographic coverage within Bengaluru over the next 1-2 months. ]]> https://biospectrumindia.com/news/104/27716/karnataka-govt-approves-rs-20-cr-coe-for-ai-in-biotechnology-at-electronics-city-bengaluru.html https://biospectrumindia.com/news/104/27716/karnataka-govt-approves-rs-20-cr-coe-for-ai-in-biotechnology-at-electronics-city-bengaluru.html Fri, 24 Apr 2026 00:00:00 +0530 The IT BT Department, Karnataka Government, continues to strengthen the state’s deep-tech ecosystem with the approval of a Rs 20 crore Centre of Excellence (CoE) for artificial intelligence (AI) in Biotechnology at Electronics City, Bengaluru.Implemented over 4 years in collaboration with Institute of Bioinformatics and Applied Biotechnology (IBAB) and Centre for Cellular and Molecular Platforms (C-CAMP), the initiative will accelerate innovation at the intersection of AI and life sciences. The AI Centre will offer labs, tools and expertise to help startups and researchers grow faster and build better products. This initative will strengthen the state's research ecosystem, accelerate innovation, and enable Karnataka to lead in high-impact, next-generation technologies.   ]]> https://biospectrumindia.com/news/104/27721/aster-whitefield-hospital-launches-karnatakas-first-dedicated-liver-icu.html https://biospectrumindia.com/news/104/27721/aster-whitefield-hospital-launches-karnatakas-first-dedicated-liver-icu.html Fri, 24 Apr 2026 00:00:00 +0530 Taking a major initiative towards expert liver care, Aster Whitefield Hospital has declared the launch of the first dedicated Liver Intensive Care Unit (ICU) in Karnataka. This is a state-of-the-art facility designed only for liver failure patients, those having biliary problems, and liver transplant cases. The ICU, named SHIELD (Specialised Hepatic Intensive & Emergency Liver Division), is a state-of-the-art facility designed only for liver failure patients, those having biliary problems, and liver transplant cases. Setting the Liver specific ICU as a real rescue for patients in critical conditions, it is a confluence of renowned doctors, modern facilities, and continuous patient monitoring to provide very specialised, multiple discipline care aimed at improving patient outcomes. The programme was honoured by the presence of Dr C. N. Manjunath, Member of Parliament (Lok Sabha) as the Chief Guest. Speaking ahead of the inauguration, Dr C. N. Manjunath said, "Liver problems are turning out to be a sneaky but major health issue in India, and usually, it's at a very severe stage when the patients are found. A liver ICU dedicated to liver care opening at Aster Whitefield Hospital is a very appropriate and great step that will enable our healthcare system to be more efficient and quicker in handling very difficult liver cases. Apart from better survival chances, specialised facilities equip the patient care to be comprehensive and in collaboration of various medical disciplines." Srikant Subudhi, Chief Operating Officer, Aster Whitefield Hospital, added, "The launching of Karnataka's first dedicated Liver ICU is a powerful indication of how we are always ready to put our money into the specialised infrastructure which is capable of dealing with the increasing complexity of liver-related diseases. Not only does this facility leverage state-of-the-art technology and a wide range of medical experts, but it also ensures continuous monitoring for better clinical results and provides easier access to specialised and high-quality treatment. " The Liver ICU will be a collaborative endeavor by a team of highly skilled and proficient physicians, including liver transplantation surgeons, hepatologists, and gastroenterologists, as well as critical care specialists. This dedicated unit will try to fill a major void in the liver care infrastructure of Karnataka, and it will be a one-stop solution for patients to get timely, cutting-edge and life-saving treatment. ]]> https://biospectrumindia.com/news/104/27712/graviti-pharma-accelerates-india-expansion-with-launch-of-karnataka-operations.html https://biospectrumindia.com/news/104/27712/graviti-pharma-accelerates-india-expansion-with-launch-of-karnataka-operations.html Thu, 23 Apr 2026 00:00:00 +0530 Graviti Pharmaceuticals, a Hyderabad-based pharmaceutical company with a strong and growing presence in international markets, has announced the launch of its operations in Karnataka. Building on the successful completion of one year of operations in Andhra Pradesh and Telangana, Graviti Pharmaceuticals is now expanding into Karnataka as part of its next phase of growth, reinforcing its ambition to emerge as a leading, quality-driven pharmaceutical player in India. Headquartered in Hyderabad, the company has established a robust foundation backed by its international business operations, particularly in the United States, and a strong focus on globally benchmarked quality and compliance systems. Graviti’s manufacturing facility at Pashamylaram, Hyderabad, operates in alignment with USFDA standards, reflecting the company’s commitment to delivering pharmaceutical products that meet stringent global benchmarks across quality, safety, and regulatory compliance. Under the leadership of its Managing Director, Dheeraj Gorukanti, and Chief Operating Officer, Thilak Vangala, Graviti Pharmaceuticals continues to strengthen its strategic vision and operational excellence across markets. Speaking on the occasion, Thilak Vangala, Chief Operating Officer, Graviti Pharmaceuticals, said, “Our entry into Karnataka represents a strategic milestone in our India growth journey. With a strong foundation in international markets and a continued focus on quality and compliance, we are committed to scaling our presence and delivering globally aligned pharmaceutical solutions across key therapy segments.” With this expansion, Graviti Pharmaceuticals aims to further strengthen its presence across India, while continuing to build a scalable, high-quality pharmaceutical platform aligned with global standards and long-term growth ambitions. ]]> https://biospectrumindia.com/news/104/27699/cent-opens-clinical-prevention-centre-in-bengaluru-deepens-partnership-with-siemens-healthineers.html https://biospectrumindia.com/news/104/27699/cent-opens-clinical-prevention-centre-in-bengaluru-deepens-partnership-with-siemens-healthineers.html Tue, 21 Apr 2026 00:00:00 +0530 CENT, the early detection healthcare company founded by Shashank ND along with a team of clinical and operating leaders, has announced the opening of its first clinical prevention centre in Bengaluru.  Alongside the launch, the company announced a deepened strategic partnership with Siemens Healthineers to power the diagnostic and imaging infrastructure across its growing centre network. Spanning 7,000 square feet, the Bengaluru centre is India's most advanced clinical prevention facility, purpose-built from the ground up for a single objective: finding silent, life-threatening disease in people who feel healthy.  Unlike conventional diagnostic labs or hospital checkup wings that run dozens of unrelated tests on shared equipment, CENT's centre runs one standardised protocol, the CCNM Protocol (Cardiac, Cancer, Neurological, Metabolic), with the throughput, clinical rigour, and quality control of a single-purpose facility. The centre is also among the most advanced in India from an imaging standpoint. State-of-the-art Siemens Healthineers MRI, CT, and DEXA systems have been configured specifically for preventive use, with CENT and Siemens Healthineers jointly developing custom MRI protocols, deploying efficiency-enhancing software on Siemens Healthineers platforms, and pursuing joint research toward a new standard for preventive imaging.  The Bengaluru centre is the first physical node of a planned multi-city rollout, with Mumbai and Delhi-NCR to follow.      ]]> https://biospectrumindia.com/news/104/27700/hcl-healthcare-deepens-bengaluru-presence-with-central-regional-office.html https://biospectrumindia.com/news/104/27700/hcl-healthcare-deepens-bengaluru-presence-with-central-regional-office.html Tue, 21 Apr 2026 00:00:00 +0530 HCL Healthcare has established a regional business office in the heart of Bengaluru, reinforcing its position in one of its largest and most mature markets, while strengthening accessibility and service delivery for enterprise clients. The office, located at Prestige Saleh Ahmed on Infantry Road, places HCL Healthcare at the centre of the city’s business district—enabling closer engagement with clients and faster, more responsive execution on the ground. The company has been servicing Bengaluru-based organisations for over a decade, building a strong footprint across corporate health, preventive care, and wellness programs. The new office does not signal a market entry, but rather a strategic intensification of an already well-established presence. Currently, the South Zone comprises 60% of HCL Healthcare’s large clientele, with Bengaluru being a key city for the company. In a city that anchors India’s technology and global capability ecosystem, proximity has become increasingly critical to delivering relevant and high-impact healthcare solutions. HCL Healthcare’s regional office is designed to function as a collaborative hub for client engagement, program management, and solution customisation, allowing teams to work more closely with organisations and adapt interventions to their specific needs. By situating itself in a central, well-connected location, the company aims to drive greater ease of access, improved coordination, and enhanced service agility—factors that are becoming essential as enterprise healthcare evolves from transactional services to continuous, outcome-driven partnerships.   ]]> https://biospectrumindia.com/news/104/27630/merck-expands-bengaluru-facility-to-boost-global-supply-of-filtration-devices.html https://biospectrumindia.com/news/104/27630/merck-expands-bengaluru-facility-to-boost-global-supply-of-filtration-devices.html Wed, 08 Apr 2026 00:00:00 +0530 Merck, a leading science and technology company, has announced the expansion of its manufacturing facility in Peenya, Bengaluru. The investment added new production lines for filtration hardware system, followed up by Pellicon® 2 Ultrafiltration Cassette in 2026. “These products are essential to producing life-saving medicines and vaccines,” said Tony Qiu, Head of APAC Operations, Life Science Business of Merck. “By expanding manufacturing in India, the company is strengthening global supply chains while supporting local innovation and skills." Merck’s Pellicon® 2 Ultrafiltration Cassette is a trusted solution for high-quality purification, supporting a wide range of applications in the pharma and life science industries. The Peenya site has been a hub for global filtration hardware production since 2006, and began manufacturing consumable products, including Prefilter cartridge in 2022. This expansion further strengthens India’s position in Merck’s global network while aligning with the Indian government’s “Make in India” initiative. ]]> https://biospectrumindia.com/news/104/27621/medgenome-unveils-indias-first-study-on-clinical-impact-of-rna-based-ngs-in-sarcoma-diagnosis.html https://biospectrumindia.com/news/104/27621/medgenome-unveils-indias-first-study-on-clinical-impact-of-rna-based-ngs-in-sarcoma-diagnosis.html Tue, 07 Apr 2026 00:00:00 +0530 On the occasion of World Health Day, Bengaluru-based MedGenome has announced the outcomes of India's first prospective study assessing the clinical utility of RNA-based next-generation sequencing (NGS) for soft tissue and bone sarcoma diagnosis. Aligning with this year’s theme “Together for health. Stand with science,” the study highlights the importance of science-led, collaborative approaches in strengthening access to accurate diagnosis and improving cancer care. This study, conducted in collaboration with India’s leading hospitals between 2022 and 2025 and published in the Journal of Global Oncology, has demonstrated that introducing targeted RNA sequencing into a multidisciplinary team (MDT) workflow can substantially enhance diagnostic clarity and aid treatment decisions for Sarcomas, especially in patients with ambiguous or complex presentations. For this study, 68 patients with unclear diagnoses based on their pathological indications were considered for evaluation after an MDT review. All samples were analysed with MedGenome's CAP-accredited indigenous RNA fusion panel, which is custom-designed for sarcomas and implemented in concordance with the WHO 2021 classification. The study showed that the RNA-based NGS provided clinically informative findings in half of all evaluated cases. Notably, diagnostic refinement or reclassification could be achieved in over 40% of patients, while treatment decisions changed in more than a quarter of cases according to molecular results. The study also highlights the opportunity of implementing cost-effective genomic testing in low and middle-income countries. MedGenome's sarcoma panel enables the detection of both canonical and ultra-rare gene fusions, many of which could have gone undetected by universal testing methods. By integrating these results into MDT discussions, clinicians can avoid ineffective chemotherapy regimens, confirm rare histologic subtypes, and make more informed therapeutic decisions. Speaking about the importance of the research, an author of the study Charu Bahl, PhD, General Manager - Scientific Affairs, MedGenome Labs Ltd, said, "Sarcomas often sit at the crossroads of overlapping morphology and unpredictable clinical behaviour. For a large proportion of patients, conventional tools such as Histopathology, Immunohistochemistry (IHC), or Fluorescence In Situ Hybridization (FISH) are not enough to arrive at a definitive diagnosis. This prospective study distinctly shows that RNA-based NGS offers the resolution we need to classify difficult tumours correctly and, in many cases, course-correct treatment plans before precious time is lost."   ]]> https://biospectrumindia.com/news/104/27622/siemens-healthineers-announces-expansion-of-manufacturing-footprint-in-india.html https://biospectrumindia.com/news/104/27622/siemens-healthineers-announces-expansion-of-manufacturing-footprint-in-india.html Tue, 07 Apr 2026 00:00:00 +0530 Siemens Healthineers has announced the expansion of manufacturing footprint in India with the local production of the Artis one Edition X angiography system at company’s Bengaluru factory. The system will be manufactured alongside the facility’s existing portfolio of mobile C-arms, CT scanners, MRI systems, and digital radiography X-ray systems, further strengthening the company’s commitment to the Make in India initiative and to advancing access to innovative healthcare technologies across the country. With its advanced capabilities, Artis One Edition X empowers clinicians with enhanced imaging and workflow efficiency while supporting improved patient outcomes. It helps interventionalists perform procedures that restore blood flow and treat blockages in arteries and veins, thereby benefitting patients with conditions such as heart disease, kidney failure, and irregular heart rhythms. Additionally, India's cath lab density currently stands at just 1.5 to 1.75 per million people, underscoring the urgent need for accessible cardiac care infrastructure. This growing demand is evident in the widespread adoption of angiography systems across metropolitan hubs and tier 2/3 cities. Designed as a compact, low-maintenance, and versatile solution, Artis One Edition X enables healthcare providers to treat a greater number of patients efficiently while maintaining high clinical standards. The universal angiography system combines flexibility with advanced imaging features, making it the need of the hour for hospitals and healthcare providers looking to expand their interventional capabilities. ]]> https://biospectrumindia.com/news/104/27613/kims-hospitals-launches-institute-of-neurosciences-and-centre-of-excellence-in-neuromodulation-in-bengaluru.html https://biospectrumindia.com/news/104/27613/kims-hospitals-launches-institute-of-neurosciences-and-centre-of-excellence-in-neuromodulation-in-bengaluru.html Mon, 06 Apr 2026 00:00:00 +0530 KIMS Hospitals (Krishna Institute of Medical Sciences), Mahadevapura, has announced the launch of the Institute of Neurosciences and Centre of Excellence in Neuromodulation, marking a significant step in advancing specialised neurological care in the region. The state-of-the-art facility aims to provide comprehensive diagnosis, treatment, and rehabilitation for a wide range of neurological disorders under one roof. This newly launched centre is designed to address the needs of patients with various neurological conditions. These include Parkinson’s disease, epilepsy, and chronic pain. It is designed to offer the latest treatment options, including neuromodulation and minimally invasive surgery. It is a multidisciplinary team of neurologists, neurosurgeons, and rehabilitation specialists. The centre also hosts an event in observance of World Parkinson’s Day on April 11th, Celebrating the Strength of Patients Living with Parkinson’s Disease. As part of this initiative, the hospital is focusing on Parkinson’s disease as part of the World Parkinson’s Day awareness programme. This program is aimed at patients as well as caregivers, where the importance of early diagnosis and intervention is emphasised. ]]> https://biospectrumindia.com/news/104/27543/manipal-hospital-mukundapur-announces-launch-of-deep-brain-stimulation-dbs-clinic.html https://biospectrumindia.com/news/104/27543/manipal-hospital-mukundapur-announces-launch-of-deep-brain-stimulation-dbs-clinic.html Tue, 24 Mar 2026 00:00:00 +0530 Manipal Hospital Mukundapur, a unit of the Manipal Hospitals Group, one of India’s largest healthcare providers, has announced the launch of its Deep Brain Stimulation (DBS) Clinic, a first-of-its-kind, disease-specific initiative in India designed to deliver precision-led care for patients with complex neurological and movement disorders in the presence of leading neurologists, neuro-surgeons from the hospital group. The clinic is led by Dr Milind Deogaonkar, Director and Senior Consultant – Neurosurgery, Manipal Hospital Mukundapur and marks a significant advancement in neuro-restoration and neuromodulation, reinforcing the hospital’s commitment to comprehensive, technology-driven and patient-centric neuroscience care. The DBS Clinic will function from the Mukundapur unit, with dedicated DBS services scheduled every Monday and a Complex Pain Clinic on Saturdays. Movement Disorder Clinics will be operational on all days to ensure uninterrupted access to specialised neurological care, with Dr Shreyasi Jha attending full-day clinics on Mondays and Saturdays and participating in DBS procedures as required. The programme follows a multidisciplinary care model that brings together neurologists, neurosurgeons, pain specialists, neuro-rehabilitation experts, emergency physicians and trained nursing teams to deliver coordinated and comprehensive care. Complementing this approach, the Neuro-Rehabilitation Clinic led by Mrs. Shivani Deshmukh will provide structured rehabilitation consultations, supported by dedicated consultation spaces and streamlined service. Together, this integrated model supports patients across the entire continuum of care, from diagnosis and advanced intervention to rehabilitation and long-term follow-up for conditions such as Parkinson’s disease, dystonia, tremors, epilepsy and complex pain syndromes. As part of the launch, Manipal Hospitals will roll out an internal awareness and academic engagement programme across its Kolkata units. These internal sessions, led by Dr Milind, will introduce the Neuro-restoration and Neuromodulation DBS Clinic to neurosurgeons, neurologists, emergency department doctors and residents. The DBS Clinic will also explore tele-connect mechanisms with other Manipal Hospitals units, including centres outside Kolkata, to extend expert neurological consultations and continuity of care beyond the Mukundapur campus. ]]> https://biospectrumindia.com/news/104/27511/manipal-academy-of-higher-education-secures-national-certification-for-high-containment-bsl-3-lab.html https://biospectrumindia.com/news/104/27511/manipal-academy-of-higher-education-secures-national-certification-for-high-containment-bsl-3-lab.html Wed, 18 Mar 2026 00:00:00 +0530 Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University, has announced the successful certification of its Biosafety Level 3 (BSL-3) Laboratory, marking a major milestone in the university’s continued commitment to excellence in biomedical research, infectious disease preparedness, and global health security. This achievement significantly strengthens the research, diagnostic, and training capabilities of the Manipal Institute of Virology (MIV), Manipal. BSL-3 laboratories are specialised high-containment facilities designed for the safe handling and study of infectious microorganisms that may cause serious or potentially lethal diseases through inhalation. The certification reflects MAHE’s strict adherence to internationally recognised biosafety and biosecurity standards and demonstrates the institution’s dedication to maintaining the highest levels of laboratory safety and scientific integrity. The BSL-3 laboratory has been developed with state-of-the-art infrastructure and advanced biosafety engineering. The facility incorporates specialised containment architecture, directional airflow with negative pressure, high-efficiency particulate air (HEPA) filtration systems, secure access controls, and rigorous operational protocols to ensure the safe handling of high-risk pathogens. The certification process involved a comprehensive and meticulous evaluation of the facility, including laboratory design, engineering controls, biosafety management systems, operational procedures, personnel competency, and emergency response preparedness. The establishment and successful certification of the BSL-3 facility were achieved under the leadership of Dr Chiranjay Mukhopadhyay, Director, Manipal Institute of Virology (MIV), whose vision and guidance were pivotal in strengthening the institution’s high-containment research capacity. With this important milestone, MAHE further consolidates its position as a leading centre for advanced research, diagnostics, and capacity building in infectious diseases. The BSL-3 facility will enable scientists and clinicians to safely investigate high-risk pathogens, study emerging and re-emerging infectious diseases, and develop innovative strategies for improved diagnostics, surveillance, and therapeutic interventions. The laboratory will also serve as a critical platform for interdisciplinary collaboration among microbiologists, virologists, clinicians, epidemiologists, and public health experts. In addition to supporting cutting-edge research, the facility will play an important role in strengthening national and regional preparedness by offering training in biosafety practices, high-containment laboratory operations, and outbreak response strategies.  ]]> https://biospectrumindia.com/news/104/27498/narayana-health-airbound-plan-medical-logistics-corridor-in-bengaluru.html https://biospectrumindia.com/news/104/27498/narayana-health-airbound-plan-medical-logistics-corridor-in-bengaluru.html Tue, 17 Mar 2026 00:00:00 +0530 Narayana Health, a leading healthcare service provider and Airbound, a Bengaluru-based aerial logistics startup, have successfully completed a medical logistics pilot connecting Narayana Health’s Chandapura Clinic to its central laboratory at Narayana Health City in Electronic City by air, demonstrating how aerial logistics can dramatically improve the speed and reliability of diagnostic transport across urban healthcare networks. Encouraged by the results of the pilot, Narayana Health is now preparing to scale these services at their upcoming hospital in Banashankari, scheduled for inauguration in the coming months. Pending final regulatory clearances and government permissions, Narayana Health and Airbound intend to initiate a new pilot corridor connecting the new Banashankari Hospital and the Flagship Hospital in Electronic City. Over the next few years, Airbound and Narayana Health plan to expand the model in phases by connecting more clinics and smaller private hospitals, including those outside the Narayana Health ecosystem, to the centralized laboratory at Narayana Health City. This will allow healthcare providers across the city to access advanced diagnostic services without needing to build full laboratory infrastructure at each facility. Following the success of the Bengaluru pilot, the partners plan to expand aerial medical logistics routes across Bengaluru in phases and eventually to other cities, including Kolkata being a key focus region for Narayana Health, while continuing to work with regulators as the network scales. ]]> https://biospectrumindia.com/news/104/27464/fortis-healthcare-launches-four-specialised-clinics-across-network-of-hospitals-in-bengaluru.html https://biospectrumindia.com/news/104/27464/fortis-healthcare-launches-four-specialised-clinics-across-network-of-hospitals-in-bengaluru.html Wed, 11 Mar 2026 00:00:00 +0530 Fortis Healthcare has announced the launch of four specialised clinics across its network of hospitals in Bengaluru, reinforcing its commitment to delivering focused, patient-centric and holistic healthcare. The newly introduced services - Man Clinic, Incontinence Clinic, Restorative Gynaecology Clinic, and Mobile Lithotripsy Services, are designed to address sensitive and often under-discussed health concerns that frequently remain untreated due to social stigma or limited awareness. The clinics were officially inaugurated by Sharan Prakash Patil, Minister for Medical Education, Government of Karnataka, in the presence of nearly 150 attendees, including leading doctors, senior hospital leadership, staff members, patients, and distinguished guests. The newly introduced services include: ü  Man Clinic: A dedicated centre focused on men’s health concerns including sexual wellness, prostate health, infertility, hormonal imbalances and lifestyle-related conditions with an emphasis on privacy, clinical excellence and a holistic, multidisciplinary treatment approach. ü  Incontinence Clinic: A specialised service addressing urinary and bowel incontinence across genders and age groups. Integrating expertise from urology, gynaecology and physiotherapy, the clinic offers advanced diagnostics and minimally invasive treatments aimed at restoring dignity, confidence and quality of life. ü  Restorative Gynaecology Clinic: A comprehensive clinic dedicated to women’s intimate health, functional concerns and aesthetic gynaecological conditions, delivered through advanced, evidence-based and discreet treatment protocols. ü  Mobile Lithotripsy Services: A technologically advanced, minimally invasive solution for kidney stone management, designed to provide precise, efficient and patient-friendly treatment with reduced hospital stay and improved outcomes.   ]]> https://biospectrumindia.com/news/104/27461/wellness-technologies-plans-commercialisation-of-ai-powered-smart-yoga-mat.html https://biospectrumindia.com/news/104/27461/wellness-technologies-plans-commercialisation-of-ai-powered-smart-yoga-mat.html Tue, 10 Mar 2026 00:00:00 +0530 Reinforcing its commitment to nurturing India's deep-tech startup ecosystem and enabling indigenous innovations to take from the lab to the market, the Technology Development Board (TDB) of the Department of Science and Technology (DST), Government of India, has provided financial support to Bengaluru-based startup Wellness Technologies for the commercialisation of its innovative product, the YogiFi Smart Yoga Mat. The project titled "Commercialisation of YogiFi Smart Sensor Fabric Mats with Autonomous and Self-Sustaining Systems" aims to strengthen the indigenous manufacturing capabilities of AI-powered health technology developed in India and enable mass production. This initiative is in line with the Government of India's vision to promote preventive healthcare, digital health technologies and self-reliant manufacturing within the larger framework of Aatmanirbhar Bharat. The YogiFi Smart Yoga Mat combines advanced sensor technology and artificial intelligence (AI) to provide real-time posture feedback, guided yoga sessions, and detailed performance analytics through a mobile application. Combining digital technology with the ancient science of yoga, this product represents a new category of AI-enabled preventive health solutions emerging from India's startup space.   ]]> https://biospectrumindia.com/news/104/27437/kims-hospitals-forays-into-karnataka-with-two-new-state-of-the-art-facilities.html https://biospectrumindia.com/news/104/27437/kims-hospitals-forays-into-karnataka-with-two-new-state-of-the-art-facilities.html Mon, 09 Mar 2026 00:00:00 +0530 KIMS Hospitals Bengaluru, division of the Krishna Institute of Medical Sciences (KIMS), Secunderabad, one among India’s largest and trusted healthcare groups, has launched two of its super-speciality hospitals located in Mahadevapura and Electronic City. The hospital was inaugurated by film star N.T.R. This is a strategic expansion in providing world-class, patient-centric, tech-enabled healthcare to the people of Bengaluru and beyond. Both the units are prominently situated in the city’s fastest-growing locations to ensure quality healthcare is easily accessible to all. Mahadevapura Unit has over 450 beds, while the Electronic City facility has 350 beds. Both facilities are equipped with 30 state-of-the-art operation theatres and over 170 outpatient consultation rooms (OPDs) to deliver the best medical care. The facilities are integrated with 25-plus super speciality centres and Centres of Excellence across Cardiology, Neurology, Oncology, Paediatrics, Orthopaedics, ENT, Obstetrics and Gynaecology, General Surgery, Internal Medicine, Critical Care, and Chronic Disease Management. The hospitals will provide a range of healthcare services, from primary care on a 24/7 basis to advanced diagnostics and treatment options, ensuring a seamless care pathway from prevention and early detection through surgery and finally to management.  Dr Nitish Shetty, Managing Director, KIMS Hospitals, Bengaluru, said, “We strive to provide timely personalised healthcare. The Mahadevapura and Electronic City facilities have been planned to meet the growing health needs of the people of Bengaluru. These facilities have state-of-the-art ICUs, high-end diagnostic facilities and experienced medical professionals to ensure seamless patient care. Apart from these two units, three more units are also slated for the launch in the next years’ time. Our units house some of the most advanced medical technologies available today.  These facilities will act as major health hubs in Bengaluru and the IT Corridor areas.”  ]]> https://biospectrumindia.com/news/104/27432/new-england-biolabs-opens-subsidiary-in-bengaluru.html https://biospectrumindia.com/news/104/27432/new-england-biolabs-opens-subsidiary-in-bengaluru.html Fri, 06 Mar 2026 00:00:00 +0530 US-based New England Biolabs (NEB), a world leader in the production of reagents for the life science industry, is extending its global subsidiary network with the opening of New England Biolabs India Pvt Ltd (NEB India) at Phoenix Asia Towers in Bengaluru, Karnataka. India has long been a global leader in the life science space as a result of both strong public sector support and private sector investments. NEB has supported researchers in India for many years through its distribution network.  NEB India will now bring a higher level of service to valued customers and local distributors in this important market. “This new subsidiary office will provide the scientific research community in India with more efficient access to the latest NEB products and technical support in the local time zone, a state-of-the-art Experience Center and footprint for local manufacturing activities, as well as custom partnership opportunities,” says Partha Chakraborty, Country Manager for NEB India. Carole Keating, Executive Director of International Business at NEB said, “This expansion of our subsidiary network in India enables NEB to offer even greater personalized service to our customers, rapid delivery, and the ability to explore higher levels of collaboration.” NEB also maintains subsidiary offices in Australia, Canada, China, France, Germany, Japan, New Zealand, Singapore, South Korea and the United Kingdom.                 ]]> https://biospectrumindia.com/news/104/27364/mahe-teams-up-with-openai-to-integrate-artificial-intelligence-to-enhance-outcomes.html https://biospectrumindia.com/news/104/27364/mahe-teams-up-with-openai-to-integrate-artificial-intelligence-to-enhance-outcomes.html Sat, 21 Feb 2026 00:00:00 +0530 Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University in Karnataka, has partnered with OpenAI to integrate advanced artificial intelligence (AI) tools across teaching, research, and academic administration.  This collaboration aims to enhance learning outcomes, accelerate research productivity, and equip students and faculty with critical AI skills for a rapidly evolving global workforce. MAHE will implement AI-powered tools and resources across its academic programs to support personalised learning, boost critical thinking, and encourage ethical AI use. Faculty will also gain access to advanced AI tools for curriculum planning, research, and innovation. The collaboration will focus on building AI literacy across disciplines, ensuring that students from Health Sciences, Technology & Science, Management, Law, Humanities & Social Sciences, and allied fields gain practical exposure to AI applications relevant to their domains. MAHE will also promote interdisciplinary research and innovation using AI to address complex real-world challenges. MAHE will also establish structured AI governance guidelines to ensure responsible, ethical, and transparent governance use of artificial intelligence across academic functions. ]]> https://biospectrumindia.com/news/104/27286/ficci-flo-bangalore-inaugurates-women-led-industrial-park-in-karnataka.html https://biospectrumindia.com/news/104/27286/ficci-flo-bangalore-inaugurates-women-led-industrial-park-in-karnataka.html Thu, 05 Feb 2026 00:00:00 +0530 FLO Bangalore has formally inaugurated the FLO Bangalore Industrial Park, a first-of-its-kind women led industrial initiative at Gowribidanur in Karnataka. The event marked the coming together of women entrepreneurs, government leadership and industry bodies around a shared belief that women are ready not just to participate in industry but to create it. The inauguration was held in the presence of senior leaders from FLO, Karnataka Industrial Areas Development Board (KIADB) and Karnataka Udyog Mitra (KUM) highlighting the strength of public–private collaboration behind the project. Planned as a 50 acre industrial park exclusively for FLO Bangalore members the initiative aims to lower long-standing entry barriers that have historically kept women especially first-generation entrepreneurs out of manufacturing and largescale enterprise. Gowribidanur was deliberately chosen for its balance of connectivity with available infrastructure and long-term potential growth, while avoiding the overcrowding and restraints of Bengaluru’s saturated industrial zones. By engaging a women-led industrial hub in an emerging region the initiative also consciously shifts the focus of industrial growth beyond metropolitan centres by creating local employment, strengthening regional ecosystems and proving that impactful industrial development does not have to be in the city.   The Industrial Park has been designed not merely as a land allocation but as a full ecosystem for women entrepreneurs. FLO Bangalore with the support of KIADB and KUM has put in place enabling backgrounds that include single window access for approvals with handholding through consultants, access to financial institutions and guidance on business planning along with compliance and project execution. The goal is to simplify a system that has long been scary for first generation entrepreneurs. Once operational the park also plans to introduce shared facilities such as skill development and capacity building centres, creche facilities and R&D support and other infrastructure that recognises the real lived needs of women building businesses alongside family responsibilities.  ]]> https://biospectrumindia.com/news/104/27279/forus-health-secures-cdsco-approval-for-ai-led-diabetic-retinopathy-screening-tool-.html https://biospectrumindia.com/news/104/27279/forus-health-secures-cdsco-approval-for-ai-led-diabetic-retinopathy-screening-tool-.html Wed, 04 Feb 2026 00:00:00 +0530 Bengaluru-based medtech firm Forus Health has received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) for its FH-POISE™ DRT (Diabetic Retinopathy Tools). FH-POISE™ (Precision Ocular Intelligence for Systemic & Eye Health) is Forus Health’s AI-powered retinal image analysis platform designed to support the detection and screening of ocular and systemic diseases using state-of-the-art algorithms. The approval enables FH-POISE™ DRT to be used as a screening tool to identify patients at risk of diabetic retinopathy, supporting earlier clinical evaluation and timely intervention to help prevent diabetes-related vision loss. The software uses deep learning models to assess retinal images and predict disease severity, allowing for more nuanced and clinically relevant screening outcomes. It has received CDSCO approval as Class C SaMD (Software as a Medical Device), one of the most stringent risk categories, with the approach validated on real-world retinal images, spanning a diverse demography, demonstrating suitability for real-world healthcare settings. India carries one of the world’s largest diabetes burdens. According to the International Diabetes Federation, approximately 89.8 million adults in India were living with diabetes in 2024, placing sustained pressure on the healthcare system.  “India’s challenge with diabetic retinopathy is not awareness alone, but scale,” said Chandrasekhar K., Founder and CEO, Forus Health, “Embedding reliable screening into routine diabetes care is essential if we are to prevent avoidable vision loss. Regulatory approval for FH-POISE™DRT enables technology-focussed screening closer to where patients already receive care, helping strengthen early detection while making better use of limited specialist capacity.” The broader economic impact of vision impairment further underscores the importance of early detection. Peer-reviewed studies estimate that vision impairment and blindness in India result in productivity losses exceeding Rs 11,000 crore annually, highlighting the societal cost of delayed diagnosis and treatment. With CDSCO approval in place, Forus Health plans to deploy FH-POISE™ DRT across hospitals, public health initiatives, and screening programs, aligned with India’s focus on preventive healthcare and digital health–enabled early diagnosis.   ]]> https://biospectrumindia.com/news/104/27227/fresenius-medical-care-opens-global-business-services-office-in-bengaluru.html https://biospectrumindia.com/news/104/27227/fresenius-medical-care-opens-global-business-services-office-in-bengaluru.html Tue, 27 Jan 2026 00:00:00 +0530 Germany headquartered Fresenius Medical Care recently celebrated the opening of the company's  Global Business Services (GBS) office in Bengaluru. This marks an important milestone for Fresenius Medical Care, and a step forward on its global journey. This new centre is designed to attract, nurture, and develop talent across India, with a ramp-up planned in the months ahead. This new workspace is designed to foster collaboration, innovation, and excellence as the company continues to advance care and deliver meaningful outcomes for the communities it serves. The inauguration brought together the company's leadership, colleagues, and partners to reflect on the journey and share their vision for the future. Through leadership messages and expert insights from a renowned nephrologist Dr Vishwanath S, Head of Department & Consultant, Nephrology & Transplant Physician at the Manipal Hospitals in Bengaluru, the company reaffirmed its purpose and commitment to care. Fresenius Medical Care is the world’s leading provider of products and services for people with chronic kidney failure. ]]> https://biospectrumindia.com/news/104/27209/kapiva-launches-rs-50-cr-innovation-fund-to-build-future-ready-ayurveda-ecosystem.html https://biospectrumindia.com/news/104/27209/kapiva-launches-rs-50-cr-innovation-fund-to-build-future-ready-ayurveda-ecosystem.html Wed, 21 Jan 2026 00:00:00 +0530 Bengaluru-based Kapiva, India’s first modern holistic Ayurvedic brand for millennials, has announced the launch of the Kapiva Innovation Fund (KIF), a commitment of up to Rs 50 crore to support research and innovation in Ayurveda. KIF will back projects across academia, labs and startups that focus on R&D in Ayurvedic science and create clinically validated solutions for real-world health problems. With this initiative, Kapiva aims to help build an Ayurveda research ecosystem that matches global pharmaceutical standards. KIF will support work in areas such as novel formulations, standardisation and phytochemistry, AI in Ayurveda, pre-clinical and clinical studies, new extraction technologies, bioactive enhancement, tech-enabled wellness models, etc. Applications will be invited from research institutions, PhD scholars, clinicians, hospitals, early-stage startups and incubators working in or adjacent to Ayurveda, plant-based therapeutics and integrative health.The fund is structured to nurture innovation throughout the entire development process. Whether a project is in the initial research phase or nearing commercialisation, KIF will offer the necessary capital, mentorship, and clinical resources. This support system ensures that high-potential scientific ideas are successfully translated into practical, real-world solutions. Kapiva already runs one of India’s most advanced Ayurveda R&D programmes, with clinical trials on flagship products and a dedicated in-house research team. The company collaborates with leading institutions like Translational Health Science and Technology Institute (Ministry of Science and Technology, GoI), Manipal College of Pharmaceutical Sciences (MCOPS, MAHE), Manipal Hospitals among others on various research projects. As part of this focus on scientific rigour and transparency, Kapiva follows stringent testing protocols across raw materials, packaging and finished products, with several Shilajit-based offerings like the Shilajit Gold Resin, already carrying Certificates of Analysis, and the same standards being progressively extended across its portfolio. ]]> https://biospectrumindia.com/news/104/27172/lantern-pharma-establishes-ai-centre-of-excellence-and-advanced-agentic-labs-in-bengaluru.html https://biospectrumindia.com/news/104/27172/lantern-pharma-establishes-ai-centre-of-excellence-and-advanced-agentic-labs-in-bengaluru.html Tue, 13 Jan 2026 00:00:00 +0530 US-based Lantern Pharma Inc., a pioneer in AI-driven precision oncology and computational therapeutic development, has announced the establishment of an AI Centre of Excellence and Advanced Agentic Labs in Bengaluru. This strategic initiative represents a critical inflection point in Lantern's evolution—transitioning from pioneering AI-enabled drug discovery in cancer to industrialising those capabilities at global scale for the broader drug development community. As pharmaceutical companies increasingly shift from AI experimentation to enterprise-scale deployment, Lantern's Bengaluru centre will serve as the company's global scale-up center for the AI platform, providing expanded computational capacity, specialised technical talent, and follow-the-sun development cycles that enable rapid iteration and deployment of advanced AI modules and functionality. The AI centre of excellence capabilities will support both Lantern's internal pipeline and growing roster of pharmaceutical and academic collaborators globally. The centre will expand the technical depth and throughput of Lantern's proprietary RADR® AI platform, which currently leverages hundreds of billions of oncology-focused data points and an expanding library of sophisticated machine learning algorithms and curated disease models and knowledge objects. Critically, the initiative will accelerate development of Lantern's specialised large language model (LLM) designed to assess, optimise, and generate novel molecular candidates across diverse therapeutic applications—translating complex computational insights into precision-targeted drug development strategies. Complementing this, Lantern will expand its specialised large quantitative models (LQMs) designed to aid in assessing and optimising chemical and molecular features, which will provide generative bioinformatic and medicinal chemistry reasoning and outputs. ]]> https://biospectrumindia.com/news/104/27104/plasmagen-biosciences-raises-rs-150-cr-marking-strong-growth-trajectory-.html https://biospectrumindia.com/news/104/27104/plasmagen-biosciences-raises-rs-150-cr-marking-strong-growth-trajectory-.html Mon, 22 Dec 2025 00:00:00 +0530 PlasmaGen Biosciences, a leading biopharmaceutical company focused on blood plasma-derived therapeutics, has raised Rs 150 crore in a minority equity financing round at an Rs 1500+ crore valuation. The round was led by ViNS Bioproducts, a specialty biopharma company, with participation from prominent HNI family offices, pharmaceutical entrepreneurs and existing investors. The financing reflects strong investor conviction in PlasmaGen’s operating model, manufacturing infrastructure, and long-term potential as a differentiated plasma biopharmaceutical platform. Since commencing commercial operations at its state-of-the-art manufacturing facility in 2024 - India's first such facility by a pure-play company and only the fifth plasma fractionation facility in the country - PlasmaGen has delivered rapid revenue growth and is now preparing to enter international markets. Founded in 2010 and headquartered in Bengaluru, PlasmaGen has raised over Rs 600 crore in total funding to date. The fresh capital will be deployed towards scaling international operations, expanding the product portfolio and strengthening organizational capabilities. The company has identified distribution partners in key export markets and is advancing regulatory approvals to commence international operations. Domestically, PlasmaGen continues to strengthen its market presence with its portfolio of plasma-derived therapeutics addressing significant unmet medical needs. ]]> https://biospectrumindia.com/news/104/27108/care-adhd-expands-global-operations-with-first-gcc-in-india.html https://biospectrumindia.com/news/104/27108/care-adhd-expands-global-operations-with-first-gcc-in-india.html Mon, 22 Dec 2025 00:00:00 +0530 Care ADHD, one of the United Kingdom’s fastest growing digital mental health companies and a key partner to the NHS, has announced the opening of its first Global Capability Centre (GCC) in India – Bengaluru. The facility was inaugurated by Deputy Trade Commissioner to South Asia (Investment) and British Deputy High Commissioner to Karnataka and Kerala. This expansion marks a strategic move to tap into India’s world-class engineering and product talent as the company scales its global operations. The GCC will accelerate technology development, strengthen operational backbone, and support the company’s virtual care business Duty Doctor. Speaking on the launch, Care ADHD CEO Mark Pattison said “Bengaluru has emerged as one of the most vibrant technology innovation hubs globally, and the company’s decision to build its GCC in the city reflects its commitment to accessing top-tier talent." James Whitebread, CTO, Care ADHD highlighted that “the GCC will focus on next generation diagnostic tools, intelligent patient engagement systems, and seamless integrations for virtual consultation services. The new centre will act as the nucleus for tech-driven product development across the organisation.” Chandru Iyer, His Majesty’s Deputy Trade Commissioner to South Asia (Investment) and British Deputy High Commissioner to Karnataka and Kerala, congratulated CARE ADHD on their decision to enter the Indian market and remarked, “It is encouraging to see UK healthcare organisations expanding in India and inspiring to witness how UK–India collaboration is strengthening the mental health ecosystem, especially through digital-first solutions.” The new centre will foster closer collaboration between clinicians, product teams, and engineering talent to create systems that improve accuracy, enhance patient experience, and accelerate innovation. ]]> https://biospectrumindia.com/news/104/27096/nethradhama-launches-karnatakas-first-mobile-unit-for-bladeless-eye-surgery.html https://biospectrumindia.com/news/104/27096/nethradhama-launches-karnatakas-first-mobile-unit-for-bladeless-eye-surgery.html Fri, 19 Dec 2025 00:00:00 +0530 In a major leap for precision eye surgery in Karnataka, Nethradhama Superspeciality Eye Hospital has launched the Ziemer Z8 Neo, a state-of-the-art multi-purpose femtosecond laser system, now being delivered across multiple centres within the city through a custom-engineered mobile unit. This strategic deployment ensures that patients across all Nethradhama branches can benefit from bladeless, high-precision procedures without the need to centralise care at a single location. The Ziemer Z8 Neo is often described as the Swiss army knife of ophthalmic lasers. It is used to perform bladeless eye surgeries that are gentle, precise, and quick to heal. These include FEMTO-assisted cataract surgery, vision correction procedures like CLEAR and LASIK to reduce dependence on glasses, and treatments for conditions such as keratoconus or damaged corneas. All of these are performed using laser pulses instead of blades, making the procedures safer, less invasive, and more comfortable for patients. With patients actively seeking the best available technology, bladeless surgeries are increasingly preferred for their accuracy, comfort, and minimal downtime. The Z8 Neo’s ability to integrate with premium intraocular lenses and advanced planning software ensures patients experience high-definition vision with reduced dependence on glasses. During the pilot phase, over 600 cataract surgeries and nearly 300 corneal and refractive procedures have already been successfully completed using the Z8 Neo, including bladeless LASIK and the increasingly popular CLEAR technique.  The mobile deployment of the Z8 Neo enables decentralised delivery of premium procedures, offering an approach that balances technological excellence with cost-efficiency. Instead of installing a unit at every branch, Nethradhama’s rotational model allows for weekly procedures at each location, offering consistent care while reducing infrastructure overheads. Nethradhama plans to expand this mobile FEMTO model further, making it accessible to more centres across southern India and continuing its legacy of bringing global-standard technology to local care. ]]> https://biospectrumindia.com/news/104/27050/mma-spectrum-foundation-presents-biospectrum-best-performing-state-of-the-year-2025-award-to-karnataka-.html https://biospectrumindia.com/news/104/27050/mma-spectrum-foundation-presents-biospectrum-best-performing-state-of-the-year-2025-award-to-karnataka-.html Wed, 10 Dec 2025 00:00:00 +0530 MMA Spectrum Foundation and BioSpectrum India, an integrated B2B media platform for the bioscience industry in India, proudly presented Karnataka, the biotech capital of India, with the BioSpectrum Best Performing State of the Year 2025 Award at a glittering function held in New Delhi on December 5. BioSpectrum India, in consultation with a six-member jury panel chaired by Dr Renu Swarup, Former Secretary, Department of Biotechnology, Government of India, selected Karnataka for this prestigious award for its overall contribution to Bioeconomy of the country. Apoorva Bidari, General Manager (Biotechnology & ESDM Policy), Karnataka Innovation and Technology Society (KITS), Government of Karnataka received the award from the Union Minister of State (Independent Charge) for Science and Technology, Dr Jitendra Singh who served as Chief Guest, in presence of Dr Renu Swarup. In his address Dr Jitendra Singh acknowledged the significant contributions of state governments—particularly Karnataka—for establishing robust biotech ecosystems. The states have built sophisticated research hubs, incubation centres, and industrial networks that support innovation from concept to commercialization. Dr Jitendra Singh congratulating BioSpectrum on completing 23 years, applauded its role in highlighting achievements across India’s biotech ecosystem. He expressed his appreciation for the BioSpectrum Awards, noting that such recognition plays an important role in celebrating the country’s scientific and technological progress. Earlier welcoming the august gathering including Union Minister of State (Independent Charge) for Science and Technology, Dr Jitendra Singh Ravindra Boratkar, Publisher & Managing Editor, BioSpectrum India and Managing Trustee, MMA Spectrum Foundation said, “Today, we come together to honour the pioneers, the visionaries, the risk-takers, and the path-breakers who are shaping the future of biotechnology, pharmaceuticals, medtech, diagnostics, digital health, and research. Your work not only strengthens India’s scientific capabilities but also touches millions of lives across the world. The Excellence Awards represent the highest recognition in this journey, celebrating commitment to innovation, ethical leadership, and societal impact.” Sharing her views as the chairperson of the Jury Panel, Dr Renu Swarup, Former Secretary, Department of Biotechnology, said “The entire selection process was extremely robust, with the BioSpectrum team conducting extensive research to identify nominees before presenting them to the jury. The most satisfying moment for the jury is when we receive strong, high-quality nominations — and this year, the nominations were exceptionally rich in contribution. All jury members would agree that it took considerable deliberation to finalise the awardees because the level of competition was so high. This reflects both the strength of the biotechnology sector and the diligence of the evaluation process. During our discussions, the jury also emphasized the importance of recognizing young talent in the future, as nurturing this pipeline is essential for sustaining leadership in the biotechnology ecosystem.” The esteemed Jury members include Dr Jitendra Kumar, Managing Director, Biotechnology Industry Research Assistance Council (BIRAC); Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Dr Sanghamitra Pati, Additional Director General, Indian Council of Medical Research; Dr Shirshendu Mukherjee, Managing Director, Wadhwani Innovation Network; and Prof. Vijay Chandru, Founder and Chairperson, Strand Life Sciences. ]]> https://biospectrumindia.com/news/104/26960/cens-develops-flexible-piezoelectric-nanocomposites-for-biomedical-and-wearable-sensors.html https://biospectrumindia.com/news/104/26960/cens-develops-flexible-piezoelectric-nanocomposites-for-biomedical-and-wearable-sensors.html Fri, 21 Nov 2025 00:00:00 +0530 An innovative piezoelectric device has been fabricated using a polymer nanocomposite of flower-shaped tungsten trioxide (WO₃) nanomaterial embedded in a polyvinylidene fluoride (PVDF) matrix, paving a viable path towards flexible, wearable, highly efficient, energy-harvesting, pressure-sensing devices.   Researchers at the Centre for Nano and Soft Matter Sciences (CeNS), Bengaluru, an autonomous institute of the Department of Science and Technology (DST) employed a systematic experimental approach to explore the interactions between polymers and nanomaterials.  The research which involves mixing of flexible piezoelectric polymer and nanoparticles and systematic study of the resultant mechanical energy conversion efficiency gives an insight into understanding/classifying what type of nanoparticle can enhance the piezoelectric properties of a piezoelectric polymer. The high sensitivity and energy efficiency of this nano-engineered system make it ideal for biomedical uses. In particular, it can be incorporated into wearable health monitoring systems that can capture biomechanical energy from minor to major body movements like heartbeats, pulses, breathing, walking, etc., and transform it into electrical signals. By using these signals, physiological parameters can be monitored in real time without requiring external power sources. ]]> https://biospectrumindia.com/news/104/26911/boheco-opens-indias-largest-cannabis-leaf-based-wellness-clinic-in-bengaluru.html https://biospectrumindia.com/news/104/26911/boheco-opens-indias-largest-cannabis-leaf-based-wellness-clinic-in-bengaluru.html Wed, 12 Nov 2025 00:00:00 +0530 India’s pioneering cannabis wellness enterprise, Bombay Hemp Company (BOHECO), has announced the launch of its largest flagship Holistic Health & Wellness Clinic & Store in Bengaluru in partnership with Soulgoal Artisan – a space that redefines how India experiences health, healing, and holistic well-being through Cannabis-Leaf based Ayurveda. The launch comes at a time when India’s wellness market is witnessing a shift towards evidence-based, plant-derived therapies, and public awareness around the clinical potential of cannabis is growing rapidly. With more than a decade of R&D and advocacy, BOHECO is at the forefront of this transformation, turning India’s ancient relationship with the Cannabis plant into a modern movement for natural, science-backed healing. The Bengaluru flagship serves as a hub for education, consultation, therapies, and discovery, combining doctor-led clinics, research-backed formulations, and immersive brand experiences under one roof. With a growing global acceptance of medicinal cannabis and a domestic wellness industry projected to cross $20 billion by 2026, BOHECO’s expansion signals a cultural shift, from curiosity to credibility. BOHECO’s formulations, spanning pain management, sleep, stress, and skincare, are developed through its in-house R&D and manufacturing facility, and prescribed via BOHECO’s growing network of doctors and virtual clinics across India. The company also collaborates with CSIR-NBRI, National Institute of Ayurveda, and the Tata Memorial Centre on research and clinical trials studying Cannabis applications in pain, sleep, and cancer management; further legitimising its role in shaping India’s medical cannabis landscape. ]]> https://biospectrumindia.com/news/104/26890/soukya-invests-rs-125-cr-to-develop-100-bed-integrative-ayush-hospital-in-bengaluru.html https://biospectrumindia.com/news/104/26890/soukya-invests-rs-125-cr-to-develop-100-bed-integrative-ayush-hospital-in-bengaluru.html Thu, 06 Nov 2025 00:00:00 +0530 Soukya International Holistic Health Centre, globally acclaimed for its premium holistic therapies, has acquired six acres of land near its existing campus in Hoskote, Bengaluru, as part of its plans to establish a 100-bedded AYUSH hospital focused on making integrative healthcare more accessible. The total project cost is estimated at Rs 125 crore, which includes Rs 50 crore for land acquisition and Rs 75 crore towards construction and development. The upcoming facility will offer integrated care for a wide spectrum of serious, chronic, rare, and complex medical conditions, combining Allopathy, Ayurveda, Homeopathy, Naturopathy, Siddha, Unani, and Yoga with complementary therapies. Renowned for setting global benchmarks in holistic wellness, Soukya has pioneered a distinctive model that seamlessly blends medical science with traditional healing, natural remedies, and preventive care. This expansion marks a pivotal milestone in its journey, extending integrative wellness to a broader community at a time when India’s AYUSH ecosystem is witnessing unprecedented growth and policy support. The Ministry of AYUSH’s FY26 allocation has risen by 14.2% to Rs 3,992.9 crore ($ 461.3 million), while the Indian AYUSH market, valued at $ 43.3 billion in 2024, is projected to reach $ 200 billion by 2030. In parallel, India’s wellness tourism sector, expected to grow from Rs 1.64 lakh crore to Rs 2.57 lakh crore by 2031, reflecting the global surge in demand for Ayurveda, yoga, and holistic rejuvenation. Construction of the new hospital is expected to begin within the next 6-9 months and will be executed in two phases. Phase I will include 50 beds and a set of core specialisations, while Phase II will expand the facility’s capacity and service portfolio. The hospital is expected to be fully functional by the end of FY 27. The 100 bedded hospital in Bengaluru will provide advanced integrative care across multiple disciplines, including cancer rehabilitation, respiratory disorders, lifestyle and metabolic conditions, pediatric developmental disorders, reproductive health, neurological and musculoskeletal disorders, gastrointestinal diseases, and addictive behaviours.  ]]> https://biospectrumindia.com/news/104/26878/28th-edition-of-bengaluru-tech-summit-to-attract-20000-delegates.html https://biospectrumindia.com/news/104/26878/28th-edition-of-bengaluru-tech-summit-to-attract-20000-delegates.html Tue, 04 Nov 2025 00:00:00 +0530 “The 28th edition of Bengaluru Tech Summit (BTS 2025), a three-day event scheduled from November 18-20 at will feature 500+ speakers, 20,000+ delegates, 1,000+ exhibitors and 50,000+ business visitors from over 60 countries at Bangalore International Exhibition Centre (BIEC), a modern, purpose-built venue offering world-class infrastructure and eco-conscious facilities” said Dr Manjula N, Secretary, Department of Electronics, IT, Bt & S&T, Government of Karnataka. Highlighting the move to the BIEC, Dr Manjula noted that the upgraded venue provides the ideal setting for a larger and more ambitious event. “BIEC offers world-class facilities and excellent connectivity, enabling BTS 2025 to host global participants and deliver an expanded experience for innovators and investors alike,” she said. Dr Manjula further emphasised that the enhanced scale of the summit reflects the Government’s commitment to driving deep tech innovation and supporting entrepreneurs shaping the future of technology. The multi-pavilion exhibition will spotlight innovations across sectors with increased global participation. The Startup Springboard will feature investor pitching, mentoring clinics, thematic sessions, and the Startup Pavilion, offering growth-stage startups critical visibility and investor access. Highlight programmes include the Rural IT Quiz, BioQuiz, Exhibitor Awards, and the Global Leaders Reception. Organised by the Department of Electronics, IT & Bt, Government of Karnataka, Bengaluru Tech Summit (BTS 2025) under the theme ‘Futurise’ will feature ten curated conference tracks spanning AI & Deep Tech, Defence & Space Tech, Electronics & Semiconductor, DigiHealth & Biotech, Energy & Mobility, Fintech, and Edutech.   With its expanded scope, global participation, and deep focus on innovation, Bengaluru Tech Summit 2025 reaffirms Karnataka’s position as the Innovation and Deep Tech Capital of India, showcasing the State’s leadership in building technologies and startups that will shape the future. ]]> https://biospectrumindia.com/news/104/26879/karnataka-unveils-rs-600-cr-deep-tech-decade-initiative.html https://biospectrumindia.com/news/104/26879/karnataka-unveils-rs-600-cr-deep-tech-decade-initiative.html Tue, 04 Nov 2025 00:00:00 +0530 The Government of Karnataka has announced an investment of over Rs 600 crore to power the state’s “Deep Tech Decade,” with the goal of establishing Karnataka as the Deep Tech Capital of India. Priyank Kharge, Minister for IT & BT, Government of Karnataka announcing this emphasised that the initiative aims to build a robust pipeline of entrepreneurs and innovators working in cutting-edge fields such as artificial intelligence (AI), machine learning (ML), quantum computing, advanced manufacturing, robotics, and sustainability-driven technologies. As part of this vision, the government is also in talks with leading venture capital firms to create a joint Deep Tech and AI fund of up to Rs 1,000 crore to support startups in the sector. The Rs 600 crore investment includes Rs 150 crore for the Deep Tech Elevate Fund, focusing on AI and frontier technologies; Rs 80 crore under the Elevate Beyond Bengaluru Fund to promote startups in Mysuru, Mangaluru, Hubballi-Dharwad, and Kalaburagi; Rs 75 crore through the KITVEN Fund for equity investments ranging between Rs 50 lakh and Rs 2 crore in Deep Tech and AI startups; and Rs 48 crore for establishing new incubators and accelerators at IIT Dharwad, IIIT Dharwad, and Kalaburagi. In addition, Rs 110 crore will be allocated for business incubators in higher education institutions, supporting early-stage innovation and entrepreneurship across 11 institutions already approved by the state cabinet. The government has further earmarked Rs 200 crore specifically for Deep Tech startups and plans to explore fund-of-funds and co-investment models in collaboration with venture capital ecosystems to ensure steady capital flow and scalability across the Deep Tech value chain. Dr Manjula N, Secretary, Department of Electronics, IT, Bt & S&T; and Rahul Sankanur, Director, Department of Electronics, IT & Bt and Managing Director, KITS were also present while Kharge made the announcements.   Photo caption: From Left to Right: Dr Manjula N., Secretary to Government, Dept. of Electronics, Information Technology, Biotechnology and Science & Technology; Priyank Kharge, Minister for Information Technology, Biotechnology and Rural Development & Panchayat Raj, Government of Karnataka; Rahul Sankanur, Director, Directorate of Electronics, Science and technology IT&Bt, MD, KITS, Govt. of Karnataka addressing the media at a press conference in Bengaluru on November 3. ]]> https://biospectrumindia.com/news/104/26880/bts-2025-to-host-indias-largest-entrepreneurship-platform-future-makers-conclave-on-nov-20-.html https://biospectrumindia.com/news/104/26880/bts-2025-to-host-indias-largest-entrepreneurship-platform-future-makers-conclave-on-nov-20-.html Tue, 04 Nov 2025 00:00:00 +0530 Ahead of the 28th edition of the Bengaluru Tech Summit (BTS 2025), scheduled to take place from 18 to 20 November 2025 at the Bangalore International Exhibition Centre (BIEC), the Department of Electronics, IT & Bt, Government of Karnataka, held a press interaction to announce the Future Makers Conclave (FMC) — a first-of-its-kind initiative and a major highlight of this year’s summit. The event was attended by Priyank Kharge, Minister for Information Technology, Biotechnology, and Rural Development & Panchayat Raj; Dr Manjula N, Secretary, Department of Electronics, IT, Bt & S&T; and Rahul Sankanur, Director, Department of Electronics, IT & Bt and Managing Director, KITS. Highlighting the significance of this initiative, Priyank Kharge described the Future Makers Conclave as India’s largest entrepreneurship platform for young innovators and disruptors. He noted that the event will serve as a confluence of entrepreneurs, venture capitalists, corporate mentors, and future innovators, acting as a powerful accelerator for startup ambitions and reaffirming Karnataka’s leadership in driving Deep Tech innovation across multiple sectors. Priyank Kharge also unveiled the official logo of the Future Makers Conclave. The Future Makers Conclave, scheduled for November 20, 2025, is envisioned as a vibrant gathering of over 10,000 founders, entrepreneurs, investors, mentors, and ecosystem leaders. Designed to be a high-energy celebration of innovation, the conclave will showcase India’s most promising AI and Deep Tech startups through show-and-tell sessions, keynote addresses by industry icons, unicorn founders, investors, and thought leaders. Positioned as a global innovation platform, the Future Makers Conclave will, for the first time, feature international participation—bringing together global startups presenting their innovations in India, while Indian startups will have the opportunity to showcase their technologies to global markets.   Photo caption: From Left to Right: Dr Manjula N., Secretary to Government, Dept. of Electronics, Information Technology, Biotechnology and Science & Technology; Priyank Kharge, Minister for Information Technology, Biotechnology and Rural Development & Panchayat Raj, Government of Karnataka; Rahul Sankanur, Director, Directorate of Electronics, Science and technology IT & Bt, MD, KITS, Govt. of Karnataka releasing the Future Makers logo before the Bangalore Tech Summit 2025 ]]> https://biospectrumindia.com/news/104/26867/max-healthcare-and-tata-institute-for-genetics-and-society-sign-mou-to-advance-healthcare-through-genomics-and-research.html https://biospectrumindia.com/news/104/26867/max-healthcare-and-tata-institute-for-genetics-and-society-sign-mou-to-advance-healthcare-through-genomics-and-research.html Mon, 03 Nov 2025 00:00:00 +0530 Max Healthcare, one of the largest private sector healthcare services companies in India, and Tata Institute for Genetics and Society (TIGS), a leading genomics research institute, have announced the signing of a Memorandum of Understanding (MoU). This landmark agreement will establish a collaborative platform for pioneering research, training, and knowledge exchange in the fields of genetics and healthcare, with the shared goal of improving patient outcomes and advancing clinical science. The MoU was signed in a ceremony attended by senior representatives from both the organisations. This partnership will focus on leveraging cutting-edge genomic research to address some of the most pressing healthcare challenges. Key areas of collaboration will include joint research projects in rare genetic diseases, a dedicated focus on neonatal care through genomic insights, and the development of personalized medicine based on genetic profiling. This collaboration will also facilitate the exchange of knowledge and expertise between scientists, clinicians, and researchers from both institutions through joint conferences, workshops, and training programmes. By combining Max Healthcare’s extensive clinical expertise and patient data with TIGS’s advanced genomics research capabilities, the partnership aims to accelerate the translation of research findings into clinical practice. The collaboration marks a significant step forward in advancing the role of genetics in haematology and neonatal care. By combining expertise in these fields, the partnership aims to deepen understanding of the genetic basis of blood disorders, cancers, and critical neonatal conditions. This will not only enable more precise diagnosis and personalized treatment strategies but also improve early identification of genetic risk factors in newborns. Together, these efforts have the potential to transform patient care and outcomes, ushering in a new era of genomic medicine. ]]> https://biospectrumindia.com/news/104/26871/remidio-unveils-neubo-130-a-breakthrough-in-ai-enabled-retinal-imaging-for-newborns.html https://biospectrumindia.com/news/104/26871/remidio-unveils-neubo-130-a-breakthrough-in-ai-enabled-retinal-imaging-for-newborns.html Mon, 03 Nov 2025 00:00:00 +0530 Bengaluru-based Remidio Innovative Solutions, a leader in artificial intelligence (AI)-powered ophthalmic devices, has announced the launch of Neubo 130, a next-generation ultra-widefield neonatal retinal imaging system designed to enhance precision diagnostics for neonatal retinal conditions like Retinopathy of Prematurity (ROP). India sees over three million premature births each year, translating to nearly 15 million retinal examinations if every baby is screened as per protocol. With the limited number of ROP specialists, it’s impossible to bridge this gap without technology. Built to support clinicians working in both hospitals and neonatal intensive care units (NICUs), Neubo 130 combines innovative optical engineering with edge AI to assist in the detection of ROP in real time, even without internet connectivity. With a 130° field of view, through-the-lens illumination, and light-shaping technology, Neubo 130 ensures uniform retinal brightness and exceptional peripheral visualisation, critical for identifying subtle changes in the newborn retina that guide timely treatment decisions. Key highlights of the Neubo 130 include: Consistent peripheral detail (uniform illumination and reduced glare). Small-pupil imaging possible (high-quality imaging at pupils ≥3 mm). Bedside triage that’s instant, private, and standardised (offline AI assists ROP and plus-disease triage; standardized workflow reduces missed cases). Panoramic views with fewer retakes (auto-montage aligns multiple gazes into a single 130° composite) Built for collaborative care (telemedicine- and cloud-ready for secure review, triage, and referral) “The launch of Neubo 130 marks a major step forward in neonatal eye care,” said Dr. Anand Sivaraman, CEO of Remidio. “This platform is our bet on certainty, reframing ROP from a resource problem to an engineering solution. By enabling dependable, on-the-spot decisions at the bedside, we move from ‘screening when possible’ to ‘protecting vision as standard’. With its lightweight design (below 500g), high-resolution imaging (2.4MP), and offline AI workflow, Neubo 130 extends Remidio’s mission to make eye care accessible, affordable, and scalable across all settings , from tertiary hospitals to special newborn care units (SNCUs). ]]> https://biospectrumindia.com/news/104/26872/inviga-healthcare-fund-acquires-21-stake-in-forus-health.html https://biospectrumindia.com/news/104/26872/inviga-healthcare-fund-acquires-21-stake-in-forus-health.html Mon, 03 Nov 2025 00:00:00 +0530 Inviga Healthcare Fund (IHF), the private equity platform founded by Dr. B. S. Ajaikumar of HCG, has acquired a 21% stake in Bengaluru-based Forus Health, an ophthalmic diagnostics pioneer whose devices have screened over 22 million patients across 75+ countries. Forus Health’s comprehensive digital platform integrated with artificial intelligence (AI) for Ocular & Oculomics has helped deliver last mile comprehensive eye diagnostics to over 5M+ patients across the world. The secondary transaction signals Inviga’s intent to back world-class, AI-driven diagnostic solutions designed and built in India, and deployed globally at scale. This marks Inviga’s second major investment following its backing of Mynvax in 2024. Founded by Dr. B. S. Ajaikumar, a doctor-preneur and Chairman of HealthCare Global Enterprises (HCG), Inviga Healthcare Fund invests in high-impact healthcare ventures and champions Indian healthcare entrepreneurial talent. Its mission is to build sustainable, accessible, and outcome-driven healthcare platforms that blend clinical excellence with scalable innovation. Forus Health is founded by K. Chandrasekhar, an industry veteran with exceptional experience in health-tech & semiconductor industries. The company is best known worldwide for its 3nethra series of ophthalmic screening devices that have improved access to affordable eye care across the world. In 2025, Forus Health was listed among TIME Magazine’s World’s Top 400 HealthTech Companies for its significant impact on making vision care more widely accessible through technology. The Forus platform now offers an integrated digital solution for managing comprehensive eye health. Its latest product, 3nethra specto, is the world’s first wearable digital refractor controlled by a smartphone, enabling remote and tele-optometry services. The global burden of preventable blindness underscores the importance of scalable eye-care innovation. It is estimated that over 270 million Indians live with some form of visual impairment, a majority of which is preventable through early detection. With around 100 million diabetics, nearly one in five are at risk of diabetic retinopathy (DR), while 3.5 million preterm births annually place nearly 2 million infants at risk of retinopathy of prematurity (ROP)—both leading causes of avoidable blindness. Globally, over 2.2 billion people suffer from vision impairment or blindness, of which more than 1 billion cases are preventable or treatable. The challenge extends even to high-income countries, where aging populations and diabetes continue to drive incidence despite advanced health systems. Forus Health’s advancements have helped bridge these diagnostic gaps worldwide, improving access to affordable, portable, and early-stage eye screening solutions across both emerging and developed markets.   ]]> https://biospectrumindia.com/news/104/26856/shilpa-medicare-opens-flow-chemistry-manufacturing-centre-in-bengaluru.html https://biospectrumindia.com/news/104/26856/shilpa-medicare-opens-flow-chemistry-manufacturing-centre-in-bengaluru.html Thu, 30 Oct 2025 00:00:00 +0530 Shilpa Medicare, a full-service contract development and manufacturing organization (CDMO), has announced the launch of its new flow chemistry Centre of Excellence (CoE) at CPHI Frankfurt. Based at the CDMO’s Bengaluru site, the Centre unites cross-functional teams across R&D and manufacturing to accelerate process development, scale-up, and commercial production for continuous flow. The new CoE is staffed by a team of more than 100 specialists and integrates Sravathi’s proprietary flow technologies with Sravathi’s advanced continuous reactor platforms, enabling the development and commercialisation of an expanded range of reactions including fluorination, bromination, nitration, chlorination, oxidation, and Grignard reactions. Sravathi’s flow chemistry group has already developed over 30 flow-based reactions, successfully transferring more than five pilot-scale processes to client sites for commercial manufacture.  In terms of reactors the site features more than 50 patented, custom-designed micro and pilot flow reactors, with lab, bench, and pilot scales ranging from 30 mL/min to 200 mL/min. These systems handle multi-phase, catalytic, and gas–liquid reactions under corrosion-resistant materials of construction, ensuring safety and reliability across highly exothermic or hazardous chemistries. Continuous downstream operations —such as crystallization, extraction, and thin-film evaporation — allow fully integrated end-to-end processing. Designed at Sravathi, the reactors have shown consistent and reliable scale-up from laboratory to commercial operations for processes involving gas–liquid and liquid–liquid reactions. By integrating scalability considerations into the design, the time-to-market and risks commonly associated with scale-up have been notably reduced. The centre includes automated processes for temperature and pressure measurements, meaning monitoring and adjustments can be done remotely. This high degree of digitalization ensures reproducibility and scalability while minimizing human intervention during flow operation.   ]]> https://biospectrumindia.com/news/104/26839/thermo-fisher-scientific-invests-rs-160-cr-to-expand-bengaluru-rd-facility.html https://biospectrumindia.com/news/104/26839/thermo-fisher-scientific-invests-rs-160-cr-to-expand-bengaluru-rd-facility.html Mon, 27 Oct 2025 00:00:00 +0530 Thermo Fisher Scientific’s expanded Research and Development (R&D) Centre of Excellence was officially inaugurated in Bengaluru by Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission (KDEM). This facility is committed to pioneering advances in antibody design, development, and manufacturing. It represents a significant milestone in the company’s efforts to accelerate innovation and scientific collaboration from India. Thermo Fisher has invested over Rs 160 crore in this expansion, reinforcing its long-term commitment to India’s research ecosystem. The expanded 37,000 sq. ft. facility incorporates advanced automation and analytical platforms to support immunoassays, protein analysis, and cell-based studies. In the coming years, the expansion will create 100+ jobs, strengthening local talent development and contributing to Karnataka’s thriving life sciences ecosystem. Speaking about the occasion, Priyank Kharge, Minister for Electronics, IT & Biotechnology and Rural Development & Panchayat Raj, Government of Karnataka, said, “Karnataka has long positioned itself as a vibrant hub for biotechnology and life sciences. The expansion of Thermo Fisher’s facility is a testament to the state’s continued emphasis of this objective. Through our Karnataka Biotechnology Mission and aligned state policies, we are enabling innovation, nurturing talent, and facilitating collaboration between government, academia and industry. This facility strengthens the state’s capability to contribute meaningfully to India’s broader biotechnology vision.”  With this expansion, Thermo Fisher’s Bengaluru Centre of Excellence continues to serve as a cornerstone of its global R&D network. Over the past 18 years, the facility has developed more than 2,000 high-quality recombinant antibodies that have contributed to advancements in infectious diseases, antiviral studies, and cancer biology. Its antibody validation programme has tested over 25,000 antibodies, while manufacturing capabilities have produced more than 2,000 primary and secondary antibodies, ensuring quality and reproducibility for researchers worldwide. Bengaluru is Thermo Fisher’s strategic hub in India, with more than 1,400 professionals working across R&D, software, and scientific product teams.    Image caption-  From L to R: Gianluca Pettiti, Executive Vice President and Sector President, Life Sciences, Diagnostics and Applied Sector, Thermo Fisher Scientific and Sanjeev Kumar Gupta, CEO, Karnataka Digital Economy Mission inaugurating the company’s expanded Research and Development (R&D) Centre of Excellence in Bengaluru ]]> https://biospectrumindia.com/news/104/26825/syngene-announces-plans-to-add-bioconjugation-suite-for-end-to-end-adc-development.html https://biospectrumindia.com/news/104/26825/syngene-announces-plans-to-add-bioconjugation-suite-for-end-to-end-adc-development.html Thu, 23 Oct 2025 00:00:00 +0530 Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru. With this new capability, Syngene will offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) – from discovery through to GMP manufacturing – placing it among a handful of CDMOs with full-service capabilities. The OEB-5 rated suite will accelerate ADC development timelines by enabling both Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single site, complementing Syngene’s existing commercial capabilities in payload and linker manufacturing. Expected to be operational within this financial year, the conjugation facility will also support a range of advanced conjugates and related modalities. These services are further strengthened by collocated analytical and bioanalytical capabilities, ensuring seamless integration across the development lifecycle. “The discovery and development of ADCs is complex, often involving multiple vendors and geographically dispersed sites, which adds substantial supply chain complexity and potential delays,” said Alex Del Priore, Head - LM CDMO, Syngene International. “By integrating bioconjugation capabilities with our commercial-scale biologics, payload, and linker production units in Bengaluru, we can significantly compress development timelines and offer a unique, end-to-end pathway from early discovery through to GMP manufacturing,” he added. Building on a decade of experience in ADC discovery and with proven expertise in handling high-potency payloads, linkers, and mAbs across well-established, GMP-compliant facilities, Syngene is scaling its capabilities to support clinical programs and plans to develop commercial-scale capabilities in the future. Additionally, the laboratories will offer process development, analytical characterisation, and scale-up for both early- and late-stage programmes. ]]> https://biospectrumindia.com/news/104/26808/dharti-bionest-incubation-centre-opens-at-indian-institute-of-technology-iit-dharwad.html https://biospectrumindia.com/news/104/26808/dharti-bionest-incubation-centre-opens-at-indian-institute-of-technology-iit-dharwad.html Wed, 15 Oct 2025 00:00:00 +0530 Union Minister of Finance and Corporate Affairs, Nirmala Sitharaman, inaugurated the dhaRti BioNEST Incubation Centre at the Indian Institute of Technology (IIT) Dharwad supported jointly through the Member of Parliament Local Area Development Scheme (MPLADS) and DBT BIRAC. The dhaRti BioNEST Centre at IIT Dharwad will serve as a catalyst for biotech and deep-tech innovation, offering startups state-of-the-art infrastructure, plug-and-play labs, mentorship, and access to funding and networks — helping transform breakthrough ideas into scalable ventures.In her address, the Minister shared her perspectives on India’s rapidly evolving innovation and entrepreneurship landscape. She emphasised that “a young innovator’s main business is to keep innovating”, highlighting the need for an enabling ecosystem that allows innovators to focus on ideation while institutions and industry facilitate pathways for product development and commercialization.The Minister highlighted India’s strong infrastructure, the increasing collaboration between academia and industry, and the importance of mentorship and teamwork in building a future-ready generation. Gracing the occasion as the Guest of Honour, Dr Jitendra Kumar, Managing Director, Biotechnology Industry Research Assistance Council (BIRAC), commended the visionary step that integrates regional development with the national biotechnology mission.In his address, Dr Kumar highlighted how the dhaRti BioNEST Centre symbolises the “crown jewel” of India’s innovation ecosystem. He emphasised that BioNEST centres have become powerful economic engines, nurturing over 20 startups annually, each contributing to high-value innovation, job creation, and the strengthening of India’s bioeconomy. ]]> https://biospectrumindia.com/news/104/26809/healthium-medtech-strengthens-cardiac-care-portfolio-through-partnership-with-tisgenx.html https://biospectrumindia.com/news/104/26809/healthium-medtech-strengthens-cardiac-care-portfolio-through-partnership-with-tisgenx.html Wed, 15 Oct 2025 00:00:00 +0530 Bengaluru-based Healthium Medtech, a global medtech company with a growing portfolio across surgical, post-surgical, advanced wound care, arthroscopy and infection prevention, has announced an exclusive partnership with US-based Tisgenx, Inc., the world’s leading manufacturer of bovine pericardial tissue patches. These patches, widely used in valve repair, vessel reconstruction and other complex cardiovascular and soft tissue interventions, are now made available to Indian surgeons through this collaboration. Under this agreement, Healthium has secured exclusive multiple rights to distribute Tisgenx’s products in India. By expanding access to proven cardiac solutions, this partnership strengthens Healthium’s position in the cardiac care segment and reinforces its commitment to innovation-led, specialty-driven offerings. Known for their superior quality and reliability, the addition of Tisgenx’s pericardial tissue patches also aligns with Healthium’s focus on delivering high-performance, surgeon-centric innovations that simplify clinical decisions and support better healthcare outcomes. Anish Bafna, CEO & MD of Healthium Medtech, said that the collaboration enhances the company’s cardiac care offerings and reinforces its commitment to providing high-quality, best-in-class products that resonate well with Indian surgeons. “We are proud to bring Tisgenx’s globally respected pericardial tissue patches to India through this exclusive partnership. As a homegrown medtech company, we remain focused on providing solutions that address the evolving needs of Indian surgeons and support them in their effort to deliver the best care for their patients,” he commented. Kris Kupumbati, CEO & President of Tisgenx, Inc., noted that India is a strategic market for the company and expressed confidence in Healthium’s ability to deliver clinical value. "India represents one of the fastest-growing healthcare markets in the world and this exclusive partnership with Healthium allows us to play a meaningful role in advancing cardiac care here,” he said, adding, “Together, we are strengthening local access to global innovation and reinforcing our shared commitment to surgeon-centric, patient-first solutions." ]]> https://biospectrumindia.com/news/104/26811/syngene-international-invests-in-dedicated-peptide-laboratory-and-advanced-automation-in-bengaluru.html https://biospectrumindia.com/news/104/26811/syngene-international-invests-in-dedicated-peptide-laboratory-and-advanced-automation-in-bengaluru.html Wed, 15 Oct 2025 00:00:00 +0530 Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has announced site upgrades to accelerate drug discovery and development, helping clients bring novel therapies to market faster. The investments included a dedicated, state-of-the-art peptide laboratory in Bengaluru and the integration of advanced automation across DMPK (Drug Metabolism and Pharmacokinetics) and Direct-to-Biology (D2B) workflows in Hyderabad— boosting scalability, cost-efficiency, and data quality to accelerate therapeutic innovation. The dedicated peptide laboratory is designed to produce a wide range of molecules, including linear peptides, cyclic peptides, and peptide-drug conjugates, and supports synthesis scale-up to 800 mmol (millimole). With six automated peptide synthesizers operating in parallel and equipped with robotic arms, the lab reduces project timelines by weeks or even months while ensuring consistent results. It also features integrated Solid-Phase Peptide Synthesis (SPPS), High-Performance Liquid Chromatography (HPLC), and Liquid-Phase purification, and coupled with Quality Control (QC) laboratories provide innovators with a seamless transition from discovery to development. In parallel, Syngene has made an automation-driven transformation in the DMPK operations. The automation includes Robotic systems for high-throughput sample preparation that reduces turnaround times from five days to three and improves cost efficiency by 30%, and triples sample capacities, providing clients access to critical data much faster. The D2B platform further accelerates hit-to-lead and lead optimization by combining rapid compound design, miniaturized synthesis, and high-throughput screening — saving at least a week for 24-compound sets and several weeks for larger sets.   ]]> https://biospectrumindia.com/news/104/26783/central-council-for-research-in-homoeopathy-and-manipal-academy-of-higher-education-join-hands-to-strengthen-public-health-preparedness.html https://biospectrumindia.com/news/104/26783/central-council-for-research-in-homoeopathy-and-manipal-academy-of-higher-education-join-hands-to-strengthen-public-health-preparedness.html Wed, 08 Oct 2025 00:00:00 +0530 The Central Council for Research in Homoeopathy (CCRH), under the Ministry of AYUSH, in collaboration with the Manipal Institute of Virology (MIV), a constituent unit of Manipal Academy of Higher Education (MAHE), Manipal, has commenced a five-day residential workshop titled “Biosafety & Outbreak Simulation Training 2025” from October 6 to 10, 2025, at the MAHE campus, Manipal, Karnataka. This specialised training programme has been meticulously designed for the research scientists of CCRH. This capacity-building programme aims to enhance preparedness, biosafety practices, and outbreak response capabilities, thereby significantly contributing to the strengthening of public health initiatives under the Ministry of Ayush. The training opportunity for CCRH research scientists sparked immense interest, with widespread participation from 33 institutes/units of CCRH across 22 states/UTs of India. Following a rigorous online assessment conducted by the Manipal Institute of Virology, 30 talented research scientists were selected from 14 states/UTs for their participation in this workshop. A Memorandum of Understanding (MoU) was exchanged between CCRH and MAHE to facilitate fruitful collaboration in the core fields of research, education, and training. Dr Subhash Kaushik, Director General, CCRH, and Dr P. Giridhar Kini, Registrar, MAHE, were the signatories of the MoU. ]]> https://biospectrumindia.com/news/104/26728/nethradhama-partners-with-london-vision-clinic-to-strengthen-ophthalmic-education-in-india.html https://biospectrumindia.com/news/104/26728/nethradhama-partners-with-london-vision-clinic-to-strengthen-ophthalmic-education-in-india.html Wed, 24 Sep 2025 00:00:00 +0530 Nethradhama Super Speciality Eye Hospital collaborates with London Vision Clinic (LoVC), to conduct the Forefront Refractive Surgery Course (APAC Edition) in Bengaluru. The course is aimed at advancing ophthalmic education by enhancing the skills of practitioners in refractive surgery through structured training and international knowledge exchange. The six-day surgical fellowship programme scheduled from September 26 to October 1, 2025 will cover LASIK, PRESBYOND Laser Blended Vision, and SMILE, focusing on practical aspects such as patient selection, surgical technique, complication management, and long-term treatment planning. The course will provide ophthalmologists and trainees with a comprehensive understanding of contemporary refractive surgery, thereby enabling them to integrate these procedures into practice with greater precision and confidence. It will be led by renowned faculties, including Professor Dan Z Reinstein, Medical Director of London Vision Clinic; Prof Dr Sri Ganesh, Chairman and Managing Director of Nethradhama Super Speciality Eye Hospital; and Dr Supriya Samak Sriganesh, Executive Director of Nethradhama Super Speciality Eye Hospital. The programme further extends beyond theoretical learning by incorporating video-based demonstrations and in-depth case discussions, enabling participants to engage directly with the finer aspects of surgical practice.   ]]> https://biospectrumindia.com/news/104/26701/datavant-and-indegene-partner-to-power-more-efficient-clinical-trial-recruitment.html https://biospectrumindia.com/news/104/26701/datavant-and-indegene-partner-to-power-more-efficient-clinical-trial-recruitment.html Fri, 19 Sep 2025 00:00:00 +0530 US-based Datavant, the data collaboration platform trusted for healthcare, has announced a strategic partnership with Bengaluru-based Indegene, a leading digital-first, life sciences commercialisation company, to enhance patient recruitment for clinical trials, with a focus on rare disease and other complex studies. By embedding Datavant’s bespoke data enrichment capabilities into Indegene’s NEXT Patient Recruitment platform, the two companies are enabling faster trial enrollment, fewer screen failures, and more efficient recruitment processes for biopharmaceutical organisations. Patient recruitment is one of the biggest hurdles in clinical development, particularly in rare diseases where eligible populations are small and dispersed. Datavant operates the nation’s largest health data retrieval network, spanning more than 80,000 hospitals and clinics and processing over 100 million patient records annually. Combined with Indegene’s suite of digitally powered solutions for clinical trial recruitment, the partnership streamlines the identification of suitable participants for studies based on specific health data criteria. The result is more eligible participants have an opportunity to connect to the trials designed for their specific health conditions, including patients with rare and complex diseases. The partnership enables biopharma companies to reduce site-level screen failures, accelerate enrollment timelines, improve the screen-to-randomisation ratios, and drive more informed decision-making.   ]]> https://biospectrumindia.com/news/104/26698/stryker-expands-rd-footprint-in-india-with-new-facility-in-bengaluru.html https://biospectrumindia.com/news/104/26698/stryker-expands-rd-footprint-in-india-with-new-facility-in-bengaluru.html Thu, 18 Sep 2025 00:00:00 +0530 US-based Stryker, a global leader in medical technologies, has announced the expansion of its R&D presence in India with the opening of a new facility in Whitefield, Bengaluru.   Building on its existing 220,000 square-foot R&D campus in Gurgaon, the new 140,000 square-foot facility further strengthens Stryker’s footprint in the country. The new state-of-the-art facility brings together cross-functional teams and industry-leading lab infrastructure, uniquely blending next-generation capabilities in robotics, artificial intelligence (AI), digital innovation and product security.   Complementing this innovation hub, a medical experience center will deepen collaboration with healthcare professionals by showcasing solutions that help save lives and improve patient care, including ICU beds, stretchers, ambulance cots, and hospital and public-access AEDs (automated external defibrillators).   “We’re growing with purpose – expanding our capabilities to innovate, collaborate and deliver solutions that address the needs of our customers and patients worldwide,” said Ram Rangarajan, Vice President, Stryker Global Technology Center. “The advanced labs will allow us to work closely with healthcare professionals, unlock valuable insights, and accelerate innovation. With a strong focus on Digital and AI technologies, our new, state-of-the-art facility is designed to attract top talent, foster excellence, and drive sustained growth – all while remaining true to our mission of making healthcare better”.    The launch of the new facility in Bangalore builds on Stryker’s existing presence and reflects its continued commitment towards India’s dynamic ecosystem of research excellence, medical technology innovation and deep talent expertise. ]]> https://biospectrumindia.com/news/104/26583/healthium-medtech-and-c-camp-launch-first-cohort-of-flagship-medtech-innovations-programme-.html https://biospectrumindia.com/news/104/26583/healthium-medtech-and-c-camp-launch-first-cohort-of-flagship-medtech-innovations-programme-.html Mon, 25 Aug 2025 00:00:00 +0530 Healthium Medtech and the Centre for Cellular and Molecular Platforms (C-CAMP) have recently launched the first cohort of the C-CAMP Healthium Innovations Programme for Surgical Interventions and Medical Technologies in Bengaluru. This programme is a part of the CSR initiative of Healthium Medtech. The partnership aims to foster deep-science innovations in digitally enabled medical technologies that are affordable, scalable and clinically impactful. In its first year, the initiative focuses on surgical interventions, an area undergoing rapid modernisation globally but still marked by limited access and affordability across large parts of India. Despite the increasing adoption of advanced surgical technologies in metropolitan hospitals, smaller healthcare systems in Tier 2 and Tier 3 cities often remain underserved. The high cost of imported solutions, along with infrastructure and training gaps, have made it difficult to scale access to modern surgical care. This program was created to address these challenges by nurturing India-led, frugal and scalable innovations that are tailored for local needs without compromising on quality or outcomes. The initiative brings together two organisations with complementary strengths. Healthium Medtech brings deep expertise in surgical and post-surgical technologies, supported by a diverse product portfolio and robust manufacturing capabilities. The company operates 6 facilities with global certifications and holds over 85 patents across India, the US and Europe. C-CAMP, an initiative supported by the Department of Biotechnology, Government of India, has built one of the country’s leading life sciences innovation ecosystems, having supported over 550 deep-tech start-ups across domains and connected with 3000 more. Together, the collaboration combines clinical insight, market access and ecosystem support to help early-stage ventures overcome critical barriers from research to commercialisation. Over the next nine months, the selected startups will receive structured mentorship and incubation support at C-CAMP and access to clinical and industry expertise to help advance their technologies toward market readiness and adoption.   ]]> https://biospectrumindia.com/news/104/26584/medgenome-unveils-indias-first-whole-genome-test-for-precise-brain-tumour-classification.html https://biospectrumindia.com/news/104/26584/medgenome-unveils-indias-first-whole-genome-test-for-precise-brain-tumour-classification.html Mon, 25 Aug 2025 00:00:00 +0530 Bengaluru-based MedGenome, India’s leading genomic diagnostics and research services company, has announced the launch of the country’s first CNS Tumour Methylation Classifier Test. This diagnostic test can differentiate and classify over 90 classes of brain and central nervous system (CNS) tumours into accurate subtypes, enabling doctors to make optimal and accurate treatment decisions. The test was unveiled in the presence of nearly 200 oncologists, neuro-onco surgeons and pathologists, researchers, and doctoral students at a precision oncology symposium in Mumbai, hosted by MedGenome jointly with Illumina, the global market leader in DNA sequencing and life sciences technologies. Brain and CNS tumours are among the most complex cancers to diagnose. MedGenome’s new test complements traditional techniques, like Histology, by offering additional insights, as it studies the entire genome, identifying molecular changes and also predicting the tumor’s treatment response. The test uses DNA methylation profiling, a technique that examines chemical modifications across the genome, to create a unique profile of the tumour. This profile is then compared to a global reference database to identify the exact tumuor type, enabling treatment planning tailored to the tumor’s molecular profile. The test has been found to be efficient even in cases that are rare or difficult to classify accurately. The results offer comprehensive support for more precise treatment decisions and guide personalised care. MedGenome’s CNS Tumour Methylation Classifier Test aligns with the World Health Organization’s 2021 guidelines for CNS tumour classification. It delivers results within 21 days and includes WHO grade assignment, genome-wide copy number profiling, and key gene alteration detection in line with the best global practices. ]]> https://biospectrumindia.com/news/104/26564/nova-ivf-fertility-brings-artificial-intelligence-into-ivf-labs-for-smarter-embryo-selection.html https://biospectrumindia.com/news/104/26564/nova-ivf-fertility-brings-artificial-intelligence-into-ivf-labs-for-smarter-embryo-selection.html Thu, 21 Aug 2025 00:00:00 +0530 Bengaluru-based Nova IVF Fertility, India’s fastest-growing fertility chain, has announced the integration of Artificial Intelligence (AI) into its in vitro fertilisation (IVF) labs to bring in greater precision and trust to embryo selection, an extremely crucial element of fertility treatment. The fertility chain will implement Vita Embryo, an AI-based embryo assessment, across its 120 clinics in 65 cities.  This is implemented through Nova IVF’s partnership with South Korea's AI technology firm Kai Health. This technology will improve pregnancy rates, reduce time of a patient’s IVF cycle, and can bring in much better transparency in the fertility treatment. Kai Health attained medical device certification for Vita Embryo in Europe, Singapore, Korea, and India. Clinical tests indicate that AI-powered Vita Embryo can double the accuracy of embryo selection compared to human evaluation, providing couples with a better chance of attaining successful outcome. Within the IVF Lab, Clinical Embryologists apply years of expertise, grading each embryo on its capacity to develop into a pregnancy. With Artificial Intelligence, now serving as an additional pair of eyes, this helps to further improve accuracy. Technology can spot tiny details about embryo health that might be too subtle for a human eye and can give couples added confidence that the best possible embryo is being selected for their journey. ]]> https://biospectrumindia.com/news/104/26546/agilus-diagnostics-deepens-footprint-in-mysuru-with-launch-of-new-centre.html https://biospectrumindia.com/news/104/26546/agilus-diagnostics-deepens-footprint-in-mysuru-with-launch-of-new-centre.html Tue, 19 Aug 2025 00:00:00 +0530 Agilus Diagnostics, a subsidiary of Fortis Healthcare Limited, has announced the inauguration of its latest Diagnostic centre at Kuvempunagar, Mysuru. Chief Guest Lakshmikanth Reddy G., IAS – Deputy Commissioner of Mysore and Guest of Honour Seema Latkar, IPS – Commissioner of Police, Mysore City inaugurated the new centre in the presence of local dignitaries, healthcare professionals and community members, which followed by a lunch gathering at noon. With a legacy spanning over 30 years, Agilus Diagnostics stands as India’s largest diagnostics company, trusted by millions for its commitment to quality and innovation. Boasting 30+ crore tests conducted, 4000+ customer touchpoints, and a network extending across 30+ states and Union Territories, Agilus continues to set benchmarks in accuracy, reliability, and patient convenience. The new Kuvempunagar centre offers residents access to an extensive suite of diagnostic and preventive healthcare services, including: CT Scan Ultrasound Scan X-Ray OPG Mammography EEG & Audiometry ECG, ECHO & TMT Full-service Pathology Lab Preventive Health Check-ups This facility complements Agilus’ existing main branch, Agilus Diagnostics – KCDC, at No.L-25/2A, Irwin Road, further strengthening its Karnataka network and reinforcing the company’s mission of delivering diagnostic excellence closer to communities. Dr Anand K, Managing Director & CEO, Agilus Diagnostics, said, “With our new centre in Kuvempunagar, Mysuru, we reaffirm our commitment to making high-quality, reliable diagnostic services accessible to all. Our focus remains on empowering patients and healthcare providers through timely, accurate testing and supportive care, right in the heart of the community.”  ]]> https://biospectrumindia.com/news/104/26527/iisc-builds-magnetically-guided-nanobots-for-tooth-sensitivity-relief.html https://biospectrumindia.com/news/104/26527/iisc-builds-magnetically-guided-nanobots-for-tooth-sensitivity-relief.html Wed, 13 Aug 2025 00:00:00 +0530 Sensitive teeth need tough toothpaste, but technology can also help. Researchers at the Indian Institute of Science (IISc), Bengaluru in collaboration with deep-tech startup Theranautilus have now engineered CalBots – magnetic nanobots that can penetrate deep into dentinal tubules, which are tiny tunnels in teeth that lead to nerve endings. These CalBots can then form durable seals for worn enamel, offering lasting relief from sensitivity in just one application. The CalBots use a completely new class of bioceramic cement. While bioceramics are widely used in orthopaedics and dentistry for their mineralising properties, the team wanted a solution tailored for hypersensitivity – a formulation that could travel deeper and last longer. To test their innovation, the team used human teeth extracted for clinical reasons and created conditions where the dentine was exposed. On these samples, they applied CalBots under a magnetic field for 20 minutes, during which the bots sealed the dentinal tubules by forming deep, stable plugs – a result confirmed through high-resolution imaging. Encouraged by this, they progressed to animal trials in collaboration with researchers at IISc’s Center for Neuroscience. The CalBots are composed entirely of materials classified as ‘Generally Recognised as Safe’ (GRAS), ensuring high biocompatibility. Toxicity tests on mice showed no adverse effects.  ]]> https://biospectrumindia.com/news/104/26510/karnataka-has-always-been-more-than-a-participant-in-indias-growth-story-siddaramaiah.html https://biospectrumindia.com/news/104/26510/karnataka-has-always-been-more-than-a-participant-in-indias-growth-story-siddaramaiah.html Mon, 11 Aug 2025 00:00:00 +0530 “Karnataka has always been more than a participant in India’s growth story; we have been its pioneer. Our mission is to make Karnataka the place the world looks to for leadership in innovation, talent, and technology”, said Siddaramaiah, Chief Minister of Karnataka. Speaking at the ‘Conversation with Chief Minister’ - CEO Breakfast Meet’ Siddaramaiah said “From launching India’s first IT policy in 1997 to unveiling the country’s first state Quantum Technology Roadmap in 2025, we have consistently anticipated and prepared for the future. With 44 per cent of India’s software exports, over 18,300 startups, 875+ Global Capability Centres, and nearly half of the nation’s AI talent, we are not just embracing emerging technologies; we are defining them.” In his address to over 100 leaders from IT and Bt industries, D.K. Shivakumar, Deputy Chief Minister, emphasised the government’s focus on inclusive growth and world-class infrastructure. He further said, “We are building a Karnataka rooted in inclusivity, empowerment and shared prosperity. Beyond policies, our focus is on trust, collaboration and real outcomes. From expanding Namma Metro and suburban rail to developing elevated corridors and the Bengaluru Business Corridor, alongside ease-of-doing-business reforms and skill initiatives, our aim is to connect people to purpose and make Bengaluru a city where world-class mobility meets world-class livability, positioning Karnataka as the global hub for talent, investment and innovation.” S. Gopalakrishnan (Kris), Chairperson, Vision Group on IT & Electronics; Dr Vijay Chandru, Member, ABLE Council of Presidents and member of Vision Group on Biotech; Prashanth Prakash, Chairman, Vision Group on Startups; Dr. A.S. Kiran Kumar, Chairperson, Vision Group on Space were also present; where each offered valuable perspectives on the current sectoral landscape, opportunities and strategic direction within their respective sectors.   The Breakfast Meet with top CEOs was held to formally announce Bengaluru Tech Summit 2025 and engage with the industry captains from diverse sectors to hear their views on key strategies and initiatives for Karnataka to continue its leadership position across technology sectors. Leading industry bodies such as NASSCOM, IESA, TiE Bangalore, ABLE, and ABAI brought together CEOs, founders, and innovators from IT & DeepTech, Biotech & HealthTech, Electronics & Semiconductors, Defence & Space Tech, FinTech, and AVGC to engage in this future-focused dialogue with the Chief Minister. ]]> https://biospectrumindia.com/news/104/26484/bouncers-stop-media-from-attending-sessions-at-qib-2025.html https://biospectrumindia.com/news/104/26484/bouncers-stop-media-from-attending-sessions-at-qib-2025.html Wed, 06 Aug 2025 00:00:00 +0530 Organised by the Karnataka Science and Technology Promotion Society (KSTePS) and the Department of Science and Technology, Government of Karnataka, in collaboration with the IISc Quantum Technology Initiative (IQTI), the inaugural edition of Quantum India Bengaluru (QIB) 2025 concluded on August 1 with resounding success, spotlighting Karnataka’s growing leadership in quantum science and technology. The media was not allowed to attend sessions on the first day of the two-day event on the theme “Building a Quantum Ecosystem: Qubits to Society.” After the inaugural sessions wherein the Chief Minister of Karnataka Siddaramaiah, who has unveiled the Karnataka Quantum Roadmap, ’outlining the State’s strategic vision for quantum leadership, this journalist wished to attend one among many parallel sessions on quantum in healthcare, but a bouncer stopped at Hall 2 for scanning the barcode of the pass given to the media. After scanning, the message popped up: “Sorry, you are not allowed in this gate.” Hence, the journalist was barred from entering the hall. The journalist tried to enter the other Hall 1; the bouncer at the door got the same message after scanning the media pass. Since the journalist is representing the media that was the media partner for this event, on request the event curator, MM Activ, provided their batch (entry pass) to attend the session. On the second day of the event, however, this issue was not there; when the journalist showed his pass for scanning while entering the hall, the permission was granted. The question is on whose instruction the media was barred from attending the sessions. The concerned government officials who always look for better promotion of the government activities and initiatives should ensure that such things don’t get repeated in the future. Built on five pillars of talent, R&D, infrastructure, industry enablement, and global partnerships, the Karnataka Quantum Roadmap adopts a phased, outcome-driven approach and focuses on aligning academia with industry, scaling indigenous hardware capabilities, and building a robust startup ecosystem. ]]> https://biospectrumindia.com/news/104/26485/karnataka-to-launch-quantum-mission-kqm-in-phases.html https://biospectrumindia.com/news/104/26485/karnataka-to-launch-quantum-mission-kqm-in-phases.html Wed, 06 Aug 2025 00:00:00 +0530 Following footsteps of the government of India, which has launched the National Quantum Mission (NQM) in April 2023 with a budget outlay of Rs 6,003 crore, Karnataka government under the leadership of Siddaramaiah, the Chief Minister of Karnataka announced Karnataka Quantum Roadmap and soon will launch of Karnataka Quantum Mission (KQM), coordinated by Department of Science & Technology under phase 1 of the Quantum Roadmap at the country’s first Quantum India Bengaluru (QIB) 2025 summit held recently. The Karnataka state is planning to leverage its very distinguished legacy in fundamental science to push the frontiers of quantum technologies to position Karnataka as a leader across the quantum technology value chain in 4 phases. Phase 1 includes Foundation, Infrastructure & Capacity Building. Phase 2, 3 and 4 will focus on Operationalising, R&D & Pilots; Manufacturing & Commercialization and Quantum Powerhouse and Export Destination respectively.   The key objective of the KQM is to publish the Karnataka Quantum Policy (KQP), detailing incentives and interventions for eligible and interested entities. The KQP will include the launch of a Quantum Hardware Park in Bengaluru. This facility will house a pilot fabrication facility which can serve as a common resource across semiconductor, analog computing, and quantum computing. It will also house cryogenic laboratories essential for developing and testing quantum chips and devices. Startups and deep-tech innovators can leverage this specialized infrastructure to accelerate hardware prototyping, reduce capital expenditure, and collaborate with academia and industry partners. Besides the KQM will form an International Quantum Advisory Board comprising members from academia, industry and government. The board will include top-tier scientists from outside India, project directors of the NQM hubs, and leading quantum scientists from Karnataka. The state will also constitute a Karnataka Quantum Task Force which will work under the guidance of the advisory board to execute the roadmap in Karnataka. Aligning with NQM, the state will develop 1000-qubit quantum computers at the Indian Institute of Science (IISc), starting with 8-qubit and then expanding to 1000-qubit over next four years, and other quantum research hubs such as Raman Research Institute (RRI)/ International Centre for Theoretical Sciences (ICTS)/ Indian Institute of Technology (IIT) Dharwad / Indian Institute of Information Technology (IIIT)/others in the state. Under the KQM the state will identify four Quantum Innovation Zones for the various Quantum themes – Quantum Computing, Quantum Communication, Quantum Sensing & Metrology and Quantum Materials and Devices and sign MoU with the four quantum hubs under NQM to showcase their incubated start-ups and their products at the Quantum Research Park (QuRP) - a Centre of Excellence (CoE) at IISc Bengaluru. The state will establish partnerships with leading industry partners to develop quantum algorithms, hardware and jointly invest in skilling to build a robust supply side and also on the demand side application of Quantum across healthcare (e.g., drug discovery), fintech and cybersecurity. To develop skilled workforce in Quantum technology, Karnataka will launch Quantum Skilling Programme across 20+ Tier 1/2 engineering colleges, potentially under Nipuna Skilling Programme, expand Q-Daksha and Q-Karyashala programs of IISc to cover entire Karnataka and will partner with international universities, MNCs and startups working on Quantum technology to scholars, researchers and industrialists with experience in quantum from global markets to work in Karnataka. ]]> https://biospectrumindia.com/news/104/26486/quantum-india-bengaluru-2025-attracts-1000-delegates.html https://biospectrumindia.com/news/104/26486/quantum-india-bengaluru-2025-attracts-1000-delegates.html Wed, 06 Aug 2025 00:00:00 +0530 The inaugural edition of Quantum India Bengaluru (QIB) 2025, organised by the Karnataka Science and Technology Promotion Society (KSTePS) and the Department of Science and Technology, Government of Karnataka, in collaboration with the IISc Quantum Technology Initiative (IQTI), on the theme “Building a Quantum Ecosystem: Qubits to Society,”  facilitated 74 B2B meetings welcomed over 1951 attendees, including 1,000+ registered delegates, 75 speakers, 37 exhibitors, and participants from more than 19 countries, alongside senior representatives from academia, industry, and government. The two-day summit started on July 31 featured over 25 sessions across five core tracks—Quantum Computing; Finance & AI; Healthcare & Security; Peripherals & Hardware; and Society & Art—illustrating the breadth of quantum applications. Keynotes by Nobel Laureates Prof. Duncan Haldane and Prof. David Gross set the tone for the event, complemented by a special plenary address by Prof. Tommaso Calarco, European Union Quantum Flagship and the Institute of Quantum Control, PGI-8, Germany. The agenda included focused panels on India’s quantum roadmap, global collaboration, academic research, industry integration, and public engagement, showcasing how India is shaping a cohesive quantum ecosystem. Throughout the summit, transformative ideas, indigenous innovations, and academic-industry partnerships came to life through a curated exhibition that offered attendees a first-hand look at Karnataka’s and India’s quantum innovation landscape. With participation from over 20 academic institutions, deep-tech startups, and research labs, the exhibition showcased emerging technologies in quantum computing, novel materials, secure communication, cryptographic protocols, and quantum sensing. Quantum in Healthcare featured cutting-edge applications across diagnostics and life sciences. On the first day, Prof. Varun Raghunathan, IISc Bengaluru presented on Towards Quantum Enhanced Nonlinear Optical Microscopy. Dr. Anupama Ray of IBM discussed Quantum Machine Learning for Healthcare. Prof. Songi Han from Northwestern University, USA, spoke on Triplet Spin State Dependent Signal Transduction in Light-Oxygen-Voltage Sensitive Receptors. Dr. Pranab Dutta of GDQ Labs shared his work on Transforming Cardiac Care with Quantum Precision. These sessions emphasized quantum’s real-world impact in clinical innovation. On the second day, the session on healthcare segment began with Prof. Kasturi Saha, IIT Bombay, who showcased the use of NV centres in nanodiamonds for real-time, non-invasive sensing of reactive oxygen species (ROS) in brain cancer cells, enabling precise monitoring of drug efficacy and laying the foundation for advanced quantum diagnostics. She also introduced early research on a quantum diamond microscope for high-resolution brain imaging.  This was followed by a panel moderated by Dr. Shesha Raghunathan, IBM, featuring Prof. Vijay Chandru, Strand Life Sciences, Prof. Deepak Kumar Saini, IISc, Bengaluru, Prof. Songi Han, Northwestern University, USA, Sohil Bhagat, pi Ventures, and Dr Pranab Dutta, GDQ Labs, among others. The discussion spanned quantum-enabled diagnostics, personalised medicine, real-time monitoring, and investor outlooks—reinforcing India’s potential to lead in accessible, next-generation quantum healthcare solutions. A dedicated Poster Showcase, inaugurated alongside the exhibition, featured more than 41 research posters from scholars and doctoral researchers, providing diverse perspectives in areas such as quantum algorithms, hardware, and cryptography. Outstanding entries from the showcase were formally awarded during the valedictory session. Winners of the poster awards, each receiving a prize of Rs 20,000, include: Shuvarati Roy, Indian Institute of Science Education and Research, Pune; Kanad Sengupta, Indian Institute of Science, Bengaluru; Ayan Majumder, Indian Institute of Technology, Bombay; Purna Pal, Indian Institute of Science, Bengaluru. ]]> https://biospectrumindia.com/news/104/26476/alveolus-bio-secures-strategic-investment-from-shilpa-medicare-.html https://biospectrumindia.com/news/104/26476/alveolus-bio-secures-strategic-investment-from-shilpa-medicare-.html Mon, 04 Aug 2025 00:00:00 +0530 Alveolus Bio, a US-based respiratory drug development biotech company founded by Dr. Vivek Lal from University of Alabama at Birmingham, has announced a strategic financing round led by Raichur-based Shilpa Medicare Limited, a prominent global pharmaceutical company with extensive expertise in respiratory therapeutics manufacturing and biotechnology innovation. Through this collaboration, Shilpa Biologics, the biologics arm of Shilpa Medicare, will become Alveolus Bio's exclusive global development and manufacturing partner. This partnership propels Alveolus Bio's live biotherapeutics and small molecule platform towards Phase 2 and first-in-human clinical trials, with a lead asset for Chronic obstructive pulmonary disease (COPD) progressing rapidly. Shilpa Medicare brings deep experience in drug discovery, development, and manufacturing, along with strong regulatory capabilities. Their investment and strategic involvement will accelerate the clinical advancement of Alveolus Bio's resMIT (respiratory microbiota-based inhaled therapeutics) platform. This novel platform enables targeted delivery of inhaled therapies to deep lung regions, addressing unmet needs in diseases such as COPD, Bronchopulmonary Dysplasia (BPD), and Pulmonary Fibrosis. "Alveolus Bio's breakthrough science is poised to transform respiratory care. Through this strategic partnership with Shilpa, we combine disruptive biotech innovation with world-class commercialization, bringing life-changing therapies faster to the market," said Dr C. Vivek Lal, Founder and CSO, Alveolus Bio. "Shilpa has always focused on enabling breakthrough biologics," said Vishnukant Bhutada, Managing Director, Shilpa Medicare. "This partnership strengthens our innovation pipeline and reinforces our role as a trusted global partner for biotech development." The financing round remains open to other strategic investors who share Alveolus Bio's vision of transforming respiratory medicine. ]]> https://biospectrumindia.com/news/104/26477/karnataka-health-minister-dinesh-gundu-rao-inaugurates-mental-health-hospital-amaha-in-bengaluru.html https://biospectrumindia.com/news/104/26477/karnataka-health-minister-dinesh-gundu-rao-inaugurates-mental-health-hospital-amaha-in-bengaluru.html Mon, 04 Aug 2025 00:00:00 +0530 Amaha, a pioneer in India’s mental health services and the largest private mental health provider in India for adult and child mental health care, has announced the launch of its first super specialty mental health hospital in Thanisandra, Bengaluru. Expanding on its presence across multiple outpatient centres in Bengaluru, Mumbai and Delhi, having served over 40,000 clients; this purpose-built facility with 27 beds marks a significant step forward in offering acute, high-quality interventions for individuals experiencing severe psychiatric conditions and acute distress. Amaha’s new facility brings together a large multidisciplinary team of experts, including psychiatrists, clinical psychologists, occupational therapists, psychiatric nurses, social workers, and peer support specialists. The team is equipped to manage a range of psychiatric needs, including trauma, bipolar disorder, schizophrenia, deaddiction, ADHD, treatment-resistant depression, and severe mood disorders. Speaking at the inaugural event, Dinesh Gundu Rao, Minister for Health and Family Welfare, Government of Karnataka, said, “Mental health is becoming a priority in our public health agenda. Today, it’s not just the elderly, young people too are increasingly affected. Rapid societal shifts, academic and career pressures, substance use, digital addiction, and poor sleep are all major contributors. Every school must have access to counselling, and I’m glad the Supreme Court has recognised this need. Specialised care is crucial. Mental health treatment isn’t just clinical, it involves emotion, deep analysis, and responsible intervention. Facilities like Amaha’s hospital offer intensive, trauma-informed, multidisciplinary care that can truly make a difference. I’m also pleased to share that psychiatric assessments are now part of the 14 core health parameters under Karnataka’s public healthcare services.”  With this facility, Amaha is setting a new benchmark for mental healthcare in India, one that delivers intensive, inpatient support for complex and lifelong conditions, in a setting built to global standards but tailored for our cultural realities.  ]]> https://biospectrumindia.com/news/104/26473/karnataka-honours-dr-r-vijayaraghavan-at-quantum-india-bengaluru-2025-.html https://biospectrumindia.com/news/104/26473/karnataka-honours-dr-r-vijayaraghavan-at-quantum-india-bengaluru-2025-.html Sat, 02 Aug 2025 00:00:00 +0530 Dr Rajamani Vijayaraghavan, Associate Professor, Dept. of Condensed Matter Physics & Materials Science, Tata Institute of Fundamental Research (TIFR), Mumbai, was felicitated for his leadership role and leading several projects in the area of quantum computers, at Quantum India Bengaluru (QIB) 2025, held in Bengaluru on July 31, 2025. Currently leading several projects to build small to medium scale quantum processors with funding from DAE, DRDO, TCS and DST, he is the Lead Principal Investigator for the Technical Group working on building superconducting quantum computers under the National Quantum Mission. Recipient of the Ramanujan Fellowship (2013-18) awarded by the Department of Science and Technology of the Government of India and he was recently elected as a Fellow of the Indian Academy of Sciences, Bengaluru. He completed his Bachelor’s degree in Physics from St. Stephen's College, Delhi University in 1999. He then spent two more years at the University of Cambridge pursuing a BA in Natural Sciences. He did his PhD at Yale University and his postdoctoral work at the University of California, Berkeley. Since December 2012, he has been the Principal Investigator at the Quantum Measurement and Control Laboratory at TIFR. Some key highlights of this group's work include development of a broadband ultralow noise amplifier for quantum measurements and a novel multi- qubit processor design. At QIB 2025, he spoke on the theme “The quantromon: A qubit-resonator system with orthogonal qubit and readout modes. Sharing his work on the topic he said, “The measurement of a superconducting qubit is implemented by coupling it to a resonator. The common choice is transverse coupling, which, in the dispersive approximation, introduces an interaction term that enables the measurement. This cross-Kerr term provides a qubit-state dependent dispersive shift in the resonator frequency. He also presented a two-mode circuit, nicknamed quantromon, with two orthogonal modes implementing a qubit and a resonator with an intrinsic cross-Kerr coupling mechanism. He further explained data characterizing some of the unique properties of this device like weak detuning dependence of the cross-Kerr shift and intrinsic Purcell protection. Finally, he presented data demonstrating a single-shot readout fidelity of 98.3 per cent, which is comparable to the state-of-the-art measurements without the use of a parametric amplifier and suggests a potential simplification of the measurement circuitry for scaling up quantum processors. ]]> https://biospectrumindia.com/news/104/26474/karnataka-honours-2016-nobel-laureate-prof-duncan-haldane-at-qib-2025.html https://biospectrumindia.com/news/104/26474/karnataka-honours-2016-nobel-laureate-prof-duncan-haldane-at-qib-2025.html Sat, 02 Aug 2025 00:00:00 +0530 In recognition of his pioneering contributions to Quantum Science, 2016 Nobel Laureate, Prof. Duncan Haldane, Princeton University, USA, was felicitated by the government of Karnataka at the Quantum India Bengaluru (QIB) 2025, a two-day summit held in Bengaluru, on July 31 and August 1, 2025. Prof Duncan M. Haldane is the Sherman Fairchild University Professor of Physics at Princeton University, and one of the 2016 Physics Nobel Prize Laureates. He is known for a number of seminal contributions to modern quantum condensed matter physics, including the earliest topological states in quantum magnetism, topological insulators, and contributions to the theory of the fractional quantum Hall effect. He also is a fellow of the US National academy of Sciences, and the Slovenian Academy of Science and Arts, and recipient of other awards such as the American Physical Society Buckley Prize, and the Dirac Medal of the International Centre for Theoretical Physics (ICTP). Later during the day Prof. Duncan Haldane spoke on the topic “Modern Quantum Mechanics is 100 years old: why all the excitement today?” by sharing his experience. He noted that the laws of quantum mechanics were established during 1925-1932, and have not changed since. But just because we know the laws, we do not know all that they make possible. While the “first quantum revolution" was characterised by the Heisenberg uncertainty principle, some believe we are in a “second quantum revolution” characterised by “entanglement”. I will describe some surprise discoveries of “topological quantum matter” that may make topologically protected quantum computing” possible. ]]> https://biospectrumindia.com/news/104/26410/medgenome-raises-series-e-funding-of-47-5-m-to-expand-access-to-genomics-offerings-in-india.html https://biospectrumindia.com/news/104/26410/medgenome-raises-series-e-funding-of-47-5-m-to-expand-access-to-genomics-offerings-in-india.html Mon, 21 Jul 2025 00:00:00 +0530 Bengaluru-based genomic diagnostics and research services company MedGenome has raised $47.5million in its Series E funding round, co-led by Maj Invest, a private equity firm joining as a new investor, along with existing investor Novo Holdings. The round also saw participation from Sofina, an existing shareholder in the company. This funding will enable the company to broaden access to its genomics and integrated diagnostics solutions across India and other emerging markets. The announcement also reiterates MedGenome’s mission to help reduce India’s disease burden through early detection and targeted disease management using genetic and integrated diagnostics tools with high affordability. Speaking about this funding aligning with the company’s vision, Dr Vedam Ramprasad, CEO of MedGenome, said, "India's healthcare ecosystem is increasingly recognizing the transformative potential of genomics, driving innovation and enhancing the country’s healthcare capabilities. This fundraise also reflects the growing adoption of genomics in personalized and preventive healthcare in India as well as other emerging economies. At MedGenome, we combine cutting-edge science with real-world application, bringing advanced omics solutions that bridge the unmet need in disease diagnosis and management. Early genomics-led intervention not only helps the patient but also helps families manage the economic and emotional burden of a disease." Dr Amit Kakar, Managing Partner and Head of Asia at Novo Holdings, and Chairman of the Board of MedGenome, commented, “Our reinvestment in MedGenome reflects our belief in the company’s potential to transform the landscape of genetic and integrated diagnostics in India and beyond. MedGenome stands out as a science-led platform with strong fundamentals, and this investment aligns with our conviction in the growing importance of genomics and personalised healthcare across emerging markets." "With its robust genomics portfolio, commitment to science and the transformative impact it has had on healthcare, MedGenome has consistently demonstrated its ability to drive innovation and precision diagnostics. We’re proud to support their next phase of growth, expanding their solutions to more markets in India and worldwide" Jannick Dam Mortensen, Partner, Maj Invest Minorities, added. ]]> https://biospectrumindia.com/news/104/26359/karnataka-to-unveil-quantum-action-plan-boseraju.html https://biospectrumindia.com/news/104/26359/karnataka-to-unveil-quantum-action-plan-boseraju.html Wed, 09 Jul 2025 00:00:00 +0530   “With world-class institutions, a rich pool of scientific talent, and a thriving innovation ecosystem, Karnataka is ready to lead India’s next technological leap in quantum science and technology. In the coming days, we will unveil Karnataka’s Quantum Action Plan, a comprehensive strategy focused on research, skilling, innovation, infrastructure, and international collaboration” said N.S. Boseraju, Minister for Science & Technology, Government of Karnataka. Speaking to media persons, the Minister said “In partnership with the Indian Institute of Science and the Department of Science and Technology, we are laying the foundation for a robust quantum ecosystem that will serve the nation and engage the world. It is our commitment to harnessing the full potential of quantum technologies and shaping a future driven by knowledge, science, and progress”. Speaking about the Quantum India Bengaluru Summit (QIB 2025) scheduled on July 31 and August 1, the Minister said that QIB 2025 is not just a summit; it is a signal of intent. An intent to build, collaborate, and lead. This event marks the beginning of a bold and strategic journey for Karnataka as we position ourselves at the forefront of quantum science and technology. The Summit with the theme ‘Building a Quantum Ecosystem: Qubits to Society’ will feature an exceptional lineup of sessions and engagements. Highlight of the Conference are the keynote lectures to be delivered by Prof. Duncan Haldane, Princeton University, USA and the 2016 Physics Nobel Laureate, Prof. David Gross, UCSB, USA and the 2004 Physics Nobel Laureate, Prof. Tommaso Calarco of European Union Quantum Flagship, & Director of the Institute of Quantum Control PGI-8, Germany, Prof. Andrea C Ferrari of the University of Cambridge, UK, Prof. Subir Sachdev of Harvard University, USA, who are among many quantum pioneers joining as speakers and panelists.  In addition to the insightful sessions, attendees can explore a dedicated Exhibition showcasing cutting-edge technologies and solutions from startups, research institutions, and quantum hardware companies. A special highlight of the summit will be the Quantum Poster Showcase, where students, PhD scholars and researchers will present their work to a global audience. For deeptech and quantum startups, QIB 2025 will also host Startup Pitch sessions, providing a platform to connect with investors and collaborators. ]]> https://biospectrumindia.com/news/104/26350/c-camp-with-support-from-icars-launches-one-health-amr-challenge-2025.html https://biospectrumindia.com/news/104/26350/c-camp-with-support-from-icars-launches-one-health-amr-challenge-2025.html Tue, 08 Jul 2025 00:00:00 +0530 Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP), with support from the International Centre for Antimicrobial Resistance Solutions (ICARS), has launched the C-CAMP One Health AMR Challenge 2025 to identify, support, and scale breakthrough technologies tackling Antimicrobial Resistance (AMR) across human, animal, and environmental health. The initiative will support ready-to-deploy AMR solutions over the next two years in alignment with India’s National Action Plan 2.0 (NAP 2.0) on AMR. Anchored under the India AMR Innovation Hub (IAIH) at C-CAMP, this call seeks novel technologies, and technological innovations in detection, diagnostics, and prevention of AMR. Selected innovations will receive financial support ranging from $50,000 to $250,000 (Rs 40 lakh to Rs 2 crore) based on technology readiness. Comprehensive technical assistance including regulatory, legal, IP, manufacturing, and market readiness support. Mentorship and implementation guidance to accelerate translation of these AMR-focused innovations into impactful, scalable products and services. Applications are open to innovators from India and abroad. Solutions must be AMR-focused with Technology Readiness Levels (TRL) 6-9, as per BIRAC guidelines. Academic or research institution-based applicants may also apply if they demonstrate the ability to validate the technology and present a clear roadmap for scale-up. This call specifically aims to identify mid to late-stage innovations for support. Up to 12 innovations will be supported for a period of 11 months, with funding commensurate with the project requirements. Dr Taslimarif Saiyed, Director-CEO, C-CAMP said “Antimicrobial Resistance is a huge threat to society and India is at its epicentre. At C-CAMP we recognise the scale of the problem and have built a strong portfolio of innovations to address AMR especially One Health as a domain crucial to bending the AMR curve. To this effect, we also anchor the India AMR Innovation Hub that is slated to be the innovation arm of the soon-to-be-announced India NAP 2.0." Prof. Ajay Sood, Principal Scientific Adviser to the Government of India remarked, “The opening of the C-CAMP One Health AMR Challenge will be one of the touch points towards India formally recognising One Health that includes human health, animal and plant health and environment holistically in our combat to tackle the rising AMR burden. Ably supported by the International Centre for Antimicrobial Resistance Solutions (ICARS) the call offers a unique scale up support module that goes beyond funding to identify solutions that address the Indian context. As Chair of India AMR Innovation Hub (IAIH), the innovation arm of India NAP 2.0, I welcome the partnership and look forward to an exciting response from stakeholders.”   ]]> https://biospectrumindia.com/news/104/26351/karnataka-to-host-indias-first-quantum-india-bengaluru-summit-2025-on-july-31.html https://biospectrumindia.com/news/104/26351/karnataka-to-host-indias-first-quantum-india-bengaluru-summit-2025-on-july-31.html Tue, 08 Jul 2025 00:00:00 +0530 The Karnataka Science and Technology Promotion Society (KSTePS), Department of Science & Technology, Government of Karnataka, in association with the IISc Quantum Technology Initiative (IQTI), will be hosting a two-day India’s first large-scale summit dedicated to Quantum research, technologies & business - Quantum India Bengaluru Summit (QIB 2025) from July 31. Speaking about the summit Dr Ekroop Caur, Secretary, Department of Electronics, IT, Bt, and S&T, Government of Karnataka, said “Karnataka, particularly Bengaluru, has firmly established itself as a leading tech hub in India and globally. With a vibrant IT, biotechnology, nanotechnology, and startup ecosystem flourishing in the city, the state government is embarking on its next venture: establishing a Quantum ecosystem in its capital. This is in close harmony with the recent initiative that the Government of India undertook to promote Quantum Technologies by launching the National Quantum Mission.” She further said that Quantum technologies are already gathering pace in Bengaluru, with multiple institutions, including the Indian Institute of Science (IISc), the Raman Research Institute (RRI), and the International Center for Theoretical Sciences (ICTS), becoming national nodes in this effort. To take advantage of this exceptionally skilled ecosystem and developing infrastructure, it is crucial for India to have a unified platform to bring experts in the field together. This will be achieved through the proposed Quantum India, Bengaluru (QIB) – a biennial conference dedicated to Quantum Technologies supported by the Government of Karnataka. “QIB will aim to showcase the latest in Quantum Science and Technologies and promote collaboration and synergy among the professionals (academics, industry, and entrepreneurs) working in India and abroad. With an ambitious goal to motivate students and young researchers, our vision is to build Bengaluru as the ‘Quantum City’ of the future. It is only fitting that QIB is being launched in 2025 – The International Year for Quantum,” she added. QIB 2025 will feature five major themes, which will be conducted as parallel sessions during the conference. These themes are, Quantum in Computing, Finance, and AI; Quantum in Healthcare: Quantum in Security: Quantum Peripherals and Hardware: Quantum in Society and Art. QIB 2025 will witness 70+ Speakers, 25+ Sessions, 20+ Exhibitors, 2000+ Attendees, 40+ Posters, 1000+ Delegates and participation of 10+ Countries. ]]> https://biospectrumindia.com/news/104/26296/astrazeneca-invests-rs-166-cr-to-expand-global-hub-in-bengaluru.html https://biospectrumindia.com/news/104/26296/astrazeneca-invests-rs-166-cr-to-expand-global-hub-in-bengaluru.html Fri, 27 Jun 2025 00:00:00 +0530 AstraZeneca, a global, science-led biopharmaceutical company, has announced the expansion of its state-of-the-art Global Hub in Bengaluru, strengthening its presence in India. The new facility will house nearly 1300 employees, including 400 new jobs, supporting the company's capabilities in artificial intelligence (AI)-powered innovation across Research and Development, Global Business Services, IT, and Digital Health operations. This announcement represents AstraZeneca's second major investment in India within a year, following the expansion of its Global Innovation and Technology Centre (GITC) in Chennai. The combined workforce now at AstraZeneca India Private Limited (AZIPL) will reach close to 4,000 employees, strengthening company's capability to deliver life-changing medicines to patients worldwide. The new facility will serve as a dynamic hub dedicated to advancing AstraZeneca's critical priorities: Advanced clinical research supporting AstraZeneca's global therapeutic areas Development of AI-powered healthcare solutions and digital health technologies Centralized data analytics to enhance clinical trial efficiency and patient outcomes Specialized support for global regulatory compliance and pharmacovigilance "AstraZeneca's investment reaffirms India's leadership in science, technology, and healthcare, and is a testament to Karnataka's robust life sciences ecosystem. This expansion aligns perfectly with our vision to create high-value employment opportunities while fostering innovation in critical sectors, making Bangalore a global hub for biotechnology and R&D," said Dinesh Gundu Rao, Minister of Health & Family Welfare, Government of Karnataka. ]]> https://biospectrumindia.com/news/104/26254/archish-fertility-ivf-unveils-indias-first-100-fully-transparent-fertility-lab.html https://biospectrumindia.com/news/104/26254/archish-fertility-ivf-unveils-indias-first-100-fully-transparent-fertility-lab.html Tue, 17 Jun 2025 00:00:00 +0530 Bengaluru-based Archish Fertility & IVF has set a new benchmark in fertility care by unveiling India’s first 100% fully transparent fertility laboratory. This groundbreaking initiative ensures patients have complete visibility into every stage of their treatment, fostering trust and transparency in an industry where clarity is often lacking. The new lab is designed to empower patients by providing real-time access to critical information, ranging from embryo development to procedural updates, through advanced digital platforms. This approach not only demystifies the fertility journey but also allows patients to make informed decisions about their care. To further enhance patient support, Archish Fertility & IVF has entered into a strategic partnership with Amaha Health, a renowned provider of mental health services. This collaboration ensures that patients receive comprehensive care, including emotional and psychological support throughout their fertility journey. Studies indicate that up to 60% of couples undergoing fertility treatments experience anxiety or depression. The emotional and mental toll can be overwhelming, with constant waiting and societal pressures compounding the challenge. Recognising that fertility treatment is more than just a medical process, Archish Fertility & IVF has also prioritized patient well-being at every step. Archish’s transparent lab model empowers couples to witness procedures in real time within state-of-the-art laboratory. Transparent and ethical care aligns with legal requirements, such as those outlined in India’s ART Act which aims to make the fertility journey safe and free from complications.  Archish Fertility & IVF operates 7 centres across Bengaluru, located in HAL (Old Airport Road), Sahakar Nagar, HSR Layout, Whitefield, Electronic City, and JP Nagar, with a new centre in Sarjapur recently opened in June 2025. ]]> https://biospectrumindia.com/news/104/26248/aster-institute-of-advanced-orthopedics-robotic-surgery-opens-in-bengaluru.html https://biospectrumindia.com/news/104/26248/aster-institute-of-advanced-orthopedics-robotic-surgery-opens-in-bengaluru.html Mon, 16 Jun 2025 00:00:00 +0530 Bengaluru-based Aster RV Hospital has recently launched their world class Aster Institute of Advanced Orthopedics & Robotic Surgery (AIAORS).  The institute leverages cutting edge robotic technology, along with world class specialists to perform minimally invasive and accurate orthopedic procedures. The institute was inaugurated by CP Yogeshwar - MLA & MP Shayam Shetty, President, RV Trustees. The launch event saw more than 250 people attend. The department is headed by Dr JV Srinivas, Lead & Senior Consultant, Orthopedic & Joint Surgery, Aster RV Hospital and can perform many complex orthopedic surgeries, using their state-of-the-art Cori Surgical System. The robotic system helps with knee replacements, hip replacements and revision knee replacement surgeries as well. The institute provides treatments for people with knee degradations, hip injuries, foot and ankle injuries, sports injuries, spine surgeries, advanced orthopedic procedures like GFC/PRP and stem cell therapy, pediatric orthopedics and Robotic Knee Replacement Surgery for accurate positioning of implants. The institute also provides services such as trauma / fracture surgeries and management of open fractures, Joint Replacement surgeries of knee and hip (TKR and THR), Ortho Onco Surgery, Hand Surgery Limb Reconstruction Surgery, Keyhole surgeries such as Arthroscopic Ligament Reconstruction (ACL, PCL and Multi-ligament), meniscus and chondral surgeries, A fusion of joints (Arthrodesis), Polytrauma Management, Complex pelvic and acetabular fracture, and Pediatric orthopaedic surgeries for clubfoot, congenital hip dysplasia, bone and joint infection management. ]]> https://biospectrumindia.com/news/104/26249/life-circle-health-services-receives-grant-worth-rs-3-cr-to-scale-tech-enabled-elder-care-.html https://biospectrumindia.com/news/104/26249/life-circle-health-services-receives-grant-worth-rs-3-cr-to-scale-tech-enabled-elder-care-.html Mon, 16 Jun 2025 00:00:00 +0530 Life Circle Health Services, a Hyderabad-based social enterprise, has been named one of four global winners of the DBS Foundation Impact Beyond Award 2024. Launched last year, the award aims to supercharge impactful businesses that are addressing urgent needs in ageing societies. As part of the recognition, Life Circle will receive SGD 500,000 (~Rs 3 crore) in grant funding, along with access to DBS Foundation’s broader ecosystem of support — including expert mentorship, capacity building, and partnership/networking opportunities. It is one of four enterprises collectively awarded SGD 3 million (~Rs 20 crore) by DBS Foundation. In addition to the funding, winners receive ongoing support from the bank to drive their next phase of growth, including new product development, operational scaling, and capacity building.  Life Circle is addressing this gap through a tech-enabled marketplace that connects trained caregivers with families based on individual health and personal care needs. It is India’s only full-stack eldercare company combining training, certification, placement, and managed home care under one brand. Life Circle’s hybrid (phygital) model — which includes a mobile app, caregiver training, and quality checks — helps improve the overall quality of home-based eldercare in India. With this award, it will expand to Tier 2 and 3 cities that are seeing heightened demand, launch new training academies, roll out digital learning tools, and upgrade its technology to better manage onboarding and quality assurance for caregivers.   ]]> https://biospectrumindia.com/news/104/26240/shilpa-medicare-signs-commercial-supply-deal-with-orion-for-recombinant-human-albumin.html https://biospectrumindia.com/news/104/26240/shilpa-medicare-signs-commercial-supply-deal-with-orion-for-recombinant-human-albumin.html Fri, 13 Jun 2025 00:00:00 +0530 Raichur-based Shilpa Biocare Private Limited, a fully-owned subsidiary of Shilpa Medicare Limited, has secured a Europe-wide commercial supply agreement with Orion Corporation for Recombinant Human Albumin. Shilpa’s Recombinant Human Albumin – a key plasma protein used in various therapeutic applications – is currently under development and will be manufactured using a robust non-human expression system. This provides improved safety, scalability, and virus-free production, addressing some of the key limitations associated with human-derived albumin. Under the terms of the agreement, Orion will gain exclusive rights to distribute, market and sell Shilpa’s Recombinant Human Albumin in Europe, with Shilpa receiving development and regulatory milestone payments from Orion. “We are pleased to strengthen our strategic partnership with Shilpa by collaborating on this novel product,” said Satu Ahomäki, EVP Generics and Consumer Health, Orion Corporation. “Recombinant human albumin will strengthen our strategy and offering in value-add hospital generics, and we look forward to making it available across Europe.” At BIO Boston event later this month, Shilpa is expected to see increased interest from biopharma innovators, particularly smaller biotech firms, leveraging its development capabilities in oncology and biologics – with the CDMO having both commercial facilities for both mammalian and microbial production. Madhav Bhutada, Managing Director, Shilpa Biocare, added: “Partnering with Orion is a significant step in bringing our innovative recombinant product to patients across Europe and is a testimonial of our developmental and manufacturing capabilities to bring Recombinant Human Albumin to market. This alliance aligns with our mission to provide high-quality, affordable biologics globally, and we are confident this partnership will further accelerate our footprint in the regulated markets.” ]]> https://biospectrumindia.com/news/104/26242/biocon-foundation-in-partnership-with-ncbs-and-best-cluster-launches-biowise-programme-to-empower-women-in-stem-.html https://biospectrumindia.com/news/104/26242/biocon-foundation-in-partnership-with-ncbs-and-best-cluster-launches-biowise-programme-to-empower-women-in-stem-.html Fri, 13 Jun 2025 00:00:00 +0530 Biocon Foundation, the Corporate Social Responsibility arm of BEngaluru-based Biocon Group, in collaboration with The Bengaluru Science and Technology (BeST) Cluster, and National Centre for Biological Sciences (NCBS), has announced the launch of first-of-its-kind programme BioWISE - Women in STEM Empowered, aimed at disadvantaged science students from tier 2 and 3 universities across Karnataka, to build a career in life sciences. BioWISE, a part of Biocon Biologics CSR initiative, is a transformative initiative aimed at enhancing access, participation, and retention of women from underserved communities in STEM, particularly life sciences. By supporting 25 women students from diverse communities through scholarships, extended internships, and mentorship, this programme is a significant step towards building a scientific ecosystem, which is diverse, inclusive, and equitable. As the first state-level cohort, the BioWISE programme will support 25 women students, including 15 postgraduates (PG) and 10 undergraduates (UG) from life sciences backgrounds. The initiative is designed to run for 6 months for PG students and 3 months for UG students, offering them extensive exposure, training, and mentorship. BioWISE provides a multi-dimensional platform to build competencies, foster mentorship, and open up research and industry pathways for women entering the STEM specifically life sciences workforce. Biocon Foundation will enable the initiative through funding and experts from Biocon Biologics, industry partner, will support with mentorship; while NCBS will serve as the host institute and academic mentoring partner. BeST Cluster will contribute to the program’s design, management, and implementation. Regular Mentor-Mentee Sessions: Participants will engage in continuous mentorship sessions with experts from Biocon Biologics, NCBS, and other institutions to gain insights into research and career opportunities. Lab Visits & Scientific Exposure: Structured visits to NCBS, TIGS (Tata Institute for Genetics and Society), IISc (Indian Institute of Science), and JNCASR (Jawaharlal Nehru Centre For Advanced Scientific Research) will provide practical exposure to world-class research labs and facilities. Bio-Incubation Centre Visits: Participants will explore bio-incubators and entrepreneurial ecosystems to understand innovation pathways in life sciences. Hands-on Training & Research Seminars: Focused workshops, wet-lab experiences, and research-oriented seminars/webinars will help participants build core technical and scientific thinking skills. Soft Skills & Communication Training: Emphasis will be placed on workplace readiness, professional communication, and career planning to ensure sustainable reintegration into STEM fields. ]]> https://biospectrumindia.com/news/104/26245/iisc-develops-novel-photoacoustic-contrast-agent-for-visualising-tumours.html https://biospectrumindia.com/news/104/26245/iisc-develops-novel-photoacoustic-contrast-agent-for-visualising-tumours.html Fri, 13 Jun 2025 00:00:00 +0530 Tumour cells have higher metabolic activity compared to healthy tissue and consequently consume a lot of glucose. Positron Emission Tomography (PET) – the current gold standard diagnostic technique – exploits this property. Clinicians inject patients with radioactive tracers like 18F-fluoro 2-deoxy glucose (18F-FDG) which accumulate at the tumour site and help pinpoint it. However, PET is expensive, and poses the risk of radiation accumulation in case of repeated scans. Researchers from the Department of Bioengineering, Indian Institute of Science (IISc), Bengaluru have now developed a biocompatible small molecule that can be used as a minimally invasive contrast agent for Photoacoustic (PA) Tomography. In this method, a near-infrared (NIR) laser beam is shined on light-absorbing molecules (chromophores) sent to the target region, which then expand, creating a pressure change. The change can be picked up as an auditory signal, and analysing these signals allows scientists to construct 3D images of the target region. The method is particularly useful for pinpointing superficial tumours. Currently, photoacoustic imaging in a clinical setting only makes use of natural chromophores like haemoglobin, which are already present in the human body. Its oxygenated and deoxygenated states have different optoacoustic signatures that act as useful biomarkers of abnormal metabolic processes. In the new study, the IISc team designed an external molecule – not typically found in human cells – to provide better sensitivity and contrast, which makes it easier to differentiate the target region from normal tissues. The molecule, referred to as GPc, consists of four glucose units conjugated to a scaffold made of zinc-phthalocyanine.  The authors, however, suggest that more studies are needed to fully evaluate GPc’s function once it enters the cells. ]]> https://biospectrumindia.com/news/104/26236/ipv-leads-iom-bioworks-rs-4-cr-funding-to-revolutionise-healthcare-through-gut-microbiome-science.html https://biospectrumindia.com/news/104/26236/ipv-leads-iom-bioworks-rs-4-cr-funding-to-revolutionise-healthcare-through-gut-microbiome-science.html Thu, 12 Jun 2025 00:00:00 +0530 Bengaluru-based startup Iom Bioworks, a deep science company pioneering microbiome-focused healthcare, has secured Seed Round funding in their Rs 4 crore Seed Round led by Inflection Point Ventures (IPV). The capital will be leveraged for marketing, secure intellectual property claims, strengthen core infrastructure and scale scientific and commercial teams. Founded in 2022, Iom Bioworks personalises health by identifying key bacteria in the gut and modulating them in a targeted manner for enhanced, improved  overall health and well-being. Their patented platform combines large-scale knowledge graphed mined through Artificial Intelligence (AI)  and advanced modelling techniques that ensures Iom achieves precise and personalised recommendations for its users. Iom Bioworks reached more than 500 customers in just the first year and have 2 patents granted and 2 in advanced stages. They have key scientific publications in leading scientific journals. Iom Bioworks have Pan India logistics and have established digital access established for personalised microbiome services. “Lifestyle diseases have been on the rise due to multiple reasons like poor diet, stress, lack of sleep and are intimately linked to poor gut health and microbial composition. The gut microbiome plays a huge role in your digestion, immunity, metabolism, and even mood. Understanding it can help prevent a myriad of these diseases and also provide a better quality of life. Iom Bioworks is making this cutting-edge science accessible, personalised and importantly, actionable. With their vision and science, they make a compelling bet in preventive and therapeutic healthcare”, says Vinay Bansal, Founder, IPV. At a compound annual growth rate (CAGR) of 28%, the worldwide market for health tests, subscriptions, and wellness platforms is expected to reach $900 billion by 2030. Iom Bioworks is well positioned to lead this transformation to personalised accessible gut health with its scalable approach, user focus and the foundation of deep science and research.   Image caption- L-R, Samik Ghosh, Co-Founder & Chief of Science & Technology; Dr Hiroaki Kitano, Co-Founder & Chief of Research & Collaboration; Bipin Pradeep Kumar, Co-Founder and CEO, Iom Bioworks ]]> https://biospectrumindia.com/news/104/26199/iisc-develops-novel-nanozyme-to-prevent-excess-blood-clotting.html https://biospectrumindia.com/news/104/26199/iisc-develops-novel-nanozyme-to-prevent-excess-blood-clotting.html Wed, 04 Jun 2025 00:00:00 +0530 Researchers at the Indian Institute of Science (IISc), Bengaluru have developed an artificial metal-based nanozyme that can potentially be used to clamp down on abnormal blood clotting caused by conditions like pulmonary thromboembolism (PTE). These “nanozymes” work by controlling toxic Reactive Oxygen Species (ROS) levels, thereby preventing the over-activation of platelets that leads to excess clot formation or thrombosis. The team injected the nanozyme in a mouse model of PTE and found that it significantly reduced thrombosis and increased the animals’ survival rates. They also observed the weight, behaviour, and blood parameters of the animal for up to five days after injecting the nanozyme, and did not find any toxic effects. Anti-platelet drugs that target thrombosis sometimes have side effects such as increased bleeding. “Unlike conventional anti-platelet drugs that interfere with physiological haemostasis, the nanozymes modulate the redox signalling and do not interfere with normal blood clotting. This means that they won’t cause bleeding complications that are a major concern with current therapies,” said the researchers. The team now plans to explore the efficacy of the nanozyme in preventing ischemic stroke, which is also caused by clogging of blood vessels. “We are hopeful about clinical studies in humans because we have done our experiments with human platelets and they worked,” said the researchers. ]]> https://biospectrumindia.com/news/104/26138/remidio-unveils-new-device-pristine-for-innovating-ai-powered-eye-diagnostics-.html https://biospectrumindia.com/news/104/26138/remidio-unveils-new-device-pristine-for-innovating-ai-powered-eye-diagnostics-.html Wed, 21 May 2025 00:00:00 +0530 After a decade of transforming access to eye care in India and beyond, Bengaluru-based Remidio Innovative Solutions has announced a pivotal evolution in its journey, the launch of its dual brand strategy, Remidio and Pristine, to address the full spectrum of eye care needs, from last-mile screening to advanced clinical diagnostics. Over the past decade, Remidio has focused on expanding access to eye care. Through portable technology and artificial intelligence (AI), the company has facilitated over 16 million screenings across 40+ countries, addressing low awareness and limited access to early detection. Its Insta series of portable tools for frontline workers has built an ecosystem that now directs millions more patients to ophthalmology clinics annually. Pristine’s suite of in-clinic innovations is built to drive measurable efficiency. Pristine 1.5 reduces retina imaging time per patient through automated workflows. Pristine 5.0 offers true-color, wide-field imaging in seconds, maximizing throughput without compromising quality. The Pristine VX650 enables comprehensive, multimodal diagnostics in high-volume settings, streamlining the workup process across retina and refractive care. The soon to be launched Pristine OBM 12 delivers 12 essential eye measurements in just 25 seconds, empowering technicians to manage myopia and pre-operative evaluations with precision and minimal intervention.  Together, these devices enable clinics to ‘see more, do more’, boosting patient volumes, diagnostic confidence, and workflow efficiency. These platforms are redefining efficiency in clinical ophthalmology, allowing more patients to be seen per day, with better insights, and fewer delays. With validated AI for Diabetic Retinopathy, Glaucoma, and age-related macular degeneration (AMD), the company is also working on expanding screening capabilities into systemic conditions such as cardiovascular disease (CVD) and chronic kidney disease (CKD), leveraging the eye as a window into overall health. From outreach to in-clinic diagnostics, from retina to systemic health, Remidio’s dual brand strategy sets the stage for the next decade of transformation in eye care. ]]> https://biospectrumindia.com/news/104/26142/shilpa-biologicals-opens-bioconjugation-manufacturing-site-in-dharwad.html https://biospectrumindia.com/news/104/26142/shilpa-biologicals-opens-bioconjugation-manufacturing-site-in-dharwad.html Wed, 21 May 2025 00:00:00 +0530 Shilpa Biologicals, a full-service contract development and manufacturing organisation (CDMO), has announced the opening of a dedicated bioconjugation suite at its Dharwad site in Karnataka. Located adjacent to the company’s existing commercial biologics manufacturing facility, the suite is currently undergoing validation and is expected to begin onboarding client programmes by September 2025. This latest expansion positions Shilpa Biologicals among a select group of global CDMOs capable of providing clinical and commercial-scale manufacturing across all three-core antibody-drug conjugate (ADC) components – payloads/linkers, monoclonal antibodies, and bioconjugation — and within a single, integrated campus. The new suite is backed by one of the industry’s largest payload and linker libraries, with a multi-ton high-potency active pharmaceutical ingredient (HPAPI) capacity. In fact, the CDMO currently manufactures approximately 40% of the oncological HPAPIs in use today from its USFDA-approved facilities. It’s 10 cGMP HPAPI suites are equipped to handle compounds with occupational exposure limits (OELs) below 0.01 µg/m³ – ensuring safe and compliant processing of even the most potent ADC payloads. The new multi-client bioconjugation suite is built to support the manufacture of ADCs and other advanced bioconjugates progressing through the pipeline, and includes 200L single use bioconjugation reactors and a lyophilisation capacity of up to 65 kg. Complementary development laboratories will provide process development, analytical characterisation, and both early and late-stage scale-up capabilities. For final dose requirements, Shilpa’s Hyderabad site is equipped with multiple isolator-based fill-finish lines dedicated to cytotoxic products. Shilpa Biologicals, Chief Executive Officer Dr Sridevi Khambhampaty commented; “We are seeing an unprecedented wave of ADC innovation entering clinical development — yet only a handful of CDMOs globally offer true end-to-end capabilities. Our co-located ADC services — spanning payloads, linkers, antibodies, and bioconjugation — are generating significant industry interest, especially from US and European biotech companies seeking a single, reliable partner to support their journey from discovery to commercial launch. ]]> https://biospectrumindia.com/news/104/26116/steerlife-redefines-potent-drug-development-with-clean-green-continuous-processing.html https://biospectrumindia.com/news/104/26116/steerlife-redefines-potent-drug-development-with-clean-green-continuous-processing.html Thu, 15 May 2025 00:00:00 +0530 Bengaluru-based STEERLife, the life sciences division of STEER World, is advancing the development and manufacturing of potent and complex drug products. This initiative marks a significant advancement in a field that has long been considered one of the most challenging areas within pharmaceutical science.   At the core of this advancement is STEERLife's proprietary solvent-free melt fusion technology, a continuous processing system that eliminates the need for harmful organic solvents. Designed to precisely handle high-potency and hard-to-develop molecules, this platform significantly enhances formulation efficiency, safety, and scalability.   As a next-generation Contract Research, Development & Manufacturing Organization (CRDMO), STEERLife provides comprehensive development capabilities for complex and potent drugs - including NCEs, hormone therapies, orphan drugs, complex generics (ANDAs) and 505(b)(2) products, assisting global pharma in overcoming development and manufacturing challenges through process-driven innovation. "Potent drug development demands more than just compliance; it requires control, care, and innovation," said Indu Bhushan, CEO & Director at STEERLife. "Our continuous, solvent-free platform brings all of that together - enabling faster, cleaner and more scalable development for the world's most demanding therapies." STEERLife has already initiated the development of several key drug products set for market release from 2026 onwards. These include generic versions of ERLEADA® (Apalutamide), XTANDI® (Enzalutamide), VENCLEXTA® (Venetoclax), and LYNPARZA® (Olaparib), reflecting the company's ability to take on complex, high-barrier drug programs with confidence. Working in tandem with partner facilities, STEERLife is strategically positioned to serve leading pharmaceutical markets across the United States, Europe, Latin America, Russia, MENA and Southeast Asia. ]]> https://biospectrumindia.com/news/104/26107/4basecare-inaugurates-new-genomics-lab-and-unveils-global-cancer-diversity-atlas.html https://biospectrumindia.com/news/104/26107/4basecare-inaugurates-new-genomics-lab-and-unveils-global-cancer-diversity-atlas.html Wed, 14 May 2025 00:00:00 +0530 4baseCare, a precision oncology company, has inaugurated its new genomics laboratory in Mahadevapura, Bengaluru, as a part of its consistent efforts to advance access to precision oncology in India. The highlight of the launch event was the unveiling of Global Cancer Diversity Atlas (GCDA) aimed at addressing the genomics data gap that exists in cancer care.  The launch event was presided over by N. R. Narayana Murthy, Chairman, Infosys, who also unveiled the Global Cancer Diversity Atlas. 4baseCare’s new genomics lab in Bengaluru will offer advanced genomic testing solutions including comprehensive gene panels, whole exome sequencing, and transcriptome analysis. These tools will enable oncologists to delve deeper into the genetic makeup of tumors, offering personalized and more effective cancer treatment options.  The Global Cancer Diversity Atlas (GCDA) is a pioneering initiative by 4baseCare designed to address a critical gap in global cancer research: the lack of genomic data from diverse populations. While most cancer genomic datasets are dominated by Western populations, GCDA is built on real-world data from India and the Global South, including South Asia, Southeast Asia, the Middle East, Central Europe, and Latin America. GCDA is the world’s most inclusive cancer genomics dataset, transforming how we develop diagnostics, conduct research, and deliver cancer care so that every patient, everywhere, is truly seen and understood. Commenting on the new lab and the unveiling of GCDA, Hitesh Goswami, CEO and Co-Founder, 4baseCare, said, “ Our new genomics lab and the unveiling of the GCDA are driven by a single goal of creating better access to precision oncology. One of the key challenges in cancer care today is the lack of genomic data from Indian and Asian populations. This data gap has a significant impact on the effectiveness of cancer diagnostics and treatment strategies for under-represented communities.”    ]]> https://biospectrumindia.com/news/104/26089/aster-dm-healthcare-to-invest-rs-480-cr-in-new-facility-in-bengaluru.html https://biospectrumindia.com/news/104/26089/aster-dm-healthcare-to-invest-rs-480-cr-in-new-facility-in-bengaluru.html Wed, 07 May 2025 00:00:00 +0530 Aster DM Healthcare, one of the largest integrated healthcare providers in India, has announced the signing of a lease agreement to establish its 4th Multispecialty Hospital in Bengaluru. This 430-bed state-of-the-art facility to come up in Sarjapur is set to revolutionise healthcare in the region with its comprehensive and specialised medical services.  Aster DM Healthcare will be making an investment of around Rs 480 crore in this facility spreading over 4 lakh sq ft. The first phase of the project with 300 beds will be operational by the second half of FY27 and the remaining 130 beds in FY29. With the establishment of its fourth hospital in Bengaluru, Aster will strategically achieve a city-wide presence, covering all major zones and solidify its position among the top three hospital chains in the city. Sarjapur Road is rapidly emerging as Bengaluru’s next major IT hub, driven by robust infrastructure development and strategic location advantages. The Karnataka Industrial Areas Development Board (KIADB) has announced plans to develop a state-of-the-art IT hub spread across 1,050 acres. This development is complemented by a surge in approved residential and commercial projects, positioning Sarjapur as a high-growth corridor. Dr Azad Moopen, Founder & Chairman, Aster DM Healthcare said, “This state-of-the-art facility is being designed to deliver world-class, patient-centric care and will cater to the rapidly growing healthcare needs of the region. As part of our broader vision to strengthen our footprint in key urban centers, the upcoming hospital reinforces our commitment to enhancing access to advanced medical services. Notably, this will be a comprehensive multi-specialty hospital in the South-East Bengaluru micro market, with a focus on cancer care, establishing a strong oncology footprint from inception."   ]]> https://biospectrumindia.com/news/104/26067/remidio-receives-regulatory-approval-from-karnataka-to-deploy-ai-based-tools-for-eye-care.html https://biospectrumindia.com/news/104/26067/remidio-receives-regulatory-approval-from-karnataka-to-deploy-ai-based-tools-for-eye-care.html Fri, 02 May 2025 00:00:00 +0530 Remidio Innovative Solutions has received approval from the State FDA, Karnataka (CDSCO), the regulatory authority for medical devices, for its Medios HI (Humanising Intelligence) Glaucoma AI and Medios HI AMD AI. This approval represents an important advancement in the use of artificial intelligence (AI) for early detection of glaucoma and age-related macular degeneration (AMD) in diverse healthcare settings. Following the success of the CDSCO-approved Medios DR HI, AI for diabetic retinopathy, which has impacted nearly 2,50,000 patients in the past year, the newly approved AI solutions for glaucoma and AMD are also designed to function offline. This offline capability allows real-time analysis without relying on internet access, making it useful for providing eye care in remote and underserved areas with limited access to specialised ophthalmic diagnostics. Medios HI Glaucoma AI exceeds conventional screening methods by analysing optic nerve head and RNFL structures, generating heat map–based reports to detect early signs of referable glaucoma. This is vital in a country like India, which accounts for 12 million glaucoma patients, nearly one in eight globally. Yet over 90% of these cases remain undiagnosed, often leading to irreversible vision loss. Early detection using portable, AI-enabled tools can drastically change this trajectory. The Medios HI AMD AI, detects early-stage age-related macular degeneration (AMD), a major cause of vision impairment among the elderly. With 2.1% of Indians over age 60 affected, amounting to nearly 6.7 million people at risk, this tool plays a crucial role in enabling timely referrals and preventive care by highlighting lesions with AI generated heat maps. Medios HI Glaucoma and Medios HI AMD Al has been clinically validated across tertiary hospitals, eye institute and vision centres showcasing high level of sensitivity and specificity. With Medios HI on Remidio’s FOP NM 10, a single tap delivers results for screening AMD, Glaucoma, and DR in few seconds.  Three critical insights, one seamless experience. Dr R. Kim, Chief Medical Officer, Senior Medical Consultant, Retina & Vitreous Services Director, Aravind Eye Hospital, Madurai said “The Remidio fundus camera isn't just an imaging device; it's a portable gateway to early detection and prevention of vision-threatening conditions, bringing quality eye care closer to those who need it most”  Dr Anand Sivaraman, CEO and Founding Director, Remidio said "The CDSCO's approval of our Medios HI Glaucoma AI and Medios HI AMD AI builds upon the foundation laid by our Medios HI DR AI, which was the first ophthalmic AI software to receive such approval in India."   ]]> https://biospectrumindia.com/news/104/26058/lifesigns-and-cura-hospital-bridge-urban-rural-healthcare-gap-with-ai.html https://biospectrumindia.com/news/104/26058/lifesigns-and-cura-hospital-bridge-urban-rural-healthcare-gap-with-ai.html Wed, 30 Apr 2025 00:00:00 +0530 Cura Hospital has partnered with Lifesigns, India’s leading artificial intelligence (AI)-powered patient monitoring platform, to enable round-the-clock, real-time tracking of vital signs across hospital, home, and in-transit care. This collaboration ensures that critical health data is continuously streamed to clinicians, helping them intervene at the right time, reduce delays, and significantly improve outcomes, especially for cardiac emergencies where every minute matters. The partnership allows the hospital to monitor patients remotely using wearable IoT devices, receive intelligent alerts, and deliver targeted care from the moment symptoms start, regardless of where the patient is located. Located in South Bangalore, Cura Hospital is emerging as a regional pioneer in advanced cardiac and emergency care. With a mission to serve both urban and rural populations, the hospital is uniquely positioned to bring state-of-the-art healthcare infrastructure to underserved communities. Through this collaboration with Lifesigns, the hospital can now deliver proactive, tech-enabled care, especially during the “golden hour”—the crucial window following a cardiac event when rapid response can save lives. Cura's clinical team receives live data to prepare and guide precise treatment plans, whether the patient is in-hospital, at home, or en route via smart ambulance. The collaboration also bridges the urban-rural healthcare divide, extending advanced monitoring, early warning systems, and expert intervention to patients from both South Bangalore and neighboring semi-urban and rural areas. The partnership reflects a shared vision between Cura Hospital and Lifesigns to create a patient-centric, technology-led healthcare future—where care is not only reactive but predictive and proactive.   ]]> https://biospectrumindia.com/news/104/26038/integrative-medicine-department-to-pen-at-tata-iisc-medical-school.html https://biospectrumindia.com/news/104/26038/integrative-medicine-department-to-pen-at-tata-iisc-medical-school.html Fri, 25 Apr 2025 00:00:00 +0530 In a significant step towards strengthening India’s traditional healthcare infrastructure through an integrative approach, a virtual meeting was recently convened to discuss the establishment of a Department of Integrative Medicine at the TATA IISc Medical School, Bengaluru. Deliberations centred around the urgent need to blend the strengths of contemporary medicine with the time-tested practices of traditional systems like Ayurveda to enhance healthcare delivery, medical education, and research. The participants unanimously agreed on developing a White Paper on Integrative Medicine, outlining its scope and strategic applications in clinical practice, academics, and scientific inquiry. The document will serve as a roadmap for nationwide implementation, following expert consultation and policy-level approvals. This initiative follows the momentum built during the ‘RISE for Healthy Ageing’ International Conference at IISc, where top scientists and Ayush leaders discussed the future of Integrative Medicine. This meeting marks a concrete development in institutionalising integrative healthcare, reaffirming India’s commitment to evidence-based, patient-centric health systems. ]]> https://biospectrumindia.com/news/104/25989/spark-radiology-unveils-new-platform-in-india-to-transform-radiology-reporting-with-ai.html https://biospectrumindia.com/news/104/25989/spark-radiology-unveils-new-platform-in-india-to-transform-radiology-reporting-with-ai.html Tue, 15 Apr 2025 00:00:00 +0530 Bengaluru-based SPARK Radiology, an innovator in medical imaging solutions, has announced the India launch of SPARK.ai, a powerful new technology platform built to transform how radiologists manage their daily reporting workflows. In a healthcare environment where radiologists are under increasing pressure, SPARK.ai introduces a reimagined approach to workflow design, reducing manual overhead, enabling faster report turnaround, and helping radiologists focus on what truly matters: delivering accurate and timely diagnoses. India currently has approximately 20,000 radiologists serving a population of over 1.4 billion, resulting in a significant gap between diagnostic demand and available expertise. For every 100 scans performed daily, there’s only one radiologist available to interpret them. SPARK.ai has been developed to address this gap by automating routine documentation tasks, simplifying case management, thus allowing radiologists to focus on making the diagnosis instead of the report. The platform has been thoughtfully built to integrate seamlessly into existing systems, allowing radiologists to work more fluidly. It bridges the gap between existing processes and an entirely new way of reporting that enables the radiologist to seamlessly share any key findings they observe in a study, automatically generate a final report, and enable a quick review, approval, and distribution process. This new workflow creates the conditions for more consistent, high-quality reporting, supporting improved diagnosis without burdening the practitioner. As AI-driven solutions like SPARK.ai reshape radiology, they pave the way for healthcare professionals to provide timely and precise care in a landscape where demand far outpaces supply. ]]> https://biospectrumindia.com/news/104/25992/remidio-with-retinarisk-to-strengthen-ai-driven-diabetic-retinopathy-screening-in-india-and-iceland.html https://biospectrumindia.com/news/104/25992/remidio-with-retinarisk-to-strengthen-ai-driven-diabetic-retinopathy-screening-in-india-and-iceland.html Tue, 15 Apr 2025 00:00:00 +0530 Bengaluru-based Remidio Innovative Solutions, a global leader in artificial intelligence (AI)-powered ophthalmic diagnostics, has announced a strategic partnership with RetinaRisk, a leading health tech company from Iceland, to enhance risk-based diabetic retinopathy (DR) screening in India and Iceland. This partnership brings together two powerful innovations, Remidio’s Medios DR AI for automated DR detection and RetinaRisk’s personalised risk triaging algorithm for progression to sight-threatening DR. Medios DR is an edge-AI solution that runs entirely on a smartphone without the need for internet access or cloud connectivity, offering real-time DR grading at the point of care. RetinaRisk calculates a patient’s risk level and suggests a recommended screening interval using key clinical inputs such as HbA1c, blood pressure, diabetes type and duration, and DR status. From a public health perspective, this enables more cost-effective DR screening programmes by individualising screening intervals, extending the frequency for low-risk individuals while ensuring timely follow-up for high-risk cases. The urgency of this collaboration is highlighted by growing global and national public health concerns. Globally, an estimated 22.27% of people with diabetes have diabetic retinopathy, and the number of affected adults is projected to rise from 103.12 million in 2020 to 160.50 million by 2045. India alone accounts for over 9.2 million cases, highlighting the urgent need for scalable, personalized screening models. The partnership will kick off with pilot programmes targeting high-prevalence diabetic populations in India, aiming to create a scalable framework for prioritised referrals, longitudinal tracking, and reduced vision loss due to DR.   ]]> https://biospectrumindia.com/news/104/25963/cureskin-to-launch-worlds-first-ai-powered-hair-analyser.html https://biospectrumindia.com/news/104/25963/cureskin-to-launch-worlds-first-ai-powered-hair-analyser.html Wed, 09 Apr 2025 00:00:00 +0530 Bengaluru-based startup Cureskin, a leader in artificial intelligence (AI)-driven dermatology solutions is set to launch the world’s first AI-powered hair analyser. It is designed to accurately detect male pattern baldness and assess hairline health with advanced precision. This breakthrough feature, integrated into the Cureskin app, leverages cutting-edge artificial intelligence (AI) and machine learning (ML) to help users monitor hair thinning early, enabling timely intervention and personalised treatment recommendations. Cureskin’s AI-powered hair analyser utilises deep-learning models trained on thousands of clinical images to identify early signs of hair recession, thinning, and density reduction. With a simple selfie in the app, users receive an instant, in-depth analysis of their hairline health, along with AI-generated insights on potential hair loss patterns. In a country where dermatologists are scarce and hair-related stigma is widespread, this innovation brings equitable, tech-enabled care to millions—especially in semi-urban and rural areas where expert access is limited. “By integrating AI and machine learning into hair health diagnostics, we are transforming how users understand and address hair loss. Our deep-learning models continuously improve, ensuring high accuracy in detecting hair loss patterns. With this feature, users can access early and expert guidance, bridging the gap between technology and personalised dermatological care,” said Ramakrishna R, Chief Technology Officer at Cureskin. Male pattern baldness (androgenetic alopecia) is a growing concern in India, with studies indicating that over 50% of Indian men experience some degree of hair loss by the age of 50, with many seeing early signs as young as their 20s. Factors such as genetics, lifestyle, and environmental stressors accelerate hair thinning, making early detection crucial for effective management. With this new AI-driven hair analysis feature, Cureskin continues to redefine personalised dermatological care through the power of technology. ]]> https://biospectrumindia.com/news/104/25948/narayana-health-deploys-ai-based-technologies-at-preventive-health-screening-centre-aarogyam.html https://biospectrumindia.com/news/104/25948/narayana-health-deploys-ai-based-technologies-at-preventive-health-screening-centre-aarogyam.html Mon, 07 Apr 2025 00:00:00 +0530 Narayana Health has announced the formal launch of Narayana Aarogyam, a preventive screening initiative designed to empower individuals through early detection and personalised health tests. Located in Bengaluru's tech corridor at Prestige Tech Park, Kadubeesanahalli, Aarogyam targets young working professionals with streamlined 90-minute checkups, advanced diagnostic tools and four customizable wellness packages. The Aarogyam centre is equipped with the latest artificial intelligence (AI)- enabled cardiac CT Scanner, which offers ultra-low radiation AI-enhanced imaging for heart health.  DEXA Scans are available for precision bone density analysis to detect osteoporosis risks. The centre is also equipped with Advanced 3D Mammograms that offer high-resolution breast cancer screening. The key highlight of our screening is that there is No Need For Fasting for any of these tests, keeping patient convenience on top of mind. Aarogyam provides tailored health packages for different age groups: Vital Care:Comprising gut health, thyroid and baseline metrics for people below 35 years of age. Prima:Heart, liver and lung screenings for those in the 35-40 years age group. Enhanced:For cancer risk profiling to people between 35 and 40 years. Comprehensive: Our most advanced package for all under 40 years that includes whole body diagnostics along with chronic disease markers. Dr Devi Shetty, Chairman of Narayana Health, stated, “Aarogyam redefines preventive care by merging clinical excellence with accessibility. It is important for healthy individuals with fast-paced lifestyles to prioritise preventive health screenings. Our goal is to shift healthcare from reactive treatment to proactive wellness, ensuring that early intervention becomes a lifestyle norm.”   ]]> https://biospectrumindia.com/news/104/25914/algorithmic-biologics-appoints-hiranjith-gh-as-chief-business-officer.html https://biospectrumindia.com/news/104/25914/algorithmic-biologics-appoints-hiranjith-gh-as-chief-business-officer.html Tue, 01 Apr 2025 00:00:00 +0530 Bengaluru-based startup Algorithmic Biologics, a pioneer in molecular computing, enabling faster, cost-effective, and highly accurate molecular testing by embedding artificial intelligence (AI) directly into the test tube, has announced the appointment of Hiranjith GH as Chief Business Officer (CBO) to lead the company’s commercial operations and its expansion globally, primarily in the US.  With decades of experience in the pharmaceutical and life sciences industries, Hiran brings valuable experience and expertise in go-to-market strategy for the US, business development, solution development, and cross-border team leadership. Based in the San Francisco Bay Area, Hiran most recently served as the Vice President and Site Head for MedGenome USA, launching and scaling its commercial operations in the US. Prior to that, he held various corporate leadership and business roles at MedGenome since its incorporation as an independent entity. He previously led teams at Novartis, ZS Associates and Accenture Management Consulting advising internal and external commercialisation teams on marketing analytics, brand planning and commercial operations primarily in the Life Sciences and Pharmaceuticals sectors.  With Algorithmic Biologics’ proprietary compression technology gaining momentum among diagnostic assay manufacturers and large-scale screening and surveillance providers—delivering an order of magnitude scalability and efficiency—the appointment strengthens the leadership team at a crucial time to drive growth and partnerships forward.    ]]> https://biospectrumindia.com/views/104/25896/we-plan-to-establish-a-coe-in-medtech-and-launch-a-bio-innovation-acceleration-programme-in-2025.html https://biospectrumindia.com/views/104/25896/we-plan-to-establish-a-coe-in-medtech-and-launch-a-bio-innovation-acceleration-programme-in-2025.html Mon, 31 Mar 2025 00:00:00 +0530 What new initiatives are planned to attract and nurture more startups in the life sciences sector? In 2024, the incubator onboarded 10 new startups and 38 existing startups, for a total of 48 startups in the life sciences, biosciences, and healthcare sectors. To attract more startups, we conducted around 57 programmes to build partnerships with innovators from universities and R&D organisations, as well as startups and MSMEs. The incubator is now focused on expanding and diversifying its incubation services and programmes to support innovators and startups. Plans include the augmentation of Bioincubator facilities with an additional 10,000 sq ft of space. A Clinical Validation Hub will be launched specifically for medtech startups at the bioincubator. The incubator also aims to establish a Centre of Excellence (CoE) in medtech with the support of the Government of Karnataka. Additionally, a GMP facility for small-scale bio-manufacturing will be set up. The incubator is also set to launch a bio-innovation acceleration programme for bio-medical startups and establish an advanced biomanufacturing facility for prototyping and scale-up. To further support the ecosystem, the incubator will host an International Bio-Innovation Summit to showcase opportunities and foster collaborations. What role are startups expected to play in advancing biomanufacturing capabilities, and how is this anticipated to impact the overall industry? In regulated sectors such as life sciences, biosciences, and healthcare, a significant challenge lies in bridging the gap between early-stage innovations, often culminating in patent filings, and their progression to biomanufacturing and market-ready products. Startups can play a crucial role in closing this gap by driving innovation in biomanufacturing. They can achieve this by developing cost-effective processes, scaling disruptive technologies, and addressing critical inefficiencies in production. These efforts are anticipated to enhance domestic manufacturing capacity, reduce reliance on imports, and position India as a leading global hub for biomanufacturing. What are the incubator's plans for the year 2025 to foster entrepreneurship and innovation? The incubator plans to expand wet lab and pilot-scale manufacturing facilities to accommodate diverse biotech startups, along with clean rooms for biomedical pilot productions. A certification programme for startups in the biomedical domain is also being planned. Additionally, a Social Bio-Innovation Initiative will be introduced to address rural and underserved healthcare challenges. The incubator aims to start a Biodesigning programme to address unmet medical needs and launch Entrepreneurial Training Modules focusing on regulatory pathways, IP management, and market strategy. Strengthening partnerships with global accelerators and research institutions will be a key focus to enhance startup support. Currently, the facility is DSIR SIRO recognised, and plans are underway to obtain ISO 9001 and NABL accreditation. Furthermore, the incubator plans to conduct 3 hackathons to scout innovations in the biomedical domains. By bridging the gap between research and commercialisation, enhancing biomanufacturing capabilities, and nurturing entrepreneurial talent, it aims to accelerate India’s standing as a global leader in biotech innovation. As the incubator continues to push boundaries, its unwavering focus on infrastructure development, international collaborations, and social innovation will undoubtedly shape the future of healthcare and the bioeconomy, creating a lasting impact on the industry.   Vrushti Kothari (vrushti.kothari@mmactiv.com) ]]> https://biospectrumindia.com/news/104/25876/iisc-suggests-blood-glucose-detection-through-painless-photoacoustics.html https://biospectrumindia.com/news/104/25876/iisc-suggests-blood-glucose-detection-through-painless-photoacoustics.html Mon, 24 Mar 2025 00:00:00 +0530 Blood glucose is usually measured using invasive methods involving pricking small needles into the skin. But people suffering from diabetes have to test their glucose levels many times in a day. This repeated use of needles is inconvenient and can increase the risk of potential infections. A new study by researchers at the Department of Instrumentation and Applied Physics (IAP), Indian Institute of Science (IISc) in Bengaluru offers an alternative solution via a technique called photoacoustic sensing. In this technique, when a laser beam is shined on biological tissue, the tissue components absorb the light and the tissue heats up slightly (less than 1°C). This causes the tissue to expand and contract, creating vibrations which can be picked up as ultrasonic sound waves by sensitive detectors. Different materials and molecules inside the tissue absorb different amounts of the incident light at different wavelengths, creating individual “fingerprints” in the emitted sound waves. Importantly, this procedure does not damage the tissue sample being studied. In the current study, the team exploited this approach to measure the concentration of a single molecule, namely glucose. They used polarised light – a light wave that oscillates only in a specific direction. Sunglasses, for example, reduce glare by blocking out light waves that oscillate in certain directions. Glucose is a chiral molecule, which means that it has an inherent structural asymmetry that causes polarised light to rotate its orientation of oscillation when it interacts with the molecule. Surprisingly, the team found that the intensity of the emitted sound waves changed when the orientation of the polarised light interacting with glucose in the solution was changed. “We don’t actually know why the acoustic signal changes when we change the polarisation state. But we can establish a relationship between the glucose concentration and the intensity of the acoustic signal at a particular wavelength,” explains Jaya Prakash, Assistant Professor in IAP and corresponding author of the study. As many commonly used drugs are chiral in nature, such a technique can have wide-ranging applications in healthcare and diagnostics. ]]> https://biospectrumindia.com/news/104/25869/prashanthi-balamandira-trust-launches-indias-largest-social-stock-exchange-issue-on-nse.html https://biospectrumindia.com/news/104/25869/prashanthi-balamandira-trust-launches-indias-largest-social-stock-exchange-issue-on-nse.html Sat, 22 Mar 2025 00:00:00 +0530 Karnataka-based public charitable non-profit organisation, Prashanthi Balamandira Trust (PBT), has launched its public issue on the Social Stock Exchange (SSE) in a bid to raise Rs 18 crore. The issue is India’s Largest Social Stock Exchange issue yet on the National Stock Exchange – Social Stock Exchange platform. The funds raised through the issue of Zero Coupon Zero Principal Bonds (ZCZP) shall be utilised towards establishing state-of-the-art Emergency & Trauma Care Wing in the upcoming 600-bed world’s largest free-of-charge hospital at Sathya Sai Grama, Muddenahalli near Bengaluru. The minimum subscription amount for this issue is Rs 10,000 and further in multiples of Rs 1. The issue opened on 19th March 2025 and closes on Monday, 24th March 2025. Sharing further details, R K Subramanya, Trustee of the Prashanthi Balamandira Trust said, “Emergency care saves lives. Yet in resource-limited settings, care is often compromised due to lack of funds. Providing access to high quality medical care, free-of-charge to all those in need, is our mission.” Notably, Prashanthi Balamandira Trust is a public charitable entity that provides free of charge quality education and healthcare to underserved communities. Registered with the Social Stock Exchange of the NSE, PBT embodies transparency, good governance and public accountability as a humanity-centric trust. The hospital being built by PBT in Karnataka is slated to be the world’s largest free-of-charge healthcare centre. The fully equipped Emergency and Trauma Care wing will be an integral part of the upcoming 600-bed hospital.   ]]> https://biospectrumindia.com/news/104/25839/peptris-technologies-out-licenses-indias-first-ai-discovered-drug-candidate-to-revio-therapeutics.html https://biospectrumindia.com/news/104/25839/peptris-technologies-out-licenses-indias-first-ai-discovered-drug-candidate-to-revio-therapeutics.html Mon, 17 Mar 2025 00:00:00 +0530 Peptris Technologies, a Bengaluru-based AI-powered drug discovery startup, has entered into a licensing agreement with US-based Revio Therapeutics, a specialty pharma startup focused on repurposing and optimizing approved medicines. Under the agreement, Peptris is licensing its preclinical-stage asset, PEPR124 (RT001) for an undisclosed amount to Revio Therapeutics for further development in Duchenne Muscular Dystrophy (DMD). The agreement is expected to accelerate Peptris’ AI-powered drug discovery efforts and expand its footprint in global biotech markets. DMD is a rare genetic disorder primarily affecting boys, leading to progressive muscle degeneration, severe disability, and reduced life expectancy.With limited treatment options available, the global DMD market is valued at over $3 billion and represents a significant unmet need, driving demand for more effective and accessible therapies. PEPR124 (RT001) was discovered by Peptris Technologies using its proprietary AI-driven drug discovery platform and has demonstrated promising efficacy in preclinical studies for DMD. It is a repurposed, mutation-agnostic, and safe therapeutic that could be a significant breakthrough therapeutic for not only DMD but other muscular dystrophies as well. Under the terms of the agreement, Revio Therapeutics will hold commercialisation rights to PEPR124 (RT001) in all markets except in BRICS countries, which will be retained by Peptris.   ]]> https://biospectrumindia.com/news/104/25844/shilpa-biologicals-inks-strategic-agreement-with-mabtree-biologics-for-a-novel-immuno-oncology-asset.html https://biospectrumindia.com/news/104/25844/shilpa-biologicals-inks-strategic-agreement-with-mabtree-biologics-for-a-novel-immuno-oncology-asset.html Mon, 17 Mar 2025 00:00:00 +0530 Swiss firm mAbTree Biologics AG has signed an exclusive co-development and commercialisation partnership with Shilpa Biologicals (a fully owned subsidiary of Raichur-based Shilpa Medicare) for its novel biologic asset [a checkpoint inhibitor] for immuno-oncological applications. Under the terms of the strategic agreement, Shilpa Biologicals will support both development – including clinical studies – as well as long-term commercial supply with GMP manufacturing. Additionally, Shilpa Group will provide mAbTree access to India and several global markets through its extensive partner network. This programme aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation and generation of strong immune responses against tumours akin to the well-established PD-1/PD-L1 blockade.  While PD-1/PD-L1 blockade has demonstrated remarkable clinical successes, recent studies suggest our novel target has as a highly attractive therapeutic potential in various immuno-oncological states both as a monotherapy and combinatorial therapy. This approach has the potential to convert cold tumours (poor immune cell infiltration) hot (good immune infiltration), suppress tumour metastasis and make the refractory tumors susceptible to chemotherapy as well and is applicable in various cancers, including lung cancer, head and neck squamous cell carcinoma, and hematologic malignancies. Shilpa Biologics will utilise its large R&D teams – providing full-service capabilities from cell line development to GMP drug product manufacturing – with manufacturing and clinical supply conducted at its state-of-the art bio manufacturing facility at Dharwad, Karnataka. Commenting on the co-development deal and its potential impact on patients, Dr Sridevi Khambhampaty, CEO, Shilpa Biologicals said, “This novel therapy represents a new frontier in immuno-oncology, with the potential to expand treatment for patients who do not benefit from current immunotherapy options – so it’s potentially a massive breakthrough.” “Our aim is to enable greater access to medicines for more patients across the world, especially focusing on India and ROW markets where access has been limited”, added Raj Andhuvan, CEO, mAbTree.   Image caption- Dr Sridevi Khambhampaty, CEO of Shilpa Biologicals, and Raj Andhuvan, CEO of mAbTree ]]> https://biospectrumindia.com/news/104/25829/longevity-india-conference-2025-concludes-highlighting-policy-elder-care-and-public-health-perspectives.html https://biospectrumindia.com/news/104/25829/longevity-india-conference-2025-concludes-highlighting-policy-elder-care-and-public-health-perspectives.html Fri, 14 Mar 2025 00:00:00 +0530 The Longevity India Conference 2025 – Rise for Healthy Aging, hosted at the Indian Institute of Science (IISc), Bengaluru (from March 10th to 12th) concluded its final day with impactful discussions on longevity science. The discussions emphasised data-driven policy interventions, advancements in elder care, and the integration of cutting-edge technology to enhance public health strategies. The conference successfully set the stage for actionable insights and collaborative efforts to extend healthspan and improve quality of life for aging populations. The final day sessions centred on Data Sciences for Longevity featured insights from experts like Tavpritesh Sethi (IIT Delhi) and Marcus Ranney (Human Edge) on AI-driven approaches to longevity, imaging technologies, and mechanistic artificial intelligence for anti-aging intervention. Some sessions were also focused on policy frameworks, senior care, palliative care, and more. Dr Prabhdeep Kaur, Longevity Investigator & Professor, IISc, said, “The Longevity India Conference has been exceptional because it brings together diverse stakeholders—academia, government, industry, and others—working on longevity. Over the past three days, it has created opportunities for collaboration, learning, and identifying areas to accelerate progress in this field. The goal was to identify evidence-based interventions that benefit many people, with relevance to both society and policy and I think we lived up to it.” "At least now, can we start talking about providing healthcare? Health is officially defined as physical, social, and mental well-being. We should refocus on what health truly means and work towards making it a reality," said MR Rajagopal, Founder Chairman, Pallium India, on attending the conference. The discussions focused on various aspects of healthy ageing, emphasising the need for national policies. Speakers like TV Sekher (IIPS) and Rajesh Dikshit (Tata Memorial Centre) presented transformative research and policy recommendations, followed by a panel with WHO India and national health leaders. Sessions on Senior Care, Communities, and Technologies highlighted inclusive ecosystems, innovations for elderly well-being and role of technology in senior care, with experts including Tausif Thangalvadi (Red Health), Nidhi Chawla (Silver Talkies), Pavithra Reddy (Vayah Vikas), Arvind Mathur (Caregivers Asha Society), Manish Arora (IISc), and Anurag Ram Chandran (Kubo Care). A keynote address by MR Rajagopal (Pallium India) and panel discussion between Mathews Numpeli (Directorate of health services, Govt. of Kerala), Dhvani Mehta (Vidhi Centre for Legal Policy and Neha Sinha (Epoch Elder Care), focused on End-of-Life and Palliative Care that stressed the need for structured frameworks, supported by discussions with policymakers and legal experts addressing unmet needs in elder care. A session on Clinical & Cohort Study Learnings explored biomarkers of aging, gut microbiome influences, and plasma proteomic signatures for longevity, with contributions from AIIMS, AEMC, and InStem. Finally, sessions on Skin Aging and Technologies for Healthy Aging covered advancements in skin longevity, lysosome roles, and more, with experts from Unilever, Longevity India, Savikalpa Sciences, and Loreal R&I. The Longevity India Conference 2025 successfully concluded after three days, with a strong call for evidence-based policy frameworks, elder care innovations, and large-scale public health interventions. Overall, the event emphasised the urgent need for multi-sector collaboration between government agencies, research institutions, and healthcare providers to develop sustainable longevity solutions.   ]]> https://biospectrumindia.com/news/104/25826/shilpa-medicare-secures-regulatory-nod-for-nor-ursodeoxycholic-acid-tablets-targets-market-launch-for-nash-treatment.html https://biospectrumindia.com/news/104/25826/shilpa-medicare-secures-regulatory-nod-for-nor-ursodeoxycholic-acid-tablets-targets-market-launch-for-nash-treatment.html Thu, 13 Mar 2025 00:00:00 +0530 Raichur-based Shilpa Medicare Limited, a leading API and formulation manufacturer, has announced that the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) has approved its Investigational New Drug (IND) – Nor Ursodeoxycholic Acid (Nor UDCA) Tablets 500 mg – and recommended marketing authorisation for treating non-alcoholic fatty liver disease (NAFLD). NAFLD, the most prevalent liver disease, affects approximately 25% of the global population (1.2 billion people), including 188 million in India. Left untreated, NAFLD can progress to non-alcoholic steatohepatitis (NASH), a severe and potentially fatal condition. Shilpa Medicare had earlier completed phase-3 clinical studies of this novel product SMLNUD07 – Nor Ursodeoxycholic Acid (Nor UDCA) tablets - and presented the results of the trial titled, "A phase - III, Randomised, Double- Blind, placebo controlled, multicenter, Parallel group study", to evaluate the safety and efficacy of Nor-Ursodeoxycholic Acid 500 mg in patients suffering from Non-alcoholic Fatty Liver Disease to the SEC. The trial met all primary efficacy endpoints, demonstrating a significant improvement in fatty liver stage. 83.3% of participants showed fibrosis reversal, with stabilization in the rest. Elevated alanine transaminase (ALT) levels, a key NAFLD marker, normalized in ~90% of participants within 12 weeks. These results position Nor UDCA as a breakthrough therapy for NAFLD, offering advantages over conventional UDCA, including enhanced choleretic effect, resistance to amidation, anti-inflammatory properties, and fibrosis reduction.   ]]> https://biospectrumindia.com/news/104/25824/sartorius-to-expand-bengalurus-manufacturing-capacity-and-enhance-global-supply-chain-capabilities.html https://biospectrumindia.com/news/104/25824/sartorius-to-expand-bengalurus-manufacturing-capacity-and-enhance-global-supply-chain-capabilities.html Wed, 12 Mar 2025 00:00:00 +0530 Based in Göttingen, Germany, Sartorius, a leading international partner of life sciences research and the biopharmaceutical industry has announced continued investments in its Bangalore site to further expand manufacturing capacity and enhance its global supply chain capabilities. Sharing this Dr Joachim Kreuzburg, Chairman- Executive Board of Sartorius AG and Chairman- Board of Directors of Sartorius Stedim Biotech S.A at the Bangalore site said “We have plans to nearly double our annual capacity for manufacturing and testing chromatography systems this year. The aim is to utilize the engineering capability to manufacture and test Resolute Flowdrive Chromatography systems for large-scale biopharmaceutical purification processes. These investments will further enhance our ability to provide cutting-edge solutions for biopharmaceutical manufacturing, ensuring the timely delivery of critical therapies to patients.” He further said “We will invest in a new production line for pallet tanks used in single-use bioreactors by 2027 to meet local and global demand. Most sample development was completed in 2024. Around 50 pallet tanks for mixing were delivered to customers in India and around the globe last year.” Sartorius India plays a vital role in the group’s global network, serving both local and international markets with high-quality products. Building on a legacy of growth and innovation in Bangalore since 1987, Sartorius has established the plant as a global competence center for stainless steel products, fermentation systems, and high-precision components now employing around 670 people. The recent addition of a state-of-the-art application centre where customers can explore the company’s technologies firsthand further strengthen the site’s strategic importance. In addition to its manufacturing capabilities, Sartorius India is a global hub for IT and Digital Solutions, with a team of around 100 experts supporting software development and product development labs worldwide. Committed to environmental sustainability, the Bangalore site achieved 100% renewable power supply already in 2023 and is actively working towards water neutrality by 2026. ]]> https://biospectrumindia.com/news/104/25813/karnataka-government-allocates-rs-57-cr-to-rebuild-bangalore-bioinnovation-centre-after-fire-damage.html https://biospectrumindia.com/news/104/25813/karnataka-government-allocates-rs-57-cr-to-rebuild-bangalore-bioinnovation-centre-after-fire-damage.html Tue, 11 Mar 2025 00:00:00 +0530 The Government of Karnataka has allocated Rs 57 crore for the reconstruction of the Bangalore Bioinnovation Centre (BBC), which suffered extensive damage due to a fire on January 14, 2025. The announcement was made by Chief Minister Siddaramaiah during the Karnataka Budget 2025, reinforcing the state’s commitment to revitalizing its biotech ecosystem. Located in Electronics City, the Bangalore Bioinnovation Centre serves as a vital incubation hub for biotechnology startups and research initiatives. The fire caused severe damage to high-end laboratory equipment and valuable research materials, disrupting the progress of numerous startups and research projects. Recognizing the centre’s critical role in Karnataka’s biotech sector, the government has prioritized its restoration. Of the Rs 57 crore allocated, ₹20 crore has been specifically earmarked for FY26 to facilitate phased reconstruction and re-equipment of the centre. This financial commitment underscores the government’s dedication to fostering innovation, supporting biotech entrepreneurs, and strengthening Karnataka’s position as a global biotechnology hub. The Bangalore Bioinnovation Centre has been instrumental in advancing biopharma, agritech, medtech, and industrial biotech solutions. The reconstruction efforts will not only restore lost infrastructure but also upgrade facilities to better serve the next generation of biotech innovators. ]]> https://biospectrumindia.com/news/104/25815/shilpa-medicare-launches-new-full-service-hybrid-cdmo.html https://biospectrumindia.com/news/104/25815/shilpa-medicare-launches-new-full-service-hybrid-cdmo.html Tue, 11 Mar 2025 00:00:00 +0530 Raichur-based Shilpa Medicare has launched its new full service ‘hybrid’ contract development and manufacturing organisation (CDMO). The newly formed CDMO will see Shilpa serve both small and large molecules customers as well as peptides – with oncology a particular therapeutic specialism.   In addition to offering comprehensive discovery, clinical, and commercial outsourcing services, Shilpa's ‘hybrid CDMO model’ also includes commercially ready ‘off-the-shelf’ novel formulations for exclusive b2b licensing.   This dual approach enables pharmaceutical companies to leverage Shilpa’s extensive expertise in oncology without the direct risks and lengthy timelines associated with development.   The CDMO currently has multiple assets in its pipeline and three late-stage products available for licencing at Drug, Chemical & Associated Technologies Association (DCAT). Through this model, pharma companies can expedite their market entry by licensing fully developed products while still benefiting from Shilpa’s robust development and manufacturing capabilities.   Commenting on the business realignment and hybrid model, Vishnukant C. Bhutada, Managing Director of Shilpa Medicare, commented, “Our goal is to offer pharmaceutical and biotech customers multiple flexible pathways to bring commercial products to market. On the one hand, they can leverage our development teams, cutting-edge technologies, and world-class facilities in a traditional CDMO partnership – with both our GLP-1 and biologics services in high demand at DCAT. On the other, we have a pipeline of fully developed products that are available for exclusive licensing, eliminating development risks for our partners. However, we remain strictly a b2b-only company, ensuring we never compete with our clients.”   Shilpa Medicare has seen rapid growth in recent years, achieving a turnover of over $150 million. The company is well-positioned to capitalise on the increasing trend of pharmaceutical outsourcing to India, offering an extensive infrastructure with five state-of-the-art R&D centres and six manufacturing facilities.     ]]> https://biospectrumindia.com/news/104/25806/longevity-india-conference-2025-opens-with-unique-insights-into-ageing-science.html https://biospectrumindia.com/news/104/25806/longevity-india-conference-2025-opens-with-unique-insights-into-ageing-science.html Mon, 10 Mar 2025 00:00:00 +0530 Bringing together eminent scientists, researchers, and industry leaders, the Longevity India Conference 2025 – Rise for Healthy Aging hosted at the Indian Institute of Science (IISc) in Bengaluru opened on 10 March with unique insights into ageing science and longevity. With the key theme of Biological Foundations and Mechanisms of Ageing, the conference highlighted notable developments and trends through four major sessions covering ageing research, biological mechanisms, lifestyle medicine, and holistic health approaches.   Dinesh Gundu Rao, Minister for Health and Family Welfare of Karnataka; Manjunath Bhandary, MLC, Government of Karnataka and Govindan Rangarajan, Director of IISc were among the key dignitaries who addressed the inaugural session. Following this, engaging discussions were held on ageing science, with thought-provoking insights from global experts. Additionally, the Indian Council of Medical Research (ICMR) has also awarded support to the Longevity India Initiative at IISc, to establish a Centre for Advanced Research in Ageing, marking a significant milestone in India's efforts to address the challenges of aging and age-related diseases.  The Centre will explore India-specific biomarkers, create organ-specific ageing models, and study the gut-brain connection, in order to develop strategies for healthy aging through biology, data science, and clinical research.  The conference featured insightful sessions on ageing science, starting with Deepak Saini (Longevity India, IISc), who discussed groundbreaking research at the Saini Lab and the launch of Longevity India. Brian Kennedy (Centre for Healthy Longevity, NUS) emphasised the need for translational research to validate longevity interventions.  In a session moderated by Narendra Dixit (IISc), experts like Satchidananda Panda (Salk Institute) and Maxim Artyomov (WashU Medicine) explored ageing mechanisms like circadian rhythms, immune aging, and cellular longevity. Prasun Chatterjee (AIIMS, Delhi) highlighted the role of biomarkers in longevity, while discussions on lifestyle medicine by Samuel Hansdak (CMC Vellore) and Shayana Chandrakant Parekh (IISc) focused on the effects of nutrition, exercise, and sleep.  G.R. Rajendran (PSG Hospitals) discussed plant-based nutrition for heart health, and Vivekanand Upadhyay (FÖNXIER Spine and Pain Center) emphasised exercise for longevity. N. Srikanth (Dy. Director General, Central Council for Research in Ayurvedic Sciences) explored Ayurveda’s connection to modern longevity science, with other panelists from across universities and the National Innovation Foundation.   ]]> https://biospectrumindia.com/news/104/25778/arva-health-raises-1m-in-pre-seed-round-to-build-indias-next-gen-fertility-clinics.html https://biospectrumindia.com/news/104/25778/arva-health-raises-1m-in-pre-seed-round-to-build-indias-next-gen-fertility-clinics.html Mon, 03 Mar 2025 00:00:00 +0530 Bengaluru-based fertility care startup Arva Health has raised $1 million in pre-seed funding, led by All In Capital, with participation from iSeed, Bharath Founders Fund, and Galaxy.The first flagship clinic in Whitefield, Bengaluru will provide fertility testing, consultations, egg freezing, and IVF in a modern, judgment-free setting.A New Model for Fertility Care in India Unlike traditional fertility centres, Arva offers comprehensive, patient-first reproductive care. From at-home fertility testing and expert consultations to IVF, egg freezing, and fertility coaching, Arva supports individuals and couples at every stage of their fertility journey—whether they are trying to conceive, freezing their eggs, or exploring options for the future.The clinic is designed to redefine the fertility experience, moving beyond cold, clinical settings to create a warm, welcoming space where patients feel comfortable, supported, and in control of their reproductive choices.The funding will fuel the launch of India’s first network of tech-enabled fertility clinics, beginning in Bengaluru. The aim is to make reproductive care affordable, accessible, and free from stigma. The company plans to open clinics in ten locations, including Mumbai and Delhi, by 2027. Additionally, the company intends to expand into men's fertility services and develop a digital platform to offer continuous support for fertility. ]]> https://biospectrumindia.com/views/104/25766/we-recognise-the-growing-demand-for-skilled-talent-in-fields-like-ai-gen-ai-robotics-and-data-analytics.html https://biospectrumindia.com/views/104/25766/we-recognise-the-growing-demand-for-skilled-talent-in-fields-like-ai-gen-ai-robotics-and-data-analytics.html Sat, 01 Mar 2025 00:00:00 +0530 Takeda has opened its third Innovation Capability Center (ICC) in Bengaluru, India, following those in Slovakia (2021) and Mexico (2024). How is this centre different from the other locations? Takeda’s ICC India stands out by leveraging the country’s unique technological strengths and innovation ecosystem to enhance the company’s global innovation efforts. The Bengaluru centre draws from the country’s rich pool of engineering talent and its culture of creative problem-solving to address complex challenges with innovative solutions. This ICC is designed to create smart, efficient solutions that can be rapidly developed and deployed across various global contexts. In addition to developing patient-centric technologies, the centre focuses on designing applications that transform the employee experience, further demonstrating its commitment to innovation. The ICC India’s emphasis on integrating local talent and expertise into Takeda’s global framework ensures it brings distinct value to the company’s digital transformation and operational excellence.   With 275 skilled professionals already on board in Bengaluru, what kind of digital solutions is the India centre offering to the Takeda Group of Companies?  The ICC India is focused on advancing innovation in key areas such as Artificial Intelligence (AI), device engineering, data science, and customer-facing technologies to enable Takeda’s global digital transformation. The centre serves as a specialised hub for developing cutting-edge digital capabilities that not only enhance patient outcomes but also drive operational efficiencies. These solutions align with Takeda’s broader mission to deliver transformative treatments, supporting the company’s ongoing efforts to improve healthcare on a global scale. Through its work, the ICC India plays a crucial role in accelerating Takeda’s digital evolution and enhancing its ability to innovate within the biopharmaceutical industry.   How many projects is Takeda Innovation India Private Limited (Takeda India ICC) working on?  The Takeda ICC India is focused on delivering impactful solutions that combine technology and innovation to address various needs across healthcare. Currently, the centre is working on several key projects, including A global donor management system for Takeda’s Plasma Derived Therapies (PDT); Data-driven tools to personalise and simplify interactions with healthcare professionals (HCPs), recommending next-best actions that enhance customer experiences and improve outcomes for both HCPs and patients; A digital platform for patients managing complex conditions, offering multi-language support for symptom tracking, appointment management, medication reminders, and more. This scalable solution improves patient outcomes and enhances quality of life finally on a global platform to simplify the management of HCP data by consolidating multiple sources into a single, reliable system. This initiative has improved compliance reporting, accelerated payment processes, and integrated research and commercial systems, leading to better patient recruitment and more efficient operations. These projects demonstrate Takeda’s commitment to leveraging innovation for meaningful healthcare improvements. By the end of 2025, ICC India aims to continue advancing these initiatives, driving digital transformation across Takeda’s global operations and contributing to the company’s broader mission of delivering transformative treatments.   What kind of technologies is the Takeda India ICC currently using, and what skillsets will it be looking for to further its focus on developing a pipeline of innovative biopharma products/solutions? The Takeda Innovation Capability Center (ICC) India is utilising a wide array of cutting-edge technologies to support its innovation initiatives. These include Data analytics to process large datasets and identify valuable patterns and insights; Artificial Intelligence and GenAI technologies, which employ machine learning algorithms to analyse data and derive actionable insights; Collaboration platforms that enhance communication and engagement among teams, such as project management tools, virtual meeting platforms, and document-sharing systems; Digital health technologies, including wearables and mobile applications, to drive patient engagement and improve health outcomes and Innovation management software to track and manage projects, from idea generation and project planning to resource allocation. To support these technologies and further its mission of developing a pipeline of innovative biopharma solutions, ICC India will be looking for skilled professionals in areas such as AI, data science, machine learning, software development, and digital health technologies. These skill sets will be critical in driving the next wave of innovation at Takeda and advancing the company’s mission to deliver transformative treatments to patients worldwide.   With many companies already having their GCCs in India, do you foresee a dearth of skilled talent in the space of AI, Gen AI, Robotics, and Data Analytics? If so, how do you plan to attract a skilled workforce?   Takeda recognises the growing demand for skilled talent in fields like AI, Gen AI, Robotics, and Data Analytics, particularly as many companies establish their GCCs in India. However, the company remains optimistic about its ability to access and nurture top talent, both locally and globally. Takeda's talent strategy is rooted in a strong commitment to developing technology professionals at various career levels, ranging from entry-level to senior roles. To address the evolving needs of the industry, Takeda has partnered with academic institutions to build a robust talent pipeline, ensuring that its workforce is equipped to navigate emerging technologies and stay ahead of the curve. The company also emphasises its learning initiatives, such as Generative AI learning, Agile methodologies, DevOps, and digital dexterity, all of which are tailored to prepare employees for future technological advancements. Moreover, as AI and digital technologies continue to reshape Takeda’s operations, particularly in areas like drug discovery, predictive analytics, and personalised healthcare, the company is dedicated to providing opportunities for employees to gain the knowledge and tools necessary to drive meaningful transformation in the healthcare sector. Through this comprehensive approach, Takeda plans to attract and retain the skilled talent required to meet the challenges of the evolving digital landscape.   What kind of partnerships (public and private) does the Takeda ICC India have in place now, and what further collaborations is it looking for to support the Takeda Group of Companies?   Takeda ICC India has established strong partnerships with local startups, universities, and research institutions, aiming to foster innovation and address healthcare challenges. In addition, collaborations with organisations such as the Biotechnology Industry Research Assistance Council (BIRAC) support healthcare entrepreneurs and promote innovation. These partnerships integrate global expertise with local insights, contributing to a vibrant ecosystem for healthcare advancement. Moving forward, Takeda plans to expand its network of collaborations, seeking further partnerships that enhance its ability to deliver transformative solutions and continue its global digital transformation.   Narayan Kulkarni  narayan.kulkarni@mmactiv.com  ]]> https://biospectrumindia.com/views/104/25767/our-goal-is-to-make-new-molecules-with-new-mutations-to-develop-an-rsv-vaccine-in-india.html https://biospectrumindia.com/views/104/25767/our-goal-is-to-make-new-molecules-with-new-mutations-to-develop-an-rsv-vaccine-in-india.html Sat, 01 Mar 2025 00:00:00 +0530 At the outset, congratulations for winning the prestigious Tata Transformation Prize 2024. What are your plans post this achievement?  We will be using the prize money to make the antigens for the RSV vaccine and to test them in small animals for their ability to elicit neutralising antibodies and to protect the animals from viral challenges. Once we have the results in hand, we will engage with other partners to take the final formulation forward, first into clinical trials and subsequently commercialisation. Our immediate industry partner is Mynvax, which is a startup that I co-founded a few years ago, and we work closely with them.    Could you shed light on the RSV vaccine that your lab is working on?  Talking about our approach; on the RSV virus, there's a protein called the F protein which is one of the two major surface proteins of the virus, that helps the virus to infect cells. The challenge is that we need to make it in the proper shape because it's a very unstable protein and during the process of infection it undergoes a change in its shape. Thus, we need to focus on that pre-infection shape, and make mutations to increase both the level of expression and to tie it down into the correct shape, that will permit the virus to enter the host cells. We know that antibodies elicited by this form of the protein prevent infection. Currently, we are in the process of screening the F protein for different kinds of mutations that will stabilise it in the correct shape. Once the molecule is identified, we need to engage with other partners; it has to be produced under GMP conditions, following which we have to do safety toxicity studies prior to subsequent clinical trials which we expect to initiate after 2-3 years.   What are the current challenges facing the RSV vaccine space in India and globally, and how is your research addressing those challenges? The main challenge is that the current vaccines are priced at around $300 per dose. RSV vaccines in the west have only been approved about a year ago, one from Pfizer, one from GSK and an mRNA one from Moderna. There is also a lot of IP around the vaccines. In order to strike a difference, our goal is to make new molecules with new mutations. Since the RSV surface protein is quite unstable, this is not easy.  Early attempts to make an RSV vaccine in the 1960s failed because of a lack of understanding of this issue.   Besides RSV vaccine development, what other projects are you working upon? Are there any industry partnerships in the pipeline for commercialising your research projects? We have a flu vaccine for which Mynvax has completed a clinical trial in Australia. We also have another version of the vaccine, which will be starting trials in India and then in the EU in the next couple of years. Those are the two immediate things that we have. We earlier developed thermostable vaccines to combat COVID-19 as well as other sarbecoviruses. For those, there is no commercial interest at the moment but we have them available, should there be another outbreak.    Dr Manbeena Chawla (manbeena.chawla@mmactiv.com) ]]> https://biospectrumindia.com/news/104/25772/strand-life-sciences-launches-portal-to-help-doctors-with-rare-disease-diagnosis.html https://biospectrumindia.com/news/104/25772/strand-life-sciences-launches-portal-to-help-doctors-with-rare-disease-diagnosis.html Fri, 28 Feb 2025 00:00:00 +0530 On the occasion of Rare Disease Day on 28 Feb, Bengaluru-based Strand Life Sciences, a Reliance Industries subsidiary and leading genomics company, has launched the StrandOmics Portal to improve diagnosis of rare diseases. This new online portal gives clinicians quick and easy access to information on genetic variants, giving them a comprehensive view for each case. This means faster and more accurate diagnosis for patients. In addition to the portal, Strand Life Sciences will offer rare disease genetic testing at a reduced cost for patients from economically disadvantaged backgrounds, making these crucial tests more accessible. The StrandOmics Portal helps doctors by providing clear and quick genetic insights for better diagnosis; allowing doctors to independently review a broader set of genetic variants; and improving prenatal diagnosis through better collaboration between specialists. Dr Ramesh Hariharan, CEO & Co-Founder of Strand Life Sciences, said, “We will continue to innovate and invest in tools like the StrandOmics Portal to empower doctors in their fight against rare diseases.”   ]]> https://biospectrumindia.com/news/104/25749/vydehi-institute-of-medical-sciences-and-research-centre-and-intuitive-collaborate-to-expand-access-to-robotic-assisted-surgery.html https://biospectrumindia.com/news/104/25749/vydehi-institute-of-medical-sciences-and-research-centre-and-intuitive-collaborate-to-expand-access-to-robotic-assisted-surgery.html Thu, 27 Feb 2025 00:00:00 +0530 Vydehi Institute of Medical Sciences and Research Centre, Bengaluru, a leading institution in multi-specialty tertiary care, has joined hands with Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery (RAS), to introduce resident surgeons to robotic-assisted surgical technology through the Intuitive Robotic Onboarding Programme and Education (I-ROPE). This initiative marks the introduction of I-ROPE in a private hospital in India, providing surgical oncology postgraduate trainees with exposure to robotic-assisted surgery and its clinical applications.   The I-ROPE programme is designed to introduce early-career surgeons to robotic-assisted surgery through structured sessions that cover the technology, its applications across various surgical disciplines, and its potential role in modern clinical practice. At Vydehi Institute of Medical Sciences and Research Centre, the programme is being conducted using the state-of-the-art da Vinci surgical system, providing residents hands-on familiarity with one of the most advanced robotic-assisted surgical platforms available today. Despite the increasing adoption of robotic-assisted surgery worldwide, exposure to this technology remains limited within traditional surgical training programs in India. This collaboration between Intuitive and Vydehi Institute of Medical Sciences and Research Centre aims to bridge this gap by integrating robotic-assisted surgery into early-stage surgical exposure, to help prepare future surgeons for evolving medical practices.  Intuitive has been expanding access to robotic-assisted surgery in India through the successful implementation of the I-ROPE programme across leading government medical institutions. These include AIIMS Delhi, Kidwai Memorial Institute of Oncology, Bengaluru, AIIMS Bhubaneswar, Dr. Ram Manohar Lohia Hospital in Delhi, and Armed Forces Medical College in Pune.     ]]> https://biospectrumindia.com/news/104/25739/c-camp-and-parisant-campus-to-establish-indo-french-life-sciences-sister-innovation-hub-.html https://biospectrumindia.com/news/104/25739/c-camp-and-parisant-campus-to-establish-indo-french-life-sciences-sister-innovation-hub-.html Wed, 26 Feb 2025 00:00:00 +0530 Bengaluru-based Centre for Cellular and Molecular Platforms (C-CAMP), India’s premier science and technology innovation hub in the life sciences domain has inked a pact to launch a bilateral innovation collaboration in the healthcare domain called the Indo French Life Sciences Sister Innovation Hub with PariSanté Campus, a leading digital health innovation cluster in France. After detailed discussions, both sides identified two focus areas – One Health and Digital Health Technologies. The intent is to enable targeted innovative solutions from one geography for challenges impacting another. The aim is to foster links between both the hubs so as to enhance science-based entrepreneurship, research, academia and businesses by leveraging upon each other’s ecosystems. The Letter of Intent (LOI) has been signed by Dr Taslimarif Saiyed, Director-CEO of C-CAMP and Prof Antoine Tesnière, Director, PariSanté Campus. The primary focus of the LoI remains the milestone agreement to jointly facilitate research and innovative solutions in a bilateral manner. This is more critical since it would initiate for the first time deeper co-operation by the two countries in terms of breaking barriers for the greater goal of mitigating challenges in the crucial UNSDG domain of healthcare. The other notable point is the two key areas to be addressed which have the potential to impact healthcare access and equity not just in Global North but also in the South. The first initiatives of the LoI will be announced soon. PM Narendra Modi and President Emmanuel Macron during bilateral talks at the Paris AI Summit have formally announced the partnership in a joint communiqué earlier this month. Dr Taslimarif Saiyed, said, “The partnership’s first goal would be to galvanise global networks of excellence and leverage mutual ecosystems to support researchers and innovators developing cutting-edge solutions from one geography to the other.  C-CAMP and PariSanté Campus will play the central role in enabling this.” ]]> https://biospectrumindia.com/news/104/25719/tata-institute-for-genetics-and-society-announces-strategic-alliance-to-advance-research-in-rare-genetic-disorders.html https://biospectrumindia.com/news/104/25719/tata-institute-for-genetics-and-society-announces-strategic-alliance-to-advance-research-in-rare-genetic-disorders.html Sun, 23 Feb 2025 00:00:00 +0530 The Avestagenome Project International Pvt. Ltd. (AGENOME) & Avesthagen Limited, in partnership with the Bengaluru-based Tata Institute for Genetics and Society (TIGS), have signed a Strategic Alliance Agreement to advance research and development in rare genetic disorders, with a focus on the Zoroastrian Parsi community. This partnership aims to deepen the understanding and develop targeted solutions for conditions such as congenital deafness, muscular dystrophies, Parkinson’s disease, multiple sclerosis and other rare disorders requiring further investigation, ultimately contributing to the development of new products that benefit the global community. The research partnership will leverage AGENOME’s extensive Biobank, which holds 4,700 blood samples from the Zoroastrian Parsi community, a valuable resource for studying genetic diseases. Of these, 350 samples have already been sequenced, marking a critical step toward uncovering genetic markers that contribute to rare disorders. This Biobank, combined with TIGS’ expertise in functional genomics and molecular biology, will help drive innovations in early diagnosis and therapeutic interventions. Additionally, AGENOME’s prior research partnership with the National Centre for Biological Sciences (NCBS) on neurological disorders such as Schizophrenia and Alzheimer's disease has already laid a strong foundation in understanding complex genetic conditions. The current partnership with TIGS further strengthens this effort, bringing together cutting-edge research in multiple disease areas. By integrating insights from both partnerships, this initiative is poised to make significant contributions to the broader field of genetic research and disease management. Key focus areas of this research partnership include- Leveraging genome data to identify novel and relevant markers for developing diagnostic and screening assays (using CRISPR technologies) at a population scale; Substituting enzyme replacement therapy (ERT) with the development of mRNA-based treatments where applicable; Jointly assessing the potential for in vivo gene therapy for diseases relevant to the population based on genome data insights; and Identifying genetic variants that influence drug efficacy and safety, contributing to advancements in precision medicine. ]]> https://biospectrumindia.com/news/104/25708/ordi-launches-crowdfunding-platform-savemylife.html https://biospectrumindia.com/news/104/25708/ordi-launches-crowdfunding-platform-savemylife.html Fri, 21 Feb 2025 00:00:00 +0530 The Organization for Rare Diseases India (ORDI), a national umbrella organization representing the collective voice of all patients with rare diseases in India has launched Savemylife, a crowdfunding platform to raise funds. Savemylife strives to improve the lives of individuals suffering from rare diseases.  The platform supports ORDI's mission to advocate for rare disease patients in India. Through collaboration, it promotes rare diseases as a human rights priority, influence public policy, and connect with advocacy organizations globally. It also accelerates diagnosis and treatment through public-private partnerships and support newborn screening, clinical trials, research, and orphan drug development. Sharing details on the platform Prasanna Shirol, Co-founder and Board Director, ORDI, said “Our foremost aim is to support the patients find monetary assistance for their treatment programmes. We typically support individuals in dire financial need suffering from a rare/chronic/genetic disorder given the financial burden of extended treatment, supportive care, medical equipment’s, therapy etc.” Having a vision of ‘Nobody in this world loses life due to lack of financial support,’ Shirol said “We believe in equal opportunity to avail funding and do not discriminate on the basis of religion, caste, class, gender or age. We believe every individual has a right to medical treatment and thereby do our best to support.” ]]> https://biospectrumindia.com/news/104/25705/crisprbits-develops-pathcrisp-for-early-detection-of-antibiotic-resistance-.html https://biospectrumindia.com/news/104/25705/crisprbits-develops-pathcrisp-for-early-detection-of-antibiotic-resistance-.html Thu, 20 Feb 2025 00:00:00 +0530 Bengaluru-based biotechnology startup CrisprBits has developed PathCrisp, a platform for CRISPR-based molecular diagnostics for early detection of antibiotic resistance in hospital-acquired infections. Antimicrobial resistance (AMR) is a critical global health challenge, requiring early and accurate detection of resistance markers in hospital-acquired infections, particularly in ICU settings. A recent analysis in The Lancet found that antimicrobial resistance (AMR) contributed to nearly 4.7 million deaths globally in 2021, with over a million directly caused by resistant infections. India alone has reported over a million AMR associated deaths in 2019. Carbapenems, a class of antibiotics, often serve as the last line of defense against multi-drug-resistant bacterial infections. However, New Delhi metallo-beta-lactamase (NDM) driven carbapenem resistance is a major concern in hospitals across India, contributing significantly to the antimicrobial resistance burden. This enzyme enables bacteria to break down carbapenems and other beta-lactam antibiotics, severely limiting treatment options and posing a significant challenge in clinical settings. CrisprBits' latest study, published in Nature Scientific Reports, showcases PathCrisp’s ability to detect carbapenem resistance in bacterial samples from patients. In the study, the PathCrisp platform was used to test the presence or absence of NDM in DNA isolated from 49 clinical bacterial samples. The data showed 100% concordance with other techniques used as the gold standard (PCR-Sanger sequencing) for the same. The study was a collaborative research between CrisprBits, with Sri Sathya Sai Institute of Higher learning, Puttaparthi, and Asoka University, NCR region.   Future R&D efforts will focus on adapting PathCrisp for low-resource settings by developing lyophilised reagents for room-temperature stability. Additionally, smart engineering approaches will be explored to create a multiplexed version, expanding its diagnostic capabilities. ]]> https://biospectrumindia.com/news/104/25699/leucine-rich-bio-expands-global-reach-with-new-partnership-in-brazil.html https://biospectrumindia.com/news/104/25699/leucine-rich-bio-expands-global-reach-with-new-partnership-in-brazil.html Wed, 19 Feb 2025 00:00:00 +0530 Bengaluru-based Leucine Rich Bio, South Asia’s first microbiome company, has announced a strategic partnership with Precision Diagnosticos, a leading diagnostics firm based in Brazil. This collaboration will bring BugSpeaks, Leucine Rich Bio’s flagship microbiome testing technology, to the Brazilian market, enhancing access to cutting-edge microbiome diagnostics and personalised health solutions across both regions. BugSpeaks is an advanced gut microbiome analysis tool designed to detect microbial imbalances that can contribute to conditions such as obesity, diabetes, and digestive disorders. Through this partnership, Precision Diagnosticos expertise and extensive distribution network will help expand the availability of microbiome testing in Brazil, empowering individuals to take proactive steps toward better health. In addition to expanding microbiome testing, the partnership will drive educational campaigns to raise awareness about gut health and its crucial role in overall well-being. Healthcare professionals will receive specialised training and resources to integrate microbiome testing into clinical practice, ensuring the technology’s widespread and effective use.     ]]> https://biospectrumindia.com/news/104/25701/zeiss-india-joins-hands-with-the-indian-institute-of-science-for-ai-based-eye-research.html https://biospectrumindia.com/news/104/25701/zeiss-india-joins-hands-with-the-indian-institute-of-science-for-ai-based-eye-research.html Wed, 19 Feb 2025 00:00:00 +0530 ZEISS in India has announced its strategic collaboration with the Indian Institute of Science (IISc), Bengaluru, to foster cutting edge research. ZEISS has established a sophisticated state-of-the-art research facility dedicated for developing high fidelity Artificial Intelligence (AI) solutions for the betterment of eye-care and to upskill students in AI technologies. The initiative, supported by the Spectrum Lab in the Department of Electrical Engineering at IISc, aims to harness the transformative potential of AI to enhance eye-care practices and improve patient outcomes. This collaboration will propel improvements in eye care solutions from India for the world considering the rising prevalence of vision impairments worldwide. The facility will act as a center for cutting-edge research, allowing IISc researchers to investigate how AI could transform early diagnosis in eye care by providing innovative solutions that streamline processes, increase accuracy, and improve patient outcomes. ZEISS India and IISc have joined forces to explore and promote the use of advanced AI technologies in ophthalmology. Ashish Modi, Head of the Centre for Application Research India (CARIn), ZEISS India expressed, "Our collaboration with IISc is a step towards bridging this gap, empowering Indian researchers with advanced resources and real-world applications. By fostering a sustainable research ecosystem, we aim to drive global breakthroughs in eye-care technology while strengthening India's position as a hub for scientific excellence."  Dr Rajesh Sundaresan, Dean of Division (Electrical Electronics, and Computer Sciences Division), IISc, said, "Long-term collaborations between industry and academia are essential for fostering a sustainable research ecosystem in India. They provide young researchers with the resources and exposure needed to drive scientific advancements while addressing real-world challenges. Our country needs more such partnerships to remain at the forefront of technological progress, ensuring that innovation is developed and applied to improve lives globally." In addition to the lab set-up, ZEISS India is also sponsoring 6 MTech students for the next 3 years through its CSR-sponsored 'MTech Fellowship Program' at IISc for students pursuing master’s degree in Signal Processing, Artificial Intelligence, Computer Science & Engineering/Computational and Data Science. ]]> https://biospectrumindia.com/news/104/25697/scientists-at-iisc-tweak-cancer-cell-response-to-ultrasound-treatment.html https://biospectrumindia.com/news/104/25697/scientists-at-iisc-tweak-cancer-cell-response-to-ultrasound-treatment.html Tue, 18 Feb 2025 00:00:00 +0530 Cells have surface receptors called integrins that bind to repetitive domains present on the extracellular matrix (ECM) surrounding the cells, allowing them to grow and spread. A new study from the Department of Bioengineering (BE), Indian Institute of Science (IISc), Bengaluru and collaborators shows that tweaking the spacing between these binding domains on the ECM can boost the efficiency of ultrasound treatment applied to kill cancer cells. Low-frequency ultrasound waves (39 kHz) can disrupt the cell membrane and trigger cell death in cancer cells. It is a relatively low-cost and non-invasive approach. Unlike normal cells, cancer cells do not have repair mechanisms that help them withstand the mechanical forces exerted by ultrasound waves. To mimic the integrin-ECM binding, the team constructed an array of gold nanodots separated by different distances (35, 50 and 70 nm) and allowed highly invasive cancer cells to attach to them. Then, they applied pulsed ultrasound waves. When ultrasound was applied to cancer cells grown on the 50 nm and 70 nm platforms, their cell membranes were found to stretch due to forces exerted by a filament protein called myosin. More extracellular calcium is then pumped into the cytoplasm, which damages mitochondria and promotes cell death.  The team has collaborated with clinicians to test this combination approach on oral cancer tissue samples. ]]> https://biospectrumindia.com/news/104/25640/nura-ai-health-screening-centre-in-bengaluru-to-expand-capacity.html https://biospectrumindia.com/news/104/25640/nura-ai-health-screening-centre-in-bengaluru-to-expand-capacity.html Wed, 05 Feb 2025 00:00:00 +0530 NURA AI Health Screening, a collaboration between Fujifilm Healthcare and Dr. Kutty’s Healthcare, recently celebrated the 4th anniversary of its Bengaluru facility. NURA aims to increase its capacity by 50%, enabling it to serve even more people every day. To further encourage the adoption of health screenings, NURA continues to run educational campaigns, social media initiatives, and on-ground activities, spreading awareness about the critical role of early diagnosis in saving lives. Since its inception, the centre has screened over 20,000 individuals, identifying critical health risks and saving more than 1,500 lives through the early detection of cancer and other lifestyle-driven diseases. NURA’s Bengaluru centre utilises REILI AI technology and Pixel Shine imaging with ultra-low-dose radiation to screen multiple organs, including the lungs, liver, kidneys, heart, pancreas, and bones, ensuring a comprehensive health assessment. Starting with 5 cancer parameters, the centre has now expanded its screening capabilities to include 10 cancer parameters, with plans for further advancements in the near future. ]]> https://biospectrumindia.com/news/104/25617/shimadzu-strengthens-business-operations-in-india-with-new-plant-in-bengaluru.html https://biospectrumindia.com/news/104/25617/shimadzu-strengthens-business-operations-in-india-with-new-plant-in-bengaluru.html Mon, 03 Feb 2025 00:00:00 +0530 In order to strengthen business operations in India, which is expected to experience high economic growth, Japan's Shimadzu Corporation will establish the manufacturing subsidiary Shimadzu Manufacturing India Private Limited (SMI) in Bengaluru, Karnataka. Construction of the new plant is scheduled to be completed and operations are to be started in the spring of 2027. In addition to the business areas where Shimadzu is focusing efforts, namely healthcare, green innovation, materials, and industry, India is also a global manufacturer of generic drugs and is expected to continue increasing domestic production of electric vehicles (EVs) and semiconductors. Currently, Shimadzu products are supplied to India from Japan or Shimadzu Malaysia Sdn. Bhd. (SML) in Malaysia. Building the new plant will not only strengthen the supply chain but also respond to governmental incentives for domestic production (“Make in India”). SMI will begin manufacturing liquid chromatograph (LC), gas chromatograph (GC), UV-VIS spectrophotometer (UV), liquid chromatograph mass spectrometer (LC-MS), and gas chromatograph mass spectrometer (GC-MS) products in 2027. In addition to analytical and measuring instruments, future manufacturing of medical systems and industrial machinery products are also being considered. Similarly, Shimadzu also plans to merge the analytical and measuring instruments and medical systems sales subsidiaries in India to establish Shimadzu India Private Limited (SIP) by the summer of 2025. The new sales subsidiary SIP will be a wholly-owned subsidiary of Shimadzu (Asia Pacific) Pte. Ltd. (SAP) in Singapore, Shimadzu’s regional headquarters for the Asia region, making SIP an indirect subsidiary of Shimadzu Corporation. The analytical and measuring instruments sales subsidiary in India was established in 2005 and the medical systems sales subsidiary in 2001. Both have been engaged in sales and service activities, but will now integrate their operations to form the new company SIP. Operating both businesses as a single organization will strengthen relationships with hospitals and other customers that use both medical and analytical/measuring systems and will help Shimadzu deploy business in clinical fields and increase customer satisfaction by supplying solutions. By establishing the new manufacturing subsidiary SMI and the new sales subsidiary SIP, Shimadzu plans to achieve about 47.0 billion yen in sales in India by FY2035 (about 2.6 times the FY2023 level).  ]]> https://biospectrumindia.com/views/104/25591/govt-should-facilitate-low-interest-loans-or-vc-funding-specifically-for-biopharma-startups-small-enterprises.html https://biospectrumindia.com/views/104/25591/govt-should-facilitate-low-interest-loans-or-vc-funding-specifically-for-biopharma-startups-small-enterprises.html Fri, 31 Jan 2025 00:00:00 +0530 What are the key objectives of your recent collaboration with Merck? How will this partnership foster innovation and strengthen India’s position in the global biotech market? The partnership combines Merck's biomanufacturing systems with GNG's Clone Development and HIND Antibody Library to drive biopharmaceutical innovation and position India as a hub for advanced R&D. The GNG-Merck collaboration creates a unique competitive edge for both companies by integrating local expertise with global biomanufacturing capabilities. Furthermore, Merck's expertise in both Upstream Processing (USP) and Downstream Processing (DSP) will support us in areas of biologics production, optimising cell culture yields, and refining end products to meet international standards.   This partnership is set to innovate and strengthen India’s biotech landscape: Platform Processes for Novel mAbs and Other Molecules: With Merck’s advanced bioprocessing systems installed at GNG, we’re positioned to efficiently develop and produce novel monoclonal antibodies (mAbs) and other therapeutic molecules. These processes ensure consistent, high-quality products that meet the highest global standards. Supporting Clone Development Services from India: With the integration of Merck’s systems into GNG’s Clone Development platform, we’re set to become a go-to provider for scalable clone development services. This will cater to a wide range of biotech firms, both in India and abroad. Infrastructure for Startups: Our collaboration creates a solid infrastructure for biotech startups, providing end-to-end support—from process development to clinical-phase production. This ensures that biotech startups in India can focus on innovation while we handle the complexities of scaling up. Future Scale-Up and Commercial Manufacturing: With Merck’s decades of expertise in drug development and manufacturing, GNG is well-positioned to advance its capabilities in scaling up production and preparing for commercial manufacturing. This strategic collaboration enables GNG to explore and pursue the commercialisation of its proprietary New Biological Entities (NBE) and biosimilar candidates, ensuring a robust pathway from development to market readiness.   What other plans are in store at GNG for driving innovation? We envision GNG as an emerging leader in novel and biosimilar asset development both as its own pipeline as well as contract research in the coming years. In line with this vision, GNG plans to expand its reach and impact across global biopharmaceuticals, diagnostics, and therapeutic antibody discovery and development. Some of our strategic goals include:  Scaling the HIND Antibody Library: We aim to expand the HIND Antibody Library’s scope to encompass a diverse range of therapeutic targets, positioning it as a vital tool for novel drug discovery and collaborative research from India. Strengthening Biosimilar and Biologic Production: Leveraging our collaboration with Merck and seeking strategic partnerships, we look forward to expanding GNG’s biosimilar offerings to meet the demand for affordable, high-quality biologics in domestic and global markets. Currently one being in pre-clinical studies supported by the National Biopharma Mission, BIRAC. Expanding Diagnostic and Custom Antibody Solutions: As precision medicine continues to gain prominence, GNG plans to develop new diagnostic and antibody solutions for emerging diseases and personalised treatments. Our aim is to be steadfast in our mission to drive innovation and contribute to the future of biotechnology by offering cutting-edge solutions that can transform global healthcare.   Would the new BioE3 policy prove to be a gamechanger for the future of biotechnology in India? Building a robust biomanufacturing ecosystem in India is crucial for accelerating innovations in bio-based product development. With the nation’s bioeconomy projected to reach $300 billion by 2030, the startup community plays a pivotal role in driving this transformation, fostering technological advancements, and addressing industry challenges. In this context, the BioE3 Policy— ‘Biotechnology for Economy, Environment, and Employment’—represents a transformative milestone for India’s biotech sector. By fostering innovation-driven R&D and championing sustainable biomanufacturing, this policy not only aligns with global climate goals but also positions India at the forefront of the circular bioeconomy.  Furthermore, the BioE3 policy will play a pivotal role in enhancing and amplifying the life sciences sector by building a skilled workforce and creating new employment opportunities, thereby strengthening the country’s research capabilities and technological expertise. Additionally, by addressing key infrastructure needs, the policy aims to streamline scaling-up processes, making biotechnology advancements more accessible and cost-efficient. Overall, this policy is a step in the right direction for India’s life science industry. As we continue to support the emerging biotechnology startup community, the advent of this policy will boost our motivation to drive the Circular Economy revolution by 2047.   Though biotech innovation is increasing in our country with technological advancements, innovators still face multiple challenges. What are your views on this and expectations from the government? In recent years, India’s biopharma industry has witnessed significant growth, fuelled by technological advancements, research, and increased manufacturing capabilities. Although the industry holds immense growth potential, it is crucial to tackle challenges that may hinder progress.  Securing adequate funding and managing budgets effectively are significant hurdles for Indian biotech startups. The sector is further challenged by complex regulatory landscapes, high production costs, limited access to advanced technologies, and a shortage of specialised talent in critical domains. Adding to these issues is the urgent need for enhancing the laboratory infrastructure to support research and development. GNG has been  grateful to BIRAC for supporting the development of one of our assets through the National Biopharma Mission Grant. Unlocking the industry’s full potential requires strategic policymaking, a stronger focus on research and innovation, and robust public-private partnerships. Recognising these critical challenges and addressing them decisively at both global and local levels is crucial for driving the next wave of advancements.  We believe the government plays a crucial role in unlocking the full potential of the biotech sector. To drive meaningful growth, a proactive approach is needed to strengthen public-private partnerships, advancing research and technologies, skill development, and constant industry/stakeholder initiatives will amplify the potential of the biotech industry.   Additionally, strengthening ties between academia and industry is essential to drive innovation and build valuable partnerships in research and technological advancements. Government policies that prioritise skill development, empower scientists, and promote R&D can help cultivate a culture of continuous innovation within the sector.  When speaking specifically for Biopharma, the government should develop and implement a comprehensive biopharma policy that incentivises research, innovation, and production and streamline regulatory frameworks to reduce bottlenecks in drug approval and manufacturing processes. The government should facilitate low-interest loans or venture capital funding specifically for biopharma startups and small enterprises. Currently, BIRAC is the only body that does it, but we need more and more government bodies to come up with biopharma-focused financial instruments to attract investors.   Dr Manbeena Chawla (manbeena.chawla@mmactiv.com) ]]> https://biospectrumindia.com/views/104/25592/lack-of-population-specific-genomic-data-is-a-significant-challenge-in-the-field-of-precision-oncology.html https://biospectrumindia.com/views/104/25592/lack-of-population-specific-genomic-data-is-a-significant-challenge-in-the-field-of-precision-oncology.html Fri, 31 Jan 2025 00:00:00 +0530 With Infosys investing in 4baseCare, how do you plan to leverage this partnership to scale your operations, enhance technological capabilities, and drive growth? At 4baseCare, we drive innovation through two core solutions: Genomics and Digital Health. Our Genomics solutions focus on leveraging advanced genomic testing to identify actionable insights for personalised cancer care, while our Digital Health solutions encompass a comprehensive ecosystem designed to support patients and clinicians alike. This includes everything from a patient-centric app that provides guidance throughout the cancer journey, to sophisticated tools that generate insights for predictive modeling, enabling personalised treatment strategies. Collaborating with Infosys, a global leader in IT and digital transformation, we are enhancing the digital backbone of 4baseCare. Their expertise enables us to build a data-driven decision platform and develop pioneering solutions like the Clinico-Genomic Digital Twin (CG Twin)—a revolutionary model that integrates clinical and genomic data to create predictive insights for tailored cancer care. Together, we are bridging the gap between data, technology, and precision oncology to empower patients and healthcare providers with innovative, impactful solutions.    Besides this recent partnership, what were some of the other major developments at 4baseCare in 2024? The year 2024 has been a year of tremendous growth and significant milestones. We raised $6 million in Series A funding led by Yali Capital, which enabled us to set up a genomics lab at Dubai Science Park in partnership with Innovate Life Sciences. We are also preparing to launch labs in the Philippines and Nepal.  We welcomed two industry leaders to our advisory board this year. Francis deSouza, former CEO of Illumina, and Lip-Bu Tan, Chairman of Walden International, to our advisory board. Their expertise in genomics and technology will play a critical role in our mission to make genomics accessible to all.   Looking ahead to 2025, what are your key goals and initiatives, particularly in terms of expansion, partnerships, and impact on the precision oncology sector, in India and Asia? Collaborating with hospitals, research institutions, and pharmaceutical companies in Nepal, Bangladesh, and the Philippines remains central to our growth strategy. We aim to strengthen partnerships both in India and globally to bring advanced precision oncology solutions to patients. In the next 1-2 years, we plan to launch educational initiatives such as workshops, webinars, and training programmes to support oncologists and clinicians in adopting genomic testing for cancer care. We also intend to expand our laboratory infrastructure, enhance bioinformatics platforms, and build a multidisciplinary team of experts in genomics, oncology, and data science. This will enable us to handle larger data and sample volumes while maintaining the highest standards of accuracy and quality. With Series A funding from Yali Capital and Infosys Innovation Fund and the guidance of our esteemed advisors, we are well-positioned to expand our reach, drive innovation, and make precision oncology accessible to more cancer patients.   Are you planning to launch new products/technologies in India or globally in 2025 or beyond? Please share details. Cancer is not a single disease- it is a collection of many diseases, each with its own unique complexities. Understanding cancer biology requires addressing the heterogeneity that makes it so intricate and challenging to treat. At 4baseCare, we believe that a comprehensive and holistic approach is essential to truly unravel the molecular pathways of cancer. This means going beyond traditional core biopsies (solid biopsy) to include insights from cellular evolution by profiling circulating tumor DNA -ctDNA (liquid biopsy). This innovative approach allows us to capture the dynamic nature of cancer, identifying genomic signatures that evolve over time and enabling precision care at every stage of the disease. We recently launched our solution SoLiQ—our cutting-edge liquid biopsy technology that integrates genomic insights from both tissue and circulating tumour DNA, paving the way for more informed, personalised treatment strategies. With SoLiQ, we are redefining how cancer is understood and managed, ensuring no aspect of its complexity is overlooked.   What are the current challenges facing the precision oncology market in India & neighbouring areas, and how are you addressing those? A significant challenge is the lack of population-specific genomic data. Much of the existing research and strategies are based on Western populations, which often fail to address the unique genomic diversity of Indian patients. Precision oncology in India is progressing but still lags behind Western nations.  Cancer is fundamentally a genomic disease making it essential to understand its molecular details to improve treatments and achieve better patient outcomes. Precision oncology, which integrates genomic biomarkers into the treatment paradigm, has rapidly emerged as a cornerstone of contemporary cancer care. However, the major challenge to Precision Oncology is that it is mostly based on genomics research and data on Caucasian population which puts our and other non-caucasian populations at a disadvantage.  4baseCare’s vision is to bridge this data gap and push towards more evidence and data backed treatment for cancer patients.   What are your views on the growth of genomics startups in India? What does the future look like?  Precision Oncology has seen steady adoption over the last decade and it is pretty clear that it is set to become a core part of cancer care in India over the next decade. Costs will decrease and more hospitals will adopt it. This change will be primarily driven by startups.  There will be easier access to targeted therapies and immunotherapies as more pharmaceutical companies enter the Indian market with cost-effective options. And with early detection becoming more common, we’ll be able to identify high-risk individuals before cancer develops, shifting from treatment to prevention.  Technological advancements like artificial intelligence (AI) and big data integration will enhance genetic profiling, allowing oncologists to make faster and more precise decisions. With increased attention to clinical trials, India has the potential to emerge as a hub for precision oncology research.   Vrushti Kothari (vrushti.kothari@mmactiv.com) ]]> https://biospectrumindia.com/views/104/25596/how-ai-innovations-at-gccs-solidifying-indias-position-in-global-life-sciences-industry-.html https://biospectrumindia.com/views/104/25596/how-ai-innovations-at-gccs-solidifying-indias-position-in-global-life-sciences-industry-.html Fri, 31 Jan 2025 00:00:00 +0530 The Indian government has launched several initiatives to support the expansion of GCCs in the life sciences sector. Programmes like the "Make in India" initiative encourage foreign investment in pharmaceutical manufacturing and R&D. The National Health Policy aims to boost healthcare solutions, with a focus on local innovation, driving life sciences companies to establish R&D-focused GCCs. In AI, the $1.25 billion IndiaAI Mission strengthens the country’s AI ecosystem, helping GCCs adopt AI for faster drug development and efficient clinical trials. The Ayushman Bharat Digital Mission connects 500 million people to digital healthcare services, enhancing India’s healthcare system. Additionally, Special Economic Zones (SEZs) and Biotechnology Parks provide critical infrastructure and tax incentives, facilitating the growth of life sciences GCCs aligning with India’s broader vision to lead in pharmaceutical R&D innovation. State-Level Leadership: Karnataka and Telangana Among Indian states, Karnataka and Telangana stand out as key locations for the development of life sciences GCCs. Both states have created strong ecosystems that attract global investment and skilled professionals, enhancing the growth of the sector. Karnataka, particularly the city of Bengaluru, accounts for nearly 32 per cent of all life sciences GCCs in India. Karnataka’s GCC Policy 2024-29 is a cornerstone of its strategy to attract and expand GCCs. The policy offers a variety of incentives and provisions like targeted financial incentives such as rent coverage, tax breaks and reimbursements. The state's vision is to double the number of GCC from 500 to 1000 by 2029. Bengaluru has become a favoured destination for companies setting up GCCs due to its vast talent pool in AI, data analytics, and bioinformatics. The state government has also established Centers of Excellence for research and development, offering crucial support for startups and larger firms alike. Telangana, with Hyderabad as its epicentre, has made significant strides in establishing itself as a global hub for life sciences. Genome Valley, located in Hyderabad, is India's largest biotech and pharmaceutical cluster, home to over 200 companies involved in R&D. In 2024 alone, Telangana attracted more than $850 million in investment to bolster its life sciences capabilities. A major recent development in Telangana is the creation of the Life Sciences GCC Consortium, which has been in the spotlight. This consortium brings together the Hyderabad-based life sciences GCCs. Its primary aim is to boost collaboration, share knowledge, and address challenges in drug development and digital transformation. The consortium is expected to strengthen Telangana’s reputation as a leader in life sciences by facilitating partnerships between GCCs, academic institutions, and the government. Telangana is home to leading R&D centres like Novartis Biome, Hyderabad's first innovation hub, which focuses on integrating AI into pharmaceutical research. It collaborates with startups, researchers, and academic institutions to drive advancements in drug discovery and clinical trials. Similarly, Bristol Myers Squibb has invested $100 million to establish a GCC in Hyderabad, employing 1,500 professionals and utilising AI to accelerate drug discovery. Driving AI Adoption Artificial intelligence (AI) is playing a vital role in streamlining operations in life sciences GCCs, particularly in drug discovery, clinical trials, and supply chain management. With the average cost of bringing a new drug to market exceeding $2 billion and development timelines stretching to 10-12 years, AI is addressing these challenges by reducing costs and accelerating the process. AI-driven solutions can cut drug development costs by up to 70 per cent and shorten timelines by 40 per cent, making it indispensable for the future of pharmaceutical research. For instance, AI has made a significant impact on protein modelling, where tools like AlphaFold can model proteins in hours instead of months. This allows companies like GSK and Sanofi to speed up R&D by 30-40 per cent, enabling faster identification of drug targets. Indian GCCs are increasingly adopting these AI technologies to improve early-stage drug discovery and contribute to global pharma innovation. In the realm of clinical trials, AI-powered platforms optimise trial protocols, improve patient recruitment, and predict trial outcomes with greater accuracy. Pfizer, for example, has used AI to streamline clinical trial design, reducing costs and improving timelines. Indian GCCs play a critical role in these efforts, using AI-driven platforms to manage clinical trials more efficiently. AI is also helping GCCs with regulatory compliance, where automation has reduced the time required for submissions by 30 per cent while increasing accuracy. Indian GCCs have implemented AI tools that make the regulatory process faster and more reliable, keeping up with global standards. Implementing AI at scale requires overcoming challenges like data fragmentation and aligning strategies with parent organisations. GCCs are excelling by overcoming data fragmentation through structured management frameworks, leveraging India’s AI expertise, and aligning with global compliance standards. By utilising effective data aggregation, cleansing, and integration methods, these centres enable seamless AI deployment and innovation. Future Prospects and AI Integration The future of life sciences GCCs in India looks promising, particularly with the growing integration of AI technologies. At its peak, AI is expected to save the global pharmaceutical industry around $26 billion annually, revolutionising how drugs are developed, trials are conducted, and patient care is managed. As more pharmaceutical companies recognise India’s strengths, the number of GCCs is expected to increase, with these centres becoming key players in advancing AI-driven healthcare innovation. India’s deep talent pool, including 3.3 million software engineers and 446,000 AI/ML specialists, is a major asset that positions the country as a leader in AI-driven life sciences R&D. With scalable infrastructure, lower operating costs, and strong government backing through programmes like the IndiaAI Mission, India is poised to continue its rise as a global hub for life sciences. As regulatory frameworks evolve to support AI technologies, India’s position in the global life sciences industry is expected to strengthen further. Collaboration between government initiatives and private sector innovation will be crucial to maintaining this momentum. Life sciences GCCs will continue to lead in addressing global healthcare challenges, using AI to deliver faster, more effective solutions.   Dr Purav Gandhi, CEO and Founder, Healthark Insights ]]> https://biospectrumindia.com/news/104/25574/aiims-jammu-and-4basecare-sign-mou-to-launch-centre-for-advanced-genomics-and-precision-medicine.html https://biospectrumindia.com/news/104/25574/aiims-jammu-and-4basecare-sign-mou-to-launch-centre-for-advanced-genomics-and-precision-medicine.html Wed, 22 Jan 2025 00:00:00 +0530 AIIMS Jammu and Bengaluru-based startup 4baseCare have signed a Memorandum of Understanding (MoU) to launch the Centre for Advanced Genomics and Precision Medicine. This state-of-the-art facility will offer cutting-edge genomic technologies to transform patient care across diverse medical fields, including cancer, rare diseases, reproductive health, and public health.  The Centre for Advanced Genomics and Precision Medicine will focus on the following areas- Precision Oncology The centre aims to redefine cancer care by focusing on targeted, biomarker-driven therapies. This approach ensures personalized treatment plans that improve outcomes and enhance quality of life for cancer patients. Rare Diseases Rare diseases often pose diagnostic challenges, leaving patients and families searching for answers. Through advanced genomics, the centre is committed to unlocking these mysteries and providing actionable insights for some of the world’s rarest conditions. Reproductive Medicine (NIPT/PGS/PGD) By integrating early genetic insights into prenatal and fertility care, the centre is revolutionizing reproductive medicine. Technologies such as Non-Invasive Prenatal Testing (NIPT), Preimplantation Genetic Screening (PGS), and Preimplantation Genetic Diagnosis (PGD) are empowering families with knowledge and options for a healthier future. Public Health – COVID and Beyond: The pandemic highlighted the critical need for precision-driven technologies in public health. This centre will continue to empower public health initiatives by providing genomic solutions for current and future health challenges.   ]]> https://biospectrumindia.com/news/104/25568/immuneel-therapeutics-unveils-indias-first-global-car-t-cell-therapy-for-non-hodgkins-lymphoma.html https://biospectrumindia.com/news/104/25568/immuneel-therapeutics-unveils-indias-first-global-car-t-cell-therapy-for-non-hodgkins-lymphoma.html Mon, 20 Jan 2025 00:00:00 +0530 In a significant step forward for India’s cancer treatment, Immuneel Therapeutics has unveiled Qartemi, country’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a group of blood cancers. A personalised therapy for adult patients with relapsed or refractory B-NHL, Immuneel, a Bengaluru-based cell and gene therapy startup, addresses a critical gap in India’s cancer immunotherapy landscape. This groundbreaking therapy, benchmarked to global standards, is now available locally, offering renewed hope to patients for whom conventional therapies including chemotherapy prove ineffective. India faces a rising burden of blood cancers, with around 120,000 new cases and over 70,000 deaths annually from leukemia, lymphoma, and multiple myeloma. Amidst the increasing incidence of blood cancer cases, Qartemi, a pioneering CAR T-cell therapy from Immuneel Therapeutics, stands as a lifeline, representing the need for advanced treatment in CAR-T therapy becomes increasingly critical.  Immuneel initiated India’s first CAR T-cell therapy trial in 2022 for a novel autologous CD19 directed CAR T-cell therapy in patients with relapsed / refractory B cell malignancies. The IMAGINE trial was conducted across Narayana Hospital in Bengaluru, Apollo Cancer Hospital in Chennai and PGIMER in Chandigarh. The results from the IMAGINE trial showed that the efficacy and safety of Qartemi is similar to CAR T-cell therapies approved by the USFDA. Immuneel’s IMAGINE Phase 2 trial achieved 83.3% ORR at Day+90, setting a new benchmark for CAR T-cell therapy in India The startup has partnered with leading hospitals, including Narayana Health, Apollo Hospitals, CMC Vellore & Ludhiana, Manipal Hospitals, RGCIRC Delhi, SGPGI Lucknow, Amrita Hospital Faridabad, HOC Vedanta Ahmedabad, Cytecare Bangalore, Sparsh Bengaluru, Marengo Asia Hospitals among others, to provide Qartemi to their patients. ]]> https://biospectrumindia.com/news/104/25555/crisprbits-opens-research-and-innovation-centre-for-gene-editing-and-diagnostics-in-bengaluru.html https://biospectrumindia.com/news/104/25555/crisprbits-opens-research-and-innovation-centre-for-gene-editing-and-diagnostics-in-bengaluru.html Fri, 17 Jan 2025 00:00:00 +0530 Bengaluru-based biotechnology startup CrisprBits has inaugurated a CRISPR gene editing and diagnostics laboratory in Bengaluru. The new facility includes advanced infrastructure laboratory features with dedicated spaces for lyophilisation (a process used to keep reagents stable at room temperature), cell and tissue culture, bacterial culture, molecular biology research, and cleanroom operations. Additionally, the laboratory includes a specialised gene editing section and a tissue culture area designed to support stem cell research. A state-of-the-art LIMS (Laboratory Information Management System) and intelligent systems for smart design of CRISPR guides round out the technology platforms at the CrisprBits innovation centre. Incubated initially at the Center For Cellular and Molecular Platforms (C-CAMP) for the past four years, the startup has been focusing on developing a rapid point-of-need molecular diagnostics platform. In the next few months, CrisprBits aims to launch several key tests in affordable rare disease diagnostics and hospital acquired infections (HAI) including antimicrobial resistance tests using the platform. CrisprBits will continue its operations at C-CAMP in the near future, on several collaborative gene editing projects. Over the next 6 months, CrisprBits plans to introduce novel applications of CRISPR in building iPSC (Induced pluripotent stem cells) models for rare diseases and targeted editing of cell lines and microbes important for industrial microbiology applications are in progress. ]]> https://biospectrumindia.com/news/104/25561/resolve360-announces-indias-first-ever-ai-ar-tech-for-online-active-physiotherapy.html https://biospectrumindia.com/news/104/25561/resolve360-announces-indias-first-ever-ai-ar-tech-for-online-active-physiotherapy.html Fri, 17 Jan 2025 00:00:00 +0530   India has only 0.6 physiotherapists per 10,000 people, compared to the WHO-recommended 1 per 10,000. In what's a significant step forward towards filling this gap, India’s first-ever Artificial Intelligence (AI) and Augmented Reality (AR) application for active physiotherapy is being developed and patented by Bengaluru-based startup Resolve360. The innovation uses deep motion algorithms to create a virtual physiotherapist, guiding patients through personalised, therapeutic active exercises. This approach contrasts with traditional passive physiotherapy, addressing underlying issues rather than just symptoms. Resolve360’s AI Virtual Therapist combines cutting-edge technology with its well-established expertise in treating the root cause of neuromuscular and musculoskeletal conditions. Unlike other AI systems prevalent in healthcare that rely on devices or infrared markers, Resolve360’s platform uses standard video cameras found on everyday electronic devices. Recently patented, the platform is currently in testing and scheduled for public release by Mid-February. It aims to tackle rising lifestyle disorders, including sedentary behaviour-related issues, by making expert-level active physiotherapy widely accessible.   ]]> https://biospectrumindia.com/news/104/25552/fire-incident-at-bangalore-bioinnovation-centre-causes-setback.html https://biospectrumindia.com/news/104/25552/fire-incident-at-bangalore-bioinnovation-centre-causes-setback.html Thu, 16 Jan 2025 00:00:00 +0530 A recent fire incident took place the Bangalore Bioinnovation Centre (BBC) facility on 15th January, in the early morning hours, which has caused significant damage to the Centre's infrastructure and equipment. According to reports, the damage caused due to the fire amounts upto Rs 150 crore. "We are relieved to share that no injuries were reported, and we remain committed to addressing the situation with resilience and determination. As a result of this incident, we will be temporarily halting operations to ensure a thorough recovery process", as per the statement released by BBC. The media reports have revealed that the fire started around 4:35 AM on Wednesday, in a lab on the second floor due to improper handling of flammable solvents. The incident caused damage to the revamped second floor, which had been designed to accommodate more startups. The fire also caused extensive damage to the first and ground floors due to interconnected HVAC lines. "It is heartbreaking to witness years of hard work and dedication by our entrepreneurs reduced to ashes. I want to reassure them that the government stands firmly by their side and will do everything we can to support them in rebuilding and bouncing back", said Priyank Kharge, Minster for IT BT, Government of Karnataka. ]]> https://biospectrumindia.com/news/104/25547/spovum-technologies-introduces-lab-management-system-to-transform-ivf-workflows.html https://biospectrumindia.com/news/104/25547/spovum-technologies-introduces-lab-management-system-to-transform-ivf-workflows.html Wed, 15 Jan 2025 00:00:00 +0530 SpOvum Technologies, a Bengaluru-based deep-tech startup in the field of in vitro fertilisation (IVF), has released the Integrated IVF Management Solution. This innovative Monitoring as a Solution (MaaS) in IVF is designed to transform IVF workflows by providing a synchronised lab and clinical management system, a first-of-its-kind in Assisted Reproductive Technology (ART). This system offers a comprehensive suite of features, including real-time lab health monitoring, smart witness technology, seamless patient data integration, and robust compliance with ART regulations. By streamlining operations, optimising workflows, and enhancing patient care, this system sets a new standard for efficiency and accuracy in IVF treatment. This seamless technology offers a holistic approach to streamline operations and enhance patient care. By providing clear procedural guidelines and efficient resource allocation, the system ensures smooth workflow execution. The easy-to-use cycle and patient data management features simplify administrative tasks, while the data-driven insights enable valuable research and educational opportunities. Mechanisms such as real-time monitoring, reporting, and alerting safeguard lab health and quality standards. Transparent tracking and traceability, including electronic workflow witnessing, guarantee accurate and reliable tracking of gametes and consumables. This increased visibility and control over critical SOPs contribute to enhanced accuracy, compliance, and consistent results. Additionally, the system's ability to generate instant reports, graphs, and statistical data empowers labs to make informed decisions and achieve long-term cost savings.   ]]> https://biospectrumindia.com/news/104/25549/jncasr-develops-new-system-for-wearable-devices-that-can-detect-stress.html https://biospectrumindia.com/news/104/25549/jncasr-develops-new-system-for-wearable-devices-that-can-detect-stress.html Wed, 15 Jan 2025 00:00:00 +0530 Using silver wire network on a stretchable material, scientists  from Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bengaluru, have developed a device that senses strain, mimics pain perception and adapts its electrical response accordingly. By recreating these pain-like responses, the device paves the way for future smart wearable systems that can help doctors detect stress.   When the material is stretched, small gaps appear within the silver network, temporarily breaking the electrical pathway. An electric pulse can then prompt the silver to fill these gaps, reconnecting the network and essentially "remembering" the event. Each time it is stretched and reconnected, the device gradually adjusts its response, much like how our bodies adapt to repeated pain over time. This dynamic process enables the device to mimic memory and adaptation, bringing humans closer to materials that respond intelligently to their environment. The device sets itself apart by combining sensing and adaptive response in a single, flexible unit and offers a streamlined, efficient way for technology to adapt to its environment naturally, without complex setups or external sensors. The research could lead to more advanced health monitoring systems that "feel" stress like the human body and adapt in real-time, giving feedback to doctors or users. Such technology could also improve robotic systems, helping machines become safer and more intuitive to work with humans. ]]> https://biospectrumindia.com/news/104/25550/takeda-expands-presence-in-india-with-launch-of-global-innovation-capability-centre-in-bengaluru.html https://biospectrumindia.com/news/104/25550/takeda-expands-presence-in-india-with-launch-of-global-innovation-capability-centre-in-bengaluru.html Wed, 15 Jan 2025 00:00:00 +0530 Takeda, a global leader in biopharmaceutical innovation, has announced the official opening of its Innovation Capability Center (ICC) in Bengaluru, a centre where digital solutions will be built as part of Takeda’s global digital transformation, which includes insourcing capabilities. This marks Takeda’s first ICC in Asia, following successful establishments in Slovakia and Mexico. The ICC help support the company’s dedication to advancing healthcare through innovative solutions. These cutting-edge solutions will help advance operations and have an impact on Takeda’s workforce. The company’s mission in India focuses on ensuring sustainable access to healthcare, bolstered by strategic partnerships. Takeda’s diverse therapeutic portfolio addresses gastrointestinal disorders, rare diseases, immunology, oncology and vaccines, underscoring its commitment to data-driven innovation and transforming treatments.  The ICC in India will develop key technology capabilities to fuel innovation by embracing data and digital solutions using an agile, patient-centric and solution focused approach. The ICC will concentrate on pioneering advancements across domains including: Artificial Intelligence (AI) and GenAI to enhance efficiency and predictive analytics in healthcare Device Engineering and Application Virtualization to drive innovation in product development and patient-centric solutions Data Science and Visualization to enable data-driven decision-making for improved patient outcomes   Image caption- Left to right: Sanjay Patel, Global Head of Innovation Capability Solutions & Services, Takeda; Gabriele Ricci, Chief Data and Technology Officer at Takeda;  Tilak Banerjee, Head of Takeda ICC India inaugurating Takeda ICC India (Bengaluru) ]]> https://biospectrumindia.com/news/104/25546/tata-group-and-iisc-partner-to-establish-medical-school-to-pioneer-healthcare-education-.html https://biospectrumindia.com/news/104/25546/tata-group-and-iisc-partner-to-establish-medical-school-to-pioneer-healthcare-education-.html Tue, 14 Jan 2025 00:00:00 +0530 The Tata Group has announced a partnership with the Indian Institute of Science (IISc) to establish the Tata IISc Medical School in the IISc Bengaluru campus. Under the MoU signed, the Tata Group will make a contribution of Rs 500 crore to support the establishment of the medical school. The Tata IISc Medical School will be a centre of excellence that seeks to catalyse a unique model of clinical research and medical education in India, by bringing basic science and engineering to bear on clinical science and practice. It will focus on a variety of specialities including oncology, cardiology, neurology, nephrology, diabetes and metabolic disorders, infectious diseases, integrative medicine, and public health. The Tata IISc Medical School will offer integrated MD-PhD and other dual degree programmes to create a new cadre of physician-scientists and medical technologists. These students will be trained simultaneously in the medical school as well as science and engineering labs at IISc, combining cutting-edge clinical practice with scientific research. The medical school seeks to establish a unique model of clinical research and training that can be emulated nationwide. It will also collaborate with renowned medical schools from across the world to enable students to acquire global expertise, knowledge and practices.   ]]> https://biospectrumindia.com/news/104/25522/brainsightai-raises-5-m-in-pre-series-a-funding-round-to-expand-presence-in-india-.html https://biospectrumindia.com/news/104/25522/brainsightai-raises-5-m-in-pre-series-a-funding-round-to-expand-presence-in-india-.html Wed, 08 Jan 2025 00:00:00 +0530 BrainSight AI, a Bengaluru-based deep-tech neuroscience startup, has raised Pre-series A funding with $5 million led by IAN Alpha Fund, with participation from IvyCap Ventures, Silver Needle, apart from existing investors. The funding is a significant milestone in BrainSightAI’s mission to revolutionise the diagnosis and treatment of complex brain disorders through its innovative neuroinformatics platform, VoxelBox. Currently, BrainSightAI collaborates with over 40 leading hospitals across India, particularly in neurosurgery and radiology departments, focusing on brain tumour cases. The company is now expanding its solutions to neurological and psychiatric disorders, paving the way for a more holistic approach to brain care. The funds from this round will be strategically utilised to expand BrainSightAI’s presence in India, increasing its reach in Tier 1 cities and extend to Tier 2 cities. The company also plans to pursue FDA certification, opening access to the US and allied markets. Additionally, the company is gearing up to explore opportunities in Africa and Southeast Asia, based on distributor interest. The funds will also support R&D for a caregiver-focused app, aimed at empowering families of patients with brain disorders. BrainSightAI is at the forefront of understanding how the physiology of the brain correlates to its functions by mapping macro-scale neural connections in the brain, to enable precise diagnosis and prognosis of neuro-oncological and neuropsychiatric disorders. Traditionally available only at leading global research institutions like Harvard and Stanford, the platform makes this cutting-edge technology accessible to hospitals and patients worldwide. ]]> https://biospectrumindia.com/news/104/25507/anthem-biosciences-limited-files-drhp-for-rs-3395-cr-ipo.html https://biospectrumindia.com/news/104/25507/anthem-biosciences-limited-files-drhp-for-rs-3395-cr-ipo.html Sun, 05 Jan 2025 00:00:00 +0530 Bengaluru-based Anthem Biosciences Limited, an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing has filed the draft red herring prospectus (DRHP) with capital markets regulator, SEBI to raise funds through an initial public offering (IPO). Ajay Bhardwaj (Chairman, MD & CEO), Ishaan Bhardwaj (Vice President), Ganesh Sambasivam (Executive Director), and K Ravindra Chandrappa (Executive Director) are the Promoters of the company. The IPO of the Bangalore based company comprises an Offer for Sale (OFS) of equity shares aggregating up to Rs 3,395 crore by the Selling Shareholders. The OFS comprises of:- Equity Shares aggregating up to Rs 350 crore each by Ganesh Sambasivam and K Ravindra Chandrappa (Promoter Selling Shareholders); Equity Shares aggregating up to Rs 1,325 crore by Viridity Tone LLP and up to Rs 320 crore by Portsmouth Technologies LLC (Investor Selling Shareholders); Equity Shares aggregating up to Rs 320 crore each by Malay J Barua, Rupesh N Kinekar, Satish Sharma, up to Rs 80 crore by Prakash Kariabettan and up to Rs 10 crore by K Ramakrishnan (Other Selling Shareholders) The company which was incorporated in 2006, has two operational manufacturing facilities in India, Unit I (Bommassandra) and Unit II (Harohalli), both in Karnataka, with an aggregate annual custom synthesis capacity and fermentation capacity of 270 kL and 142 kL, respectively, as of September 30, 2024. The third manufacturing facility - Unit III in Harohalli is under construction and is expected to be fully operational in the first half of 2025. Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients. Its revenue from operations increased by 34.3% to Rs 1,419 crore in Fiscal 2024 from Rs 1,056 crore in Fiscal 2023. The PAT for the year ended March 31, 2024 was Rs 367 crore.   ]]> https://biospectrumindia.com/news/104/25472/dr-raghavan-varadarajan-wins-tata-transformation-prize-of-rs-2-cr-for-rsv-vaccine-development.html https://biospectrumindia.com/news/104/25472/dr-raghavan-varadarajan-wins-tata-transformation-prize-of-rs-2-cr-for-rsv-vaccine-development.html Tue, 17 Dec 2024 00:00:00 +0530 Raghavan Varadarajan, PhD., from the Indian Institute of Science (IISc), Bengaluru has won the Tata Transformation Prize in the healthcare category. Dr Varadarajan is working to develop a cost-effective Respiratory syncytial virus (RSV) vaccine that will allow for greater access to wide-spread deployment of vaccination programmes. His scientific advances will surmount the challenges that have hindered RSV vaccine development for decades and will provide broad, longer-lasting protection against RSV infection. The Tata Group and The New York Academy of Sciences honoured the 2024 Tata Transformation Prize winners at an award ceremony and dinner at Taj Mahal Palace in Mumbai. Launched in 2023, the Tata Transformation Prize aims to identify and support visionary scientists in India who are developing breakthrough technologies that address India’s most significant societal challenges in Food Security, Sustainability, and Healthcare. The 2024 Tata Transformation Prize Winners were selected from 169 entries from 18 Indian states by an international jury of leading experts. Intending to drive impactful innovation and scale-up implementation of high-reward research, each Winner received Rs 2 crore (approximately $240,000) in prize money and was honoured with a Tata Transformation Prize medal at the ceremony. C. Anandharamakrishnan , PhD, from CSIR - National Institute for Interdisciplinary Science and Technology won in the Food Security category; while Amartya Mukhopadhyay, DPhil, from the Indian Institute of Technology Bombay won in the sustainability category.   Image caption- (L-R) N. Chandrasekaran, Chairman, Tata Sons; Dr Raghavan Varadarajan, PhD, Indian Institute of Science (IISc), Bengaluru, Dr Soumya Swaminathan, Former Chief Scientist of the WHO ]]> https://biospectrumindia.com/news/104/25463/sahyadri-hospitals-introduces-maharashtras-first-ai-powered-command-centre-in-partnership-with-dozee.html https://biospectrumindia.com/news/104/25463/sahyadri-hospitals-introduces-maharashtras-first-ai-powered-command-centre-in-partnership-with-dozee.html Sat, 14 Dec 2024 00:00:00 +0530 Sahyadri Group of Hospitals, a leading name in delivering cutting-edge healthcare, has announced the launch of its groundbreaking ‘AI-Powered Health Command Centre’ initiative in collaboration with Dozee, Bengaluru-based remote patient monitoring company. This transformative programme redefines patient safety standards, leveraging advanced artificial intelligence (AI) technology to deliver precision care, proactive interventions, and unparalleled clinical outcomes. It features an AI-powered patient monitoring system that continuously monitors patients' conditions and detects early signs of deterioration. Additionally, it identifies critical and severely critical cases, notifying emergency teams for immediate action, ensuring timely and life-saving interventions. Currently active in Sahyadri’s Hadapsar and Deccan units, the Command Centre will be expanded across all Sahyadri hospitals in the next six months, ensuring seamless adoption of this transformative technology chain wide. The initiative equips non-ICU ward beds with Dozee’s state-of-the-art Remote Monitoring System (RMS) and Early Warning System (EWS), enabling continuous, real-time monitoring of vital parameters such as heart rate, respiration rate, blood pressure, SPO2 levels, temperature, and ECG. Dozee’s Early Warning System (EWS) tracks the trends of vital parameters and provides alerts to healthcare providers for early detection of patients' clinical deterioration, enabling timely medical intervention. Dozee uses AI-based Ballistocardiography (BCG) for contactless vitals monitoring. Dozee’s technology is patented and made in India. ]]> https://biospectrumindia.com/news/104/25454/pangia-biotech-announces-landmark-partnership-agreement-for-first-liquid-biopsy-prostate-cancer-assay-in-india.html https://biospectrumindia.com/news/104/25454/pangia-biotech-announces-landmark-partnership-agreement-for-first-liquid-biopsy-prostate-cancer-assay-in-india.html Fri, 13 Dec 2024 00:00:00 +0530 PanGIA Biotech, a pioneer in liquid biopsy technology, has announced its first international partnership, collaborating with Canary Oncoceutics (Canary Oncoceutics, Inc., Phoenix, AZ, and Canary Oncoceutics India, Tamil Nadu). This collaboration introduces the PanGIA Prostate Assay, the world’s first artificial intelligence (AI)-integrated urine-based liquid biopsy for prostate cancer detection, marking its commercial debut in India. PanGIA Biotech is actively advancing its R&D pipeline, targeting ten additional cancers including lung, pancreatic, ovarian, and breast. The company is also focused on validating its multi-cancer assay and expanding its global impact through continued innovation, offering long-term growth potential for partners. "Launching our patented PanGIA Prostate Assay in India marks an important milestone for our company and healthcare innovation. This non-invasive, accurate, and culturally sensitive diagnostic tool is poised to enhance early prostate cancer detection and improve patient outcomes," said Holly Magliochetti, CEO of PanGIA Biotech. "Partnering with Canary Oncoceutics enables us to bring life-changing technology to a population in need, reinforcing our commitment to saving lives, changing lives, and giving back by advancing healthcare equity." The PanGIA platform is a transformative solution for detecting, monitoring, and managing diseases, including cancers as early as Stage 1. Powered by machine learning, this urine-based platform profiles biomolecular patterns to deliver accurate diagnostic insights. ]]> https://biospectrumindia.com/news/104/25456/jncasr-develops-flexible-near-infrared-plasmonic-devices-for-wearable-sensors-and-medical-imaging-tools.html https://biospectrumindia.com/news/104/25456/jncasr-develops-flexible-near-infrared-plasmonic-devices-for-wearable-sensors-and-medical-imaging-tools.html Fri, 13 Dec 2024 00:00:00 +0530 In a significant advancement in nano-photonics, scientists at the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bengaluru, an autonomous institute under the Department of Science and Technology (DST), have introduced a new approach to achieve flexible near-infrared plasmonic devices using affordable scandium nitride (ScN) films. This could revolutionise the design of future optoelectronic devices, flexible sensors, and medical imaging tools that rely on NIR light, by introducing scalable and cost-effective plasmonic materials Plasmonics is a field that leverages the interaction between light and free electrons in metals to create extremely confined electromagnetic fields. Traditionally, plasmonic materials have been rigid and possess limited design possibilities. Most of them like gold or silver, tend to be costly and possess limited versatility. The team used a process by which single-crystal layers are deposited onto a substrate, technically called epitaxial growth. The technique they used stacks layers of materials with weak interlayer bonding to enable new device architecture (van der Waals heteroepitaxy). The study, recently published in Nano Letters, highlights the potential of scandium nitride as a promising plasmonic material for applications that require both flexibility and precision in near-infrared (NIR) optics.   ]]> https://biospectrumindia.com/news/104/25433/illumina-celebrates-opening-of-global-capability-centre-in-bengaluru.html https://biospectrumindia.com/news/104/25433/illumina-celebrates-opening-of-global-capability-centre-in-bengaluru.html Tue, 10 Dec 2024 00:00:00 +0530 US-based Illumina Inc., a global leader in DNA sequencing and array-based technologies, recently celebrated the opening of a global capability centre in Bengaluru, to grow its global workforce, deepen technology talent in the region, and support a global customer base. This planned move was originally announced in early September. The Illumina office is located within Bengaluru’s Manyata Technology Park, a complex shared among global technology, health care, and biopharma companies. More than 80 Illumina employees currently work at the Manyata facility, with more than 200 employees anticipated at the site by the end of 2025. Illumina also operates a customer solutions centre in Bengaluru.   Illumina’s investment in a global capability centre reflects a growing trend of companies establishing operations in India. More than 3000 multinational companies have joined India’s vibrant innovation ecosystem, building highly skilled teams to enable global scaling of business processes and to drive growth.The growing adoption of genomics in India holds tremendous potential for public health and personalised medicine for the region’s nearly 1.5 billion people. It is estimated that up to 96 million people in India have a rare disease, and one in nine people in India are likely to develop cancer in their lifetime.Illumina’s workforce strategy is to build global teams with the skills and capabilities to enable innovation at scale and strengthen the company’s impact around the world. In addition to two sites in India, Illumina has a sequencing centre in Cambridge, England, and an innovation centre in Singapore, along with commercial offices in Asia, Oceania, Africa, the Middle East, Europe, and the Americas.Illumina’s new global capability centre adds to an already growing footprint in the region. In 2023, Illumina opened a new office and state-of-the-art genomics lab, known as an Illumina Solutions Centre, in Bengaluru. The facility provides training and education and features a fully equipped laboratory with the latest next-generation-sequencing technologies. ]]> https://biospectrumindia.com/news/104/25430/hcg-and-accenture-collaborate-on-cancer-research-and-care-using-advanced-ai.html https://biospectrumindia.com/news/104/25430/hcg-and-accenture-collaborate-on-cancer-research-and-care-using-advanced-ai.html Wed, 04 Dec 2024 00:00:00 +0530 Bengaluru-based HealthCare Global Enterprises Limited (HCG), one of the largest cancer care networks in India, is collaborating with Accenture to accelerate cancer research and care through the use of advanced artificial intelligence (AI), including generative AI and deep learning on multi-dimensional and multi-omic patient data.  This strategic teaming combines Accenture’s global expertise and talent in data and AI including AI/ML, generative AI, and quantum computing with deep clinical insights from HCG in oncology to enable early detection and treatment for various types of cancer. As part of the joint effort, Accenture will use advanced technologies including image analysis software, informatics, and novel algorithms to analyse data from cancer patients and study molecular alterations that can have a broader impact on patient care. The programme, the first of its kind in South Asia, will leverage Accenture’s generative AI studios to spur innovative research for the discovery and development of new drug targets, mechanisms and pathways, and biomarkers associated with different forms of cancer. Additionally, the initiative aims to enhance the understanding of various cancers, including their development, symptoms, and origins, to enable new treatment algorithms for precision medicine and advance the quality of therapy and care. It will showcase data-driven clinical practice and enhance the overall efficiency of patient care by applying AI, generative AI, cloud, machine learning, and quantum computing, among others. The collaboration is currently focused on identifying molecular signatures for the prognosis and response to therapy for lung adenocarcinoma, and head and neck cancers, which will then be extended to other cancer types.   ]]> https://biospectrumindia.com/news/104/25424/strand-life-sciences-launches-blood-based-test-for-early-detection-of-multiple-cancers.html https://biospectrumindia.com/news/104/25424/strand-life-sciences-launches-blood-based-test-for-early-detection-of-multiple-cancers.html Mon, 02 Dec 2024 00:00:00 +0530 Bengaluru-based genomics and bioinformatics company Strand Life Sciences, a subsidiary of Reliance Industries Limited, has launched a novel blood-based test for early detection of multiple cancers. Called CancerSpot, the test uses the latest globally accepted methylation profiling technology to identify cancer tumor DNA fragments. CancerSpot works off a simple blood sample and uses a proprietary genome sequencing and analysis process to identify DNA methylation signatures of cancer in the blood. CancerSpot’s signatures, derived from Indian cohorts, have been shown to be robust and applicable across global ethnicities. The test provides a simple and convenient option for proactive and routine cancer screening. Isha Ambani Piramal, Member of the Board, Reliance Industries Limited, said, "Reliance is committed to pioneering breakthroughs that reshape the future of medicine in service of humanity. Cancer in India is emerging as a major cause of morbidity and mortality.  It is a source of heavy financial, social and psychological burden on patients, families and communities. Therefore, Strand’s novel cancer early detection test exemplifies our vision of delivering transformative healthcare solutions." Speaking at the grand opening of Strand’s new state-of-the-art Genomics Diagnostics & Research Centre in Bengaluru, company CEO and Co-Founder Dr Ramesh Hariharan said, “Early warning is the key to battle cancer ─ and win it.  We are proud to launch an accessible early cancer detection test that will enable people to stay ahead of cancer. Over our 24-year history, Strand has been a pioneer in genomics, and this is another FIRST for India resulting from a rigorous multi-year research study.” He further added, “This new Genomics Diagnostics & Research Centre will drive the CancerSpot program and accelerate efforts to develop new solutions, support research efforts, and deliver novel life-saving diagnostics for both Indian and global populations.” The Genomics Diagnostics & Research Center was inaugurated today by Dr Charles Cantor, a global expert in genomics and biophysical chemistry, and previously Professor at Columbia University, UC Berkeley, and Boston University, in the presence of other luminaries in the field of genomics. This 33,000 square feet facility comprises a cutting-edge genomics laboratory with the latest sequencing technologies and workflows designed to foster collaboration among bioinformatics experts, molecular biologists, and clinical teams. ]]> https://biospectrumindia.com/news/104/25408/british-association-of-physicians-of-indian-origin-uk-inks-mou-with-shri-balaji-institute-of-neuroscience-and-trauma-hubli.html https://biospectrumindia.com/news/104/25408/british-association-of-physicians-of-indian-origin-uk-inks-mou-with-shri-balaji-institute-of-neuroscience-and-trauma-hubli.html Thu, 28 Nov 2024 00:00:00 +0530 A Memorandum of Understanding (MoU) has been signed between British Association of Physicians of Indian Origin UK and Shri Balaji Institute of Neurosciences and Trauma, Hubli to provide UK standard super-specialisation post-graduate medical education and training in general surgery, emergency medicine, neurosurgery and critical care to Indian clinicians and training for nurses in intensive & emergency room care and announcement of BAPIO’s multi-million commercial partnerships with leading Indian hospitals. The MoU was signed by Prof. Parag Singhal, Executive Director BAPIO Training Academy UK with D. Kranthi Kiran, Chief Neurosurgeon and Chairman, Shri Balaji Institute of Neuroscience and Trauma, Hubli in presence of Prof. Sir. Stephen Powis, NHS England National Medical Director & Anna Shotbolt, Deputy Trade Commissioner, South Asia (Exports). The MoU's objective is to upskill Indian nurses and clinicians at primary and secondary care levels to UK standards, promote professional clinical excellence and knowledge exchange, improve capacity and capability of nurses in Northern Karnataka and helping nurses & clinicians grow and expand their horizons while providing best in class health education and training in India. The MoU will also deepen academic-collaboration, improve patient safety and create joint-research opportunities between India and the UK. ]]>